ID,SUB_ID,Country,Province/State,Study Pop Size (N),Proportion of values entered in row (%),Paper Title,Journal,Author,Source,Language,Peer-Reviewed? (As of 2 April 2020),Study Type: Observational or Randomized Clinical Trial (RCT)?,Study start date (mm/dd/yyyy),Study end date (mm/dd/yyyy),Study length (days),Overall study population or subgroup?,Subgroup,Positive/negative cases,End-point vs Active,Survivors,Discharged,Contains Any Treatment?,ICU vs. non-ICU,Severity,Ventilation,Median Age,Mean Age,Age SD,Age LQ,Age UQ,% Healthcare Worker,% Male,% White or European,% African American,% Asian,% Hispanic or Latino,% Multiple ethnicities or other,Exposure history (%),Exposure - Wuhan Travel (%),Exposure - Personal Contact (%),Incubation period (days) - Mean,Incubation period (days) - Median,Incubation period (days) - LQ,Incubation period (days) -  Higher Quartile,Time From Symptoms Appearance to Hospitalization (days) - Mean,Time From Symptoms Appearance to Hospitalization (days) - Median,Time From Symptoms Appearance to Hospitalization (days) - LQ,Time From Symptoms Appearance to Hospitalization (days) - UQ,Smoking history,Current drinker,BMI,Obesity,Any Comorbidity,Hypertension,Diabetes,Cardiovascular Disease (incl. CAD),Chronic obstructive lung (COPD),Cancer (Any),Liver Disease (any),Cerebrovascular Disease,Chronic kidney/renal disease,Other,Fever (temperature ≥37·3°C),Average temperature (celsius),Max temperature (celsius),Respiratory rate > 24 breaths per min,Cough,Shortness of Breath (dyspnoea),Headache,Sputum (/Expectoration),Myalgia (Muscle Pain),Fatigue,Upper air-way congestion,Diarrhoea,Nausea or Vomiting,Loss of Appetite/Anorexia,Sore Throat/Stuffy Nose,Chills,Chest Pain,Loss of smell/taste,Disease Severity Asymptomatic,Disease Severity General,Disease Severity Severe,Disease Severity Critical,"Imaging Findings Available? (yes=1, no=0)",White Blood Cell Count (10^9/L) - Median,White Blood Cell Count (10^9/L) - LQ,White Blood Cell Count (10^9/L) - UQ,Lymphocyte Count (10^9/L) - Median,Lymphocyte Count (10^9/L) - LQ,Lymphocyte Count (10^9/L) - UQ,CD4+ T Lymphocyte (Count),CD8+ T Lymphocyte (Count),Platelet Count (10^9/L) - Median,Platelet Count (10^9/L) - LQ,Platelet Count (10^9/L) - UQ,Neutrophil Count (10^9/L) - Median,Neutrophil Count (10^9/L) - LQ,Neutrophil Count (10^9/L) - UQ,Hemoglobin (g/L) - Median,Hemoglobin (g/L) - LQ,Hemoglobin (g/L) - UQ,Hematocrit (%),Albumin (g/L),Alanine Aminotransferase (U/L),Aspartate Aminotransferase (U/L),Total Bilirubin (umol/L) - Median,Total Bilirubin (umol/L) - LQ,Total Bilirubin (umol/L) - UQ,Blood Urea Nitrogen (mmol/L),Creatinine (μmol/L),Creatine Kinase (U/L),C-Reactive Protein (mg/L),Gamma-Glutamyl Transferase (U/L),Interleukin-6 (pg/mL),Procalcitonin (ng/mL),D-Dimer (mg/L),Prothrombin Time (s),Antibiotic,Antiviral (Any),Uses Kaletra (lopinavir–ritonavir),Uses Favipiravir,Uses Tamiflu (oseltamivir),Uses Remdesivir,Uses umif+lop-rit,Uses Arbidol (umifenovir),Uses hydroxychloroquine and/or chloroquine,"Corticosteroid (including Glucocorticoid, Methylprednisolone)",Intravenous immunoglobin,Nasal cannula,High-flow nasal cannula oxygen therapy,Oxygen therapy,Noninvasive mechanical ventilation,Invasive mechanical ventilation,ECMO,Renal replacement therapy,Interferon Alpha-1b,Thymalfasin and/or Thymosin,Sepsis,Respiratory failure or ARDS,Respiratory failure,ARDS,Hypoxemia,Heart failure,Septic shock / shock,Liver dysfunction,Coagulopathy,Acute cardiac injury,Acute kidney injury (AKI),Secondary infection/ Bacterial infection,Hypoproteinaemia,Acidosis,Hospital admission (%),ICU admission,Discharged (%),"ICU length of stay, days","Hospital length of stay, days",Days to Viral Clearance (Median),Mortality,Projected Mortality (accounting for patients not currently discharged)
1,0,China,Wuhan,191,60.11%,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,Yes,Observational,12/29/19,1/31/20,33,Top-level,General,Positive only,End-point only,Both,Both,Yes,Both,All,Both,56,,,46,67,,62.30%,0%,0%,100%,0%,0%,38%,,,,,,,,11,8,14,5.76%,,,,47.60%,30%,19.00%,8.00%,3.00%,1.68%,,,1.68%,12.00%,94%,,,29.00%,79%,,,23.00%,15.00%,23.03%,,4.71%,4.00%,,,,,,,37.70%,34.55%,27.75%,,6.2,4.5,9.5,1,0.6,1.3,,,206,155,262,,,,128,119,140,,32.3,30,,,,,,,21.5,,,7.4,0.1,0.8,11.6,94.76%,21.47%,21.47%,0.00%,0.00%,,0.00%,0.00%,0.00%,29.84%,24.08%,,21.47%,,13.61%,16.75%,1.57%,5.24%,0.00%,,58.64%,,53.93%,30.89%,,23.04%,19.90%,,19.37%,17.28%,14.66%,14.66%,11.52%,8.90%,1,0.26,0.72,8,11,20,0.28,0.28
1,1,China,Wuhan,54,60.11%,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,Yes,Observational,12/29/19,1/31/20,33,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,Both,Severe/Critical Only,Both,69,,,63,76,,70.37%,0%,0%,100%,0%,0%,25.93%,,,,,,,,11,8,15,9.26%,,,,66.67%,48.15%,31.48%,24.07%,7.41%,0.00%,,,3.70%,20.37%,94.44%,,,62.96%,72.22%,,,25.93%,14.81%,27.78%,,3.70%,5.56%,,,,,,,0.00%,22.22%,77.78%,,9.8,6.9,13.9,0.6,0.5,0.8,,,165.5,107,229,,,,126,115,138,,29.1,40,,,,,,,39,,,11,0.1,5.2,12.1,98.15%,22.22%,22.22%,0.00%,0.00%,,0.00%,0.00%,0.00%,48.15%,66.67%,,61.11%,,44.44%,57.41%,5.56%,18.52%,0.00%,,100%,,98.15%,92.59%,,51.85%,70.37%,,50.00%,59.26%,50.00%,50.00%,37.04%,29.63%,1,0.72,0,8,7.5,7.5,1,1
1,2,China,Wuhan,137,60.11%,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Lancet,Zhou et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext,English,Yes,Observational,12/29/19,1/31/20,33,Subgroup,Survivors,Positive only,End-point only,Survivors only,Discharged only,Yes,Both,All,Both,52,,,45,58,,59.12%,0%,0%,100%,0%,0%,43.07%,,,,,,,,11,8,13,4.38%,,,,40.15%,23.36%,13.87%,1.46%,1.46%,7.00%,,,0.00%,8.03%,94.16%,,,16.06%,81.75%,,,21.90%,15.33%,21.17%,,5.11%,2.92%,,,,,,,52.55%,39.42%,8.03%,,5.2,4.3,7.7,1.1,0.8,1.5,,,220,168,271,,,,128,120,140,,33.6,27,,,,,,,18,,,6.3,0.1,0.6,11.4,93.43%,21.17%,21.27%,0.00%,0.00%,,0.00%,0.00%,0.00%,22.63%,7.30%,,5.84%,,1.46%,0.73%,0.00%,0.00%,0.00%,,42.34%,,36.50%,6.57%,,11.68%,0.00%,,7.30%,0.73%,0.73%,0.73%,1.46%,0.73%,1,0.08,1,7,12,20,0,0
2,0,China,Wuhan,199,44.94%,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,Yes,RCT,1/18/20,2/3/20,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,49,68,,60.30%,0%,0%,100%,0%,0%,,,,,,,,,13,11,16,,,,,,,11.60%,,,3.00%,,6.50%,,,91.50%,36.5,,18.80%,,,,,,,,2.06%,4.25%,1%,,,,,,,,,,7,5.1,9.4,0.9,0.6,1.2,,,207,158,284,,,,,,,,,33,34,,,,,69.5,69,,,,,,,95%,47%,47%,0%,0%,,0%,0%,0%,33.70%,,,,,14.60%,16.10%,2%,4.50%,,,0.49%,20.10%,,,,0.51%,2.05%,,,,4.68%,3.65%,,,1,,0.72,10,15,28,0.16,0.18
2,1,China,Wuhan,99,44.94%,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,Yes,RCT,1/18/20,2/3/20,16,Subgroup,With treatment,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,50,68,,61.60%,0%,0%,100%,0%,0%,,,,,,,,,13,11,17,,,,,,,10.10%,,,5.10%,,5.10%,,,89.90%,36.5,,21.60%,,,,,,,,4.20%,9.50%,2.10%,,,,,,,,,,7.3,5.3,9.6,0.8,0.6,1.4,,,201,155,287,,,,,,,,,33,33,,,,,70.7,57,,,,,,,94.90%,94.90%,94.90%,0%,0%,,0%,0%,0%,32.30%,,,,,10.10%,14.10%,2%,3.00%,,,0%,12.60%,,,,0%,2.10%,,,,3.20%,1.10%,,,1,,0.75,6,14,28,0.15,0.17
2,2,China,Wuhan,100,44.94%,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,NEJM,Cao et. al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus,English,Yes,RCT,1/18/20,2/3/20,16,Subgroup,Control,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,,,48,68,,59.00%,0%,0%,100%,0%,0%,,,,,,,,,13,10,16,,,,,,,13.00%,,,1.00%,,8.00%,,,93.00%,36.5,,16.00%,,,,,,,,0%,0%,0%,,,,,,,,,,6.9,4.9,9.1,0.9,0.5,1.2,,,210,163,269.5,,,,,,,,,34,34,,,,,67.4,72,,,,,,,95%,0%,0%,0%,0%,,0%,0%,0%,35.00%,,,,,19.10%,18.00%,2%,6.00%,,,1%,27.30%,,,,1%,2.00%,,,,6.10%,6.10%,,,1,,0.7,11,16,28,0.17,0.2
3,0,China,Wuhan,81,46.63%,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Yes,Observational,12/20/19,2/8/20,50,Top-level,General,Positive only,End-point and active,Both,Both,No,Both,All,Both,50,49.5,11,,,,52%,0%,0%,100%,0%,0%,38%,38%,,,,,,,,,,,,,,26%,15%,12%,10%,11%,5%,9%,7%,4%,16%,73%,37.93,37.93,,59%,42%,6%,19%,9%,9%,,4%,5%,1%,,,,,18.51%,,,,1,8.1,4.7,11.5,1.1,0.8,1.4,,,212.2,112.5,311.9,,,,123.9,111.9,135.9,,32.9,46.2,40.8,11.9,8.3,15.5,,75.4,,47.6,6.4,,,6.5,10.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.77,,23.2,,0.04,0.05
3,1,China,Wuhan,15,44.94%,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Yes,Observational,12/20/19,2/8/20,50,Subgroup,Subclinical,Positive only,End-point and active,Both,Both,No,Both,All,Both,,44.9,9,,,,27.00%,0%,0%,100%,0%,0%,0.00%,0.00%,,,,,,,,,,,,,,27.00%,13%,20%,20%,7%,7%,0%,7%,0%,7%,0.00%,,36.6,,0.00%,0.00%,0.00%,0.00%,0.00%,0%,,0%,0.00%,0%,,,,,100%,0%,0%,0%,1,8,5.5,10.5,1.1,0.8,1.4,,,202.9,135.5,270.3,,,,125.1,111.6,138.6,,,30.8,30.2,9.2,8.6,9.8,,63.7,,6.9,6.4,,,6.5,10.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
3,2,China,Wuhan,21,43.82%,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Yes,Observational,12/20/19,2/8/20,50,Subgroup,Scans done <= 1 week after symptom onset,Positive only,End-point and active,Both,Both,No,Both,All,Both,,48.8,13,,,,52.00%,0%,0%,100%,0%,0%,38.00%,38.00%,,,,,,,,,,,,,,24.00%,5%,10%,5%,14%,5%,10%,5%,0%,15%,86.00%,,38.1,,71.00%,43.00%,10.00%,14.00%,5.00%,9%,,5.00%,10.00%,5%,,,,,0%,,,,1,7.8,4.2,11.4,1,0.7,1.3,,,213.5,112.7,314.3,,,,126.7,113.3,140.1,,34,50.6,47.7,14.1,9.8,18.4,,68,,61.4,5.2,,,6.9,10.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
3,3,China,Wuhan,30,43.82%,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Yes,Observational,12/20/19,2/8/20,50,Subgroup,Scans done 1-2 weeks after symptom onset,Positive only,End-point and active,Both,Both,No,Both,All,Both,,52.3,13,,,,67.00%,0%,0%,100%,0%,0%,47.00%,47.00%,,,,,,,,,,,,,,30.00%,23%,10%,10%,10%,7%,10%,10%,10%,20%,90.00%,,38.2,,70.00%,43.00%,7.00%,20.00%,13.00%,5%,,3.00%,7.00%,0%,,,,,0%,,,,1,8.4,4.9,11.9,1.1,0.8,1.4,,,206.8,110.7,302.9,,,,119.6,106.8,132.4,,30.1,48.7,42.7,11.9,8,15.8,,115.4,,71.3,6.8,,,5.8,10.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0.07,
3,4,China,Wuhan,15,42.13%,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study",Lancet Infectious Diseases,Shi et. al.,https://reader.elsevier.com/reader/sd/pii/S1473309920300864?token=A0D8E0A815A81A197FBA5FBC028C41D29B7899BFA37779DD83AA14652314A5C8D415DCB92CEEC6704387954EBD8E0864,English,Yes,Observational,12/20/19,2/8/20,50,Subgroup,Scans done >2 weeks after symptom onset,Positive only,End-point and active,Both,Both,No,Both,All,Both,,49.5,11,,,,47.00%,0%,0%,100%,0%,0%,60.00%,60.00%,,,,,,,,,,,,,,20.00%,13%,13%,7%,13%,0%,13%,7%,0%,20%,93.00%,,38.5,,80.00%,80.00%,7.00%,40.00%,13.00%,13%,,7.00%,0.00%,0%,,,,,0%,,,,1,8.2,4,12.4,1.1,0.8,1.4,,,230.5,95.7,365.3,,,,124.8,115.7,133.9,,,50.6,37.8,na,na,na,,58.4,,49.8,,,,,10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0.07,
4,0,China,Zhejiang,149,50.56%,"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China",Journal of Infection,Yang et al.,https://reader.elsevier.com/reader/sd/pii/S0163445320300992?token=9163263C94899C48B765689929BEFCC2B1AD126DCC83E3753645A68BB99CF497BB124D1BB7AB61F22F586414124183AD,English,Yes,Observational,1/17/20,2/15/20,29,Top-level,General,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Both,,45.11,,,,0%,54.40%,0%,0%,100%,0%,0%,89.90%,53.69%,32.89%,,,,,6.83,6.83,1.83,11.83,,,23.75,,34.90%,,,,,1.34%,,18.79%,,,76.50%,37.86,,,58.40%,1.34%,8.72%,32.20%,3.36%,,,7.38%,1.34%,,14.09%,14.09%,,,,,,,,4.56,2.08,6.64,1.21,0.53,1.89,,,174.5,96.25,252.75,2.6,0.57,4.63,,,,,41.65,20,23,9.9,3.95,15.85,3.8,66.07,76.5,7.25,5.83,,,0.22,12.2,22.82%,93.96%,,,,,,,,3.36%,12.75%,,89.93%,89.93%,1.34%,0%,0%,3.36%,,,,,,,,,,,,,,,,,1,0,0.49,,,,0,0
5,0,China,Wuhan,21,37.08%,Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia,Radiology,Pan et. al.,https://pubs.rsna.org/doi/full/10.1148/radiol.2020200370,English,Yes,Observational,1/12/20,2/6/20,25,Top-level,Non-severe,Positive only,End-point only,Both,Discharged only,No,ΝΑ,Mild only,Both,40,40,9,30,57,,29.00%,0%,0%,100%,0%,0%,,,,,,,,,6,5,7,,,,,,,,,,,,,,,86%,,,,57%,,,,24%,52%,,,,43%,,29%,,,,0%,0%,0%,1,4.9,4.1,5.7,1.4,1,1.8,,,,,,3.1,,,,,,,,42,32,,,,,,,17.2,,,,0.93,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,1,,1,,17,,0,0
6,0,China,Beijing,77,50.00%,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,No,Observational,1/21/20,2/7/20,17,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,52,52,20,,,2.60%,44.16%,0%,0%,100%,0%,0%,89.60%,70.10%,19.50%,4,4,3.5,6,5,5,3,6,,,,,31.20%,20.80%,7.80%,11.70%,7.79%,5.20%,,2.60%,6.50%,,85.70%,,,,63.64%,20.80%,13.00%,,27.30%,27.30%,,1.30%,7.79%,9.10%,6.50%,,,,0.00%,25.97%,,,1,4.04,3.48,5.58,,,,,,190,149,245,,,,137,125,145,,,28,29,,,,,64,80,17,,,0.12,,12.7,,,,,,,,,,,,,,,,,,,,,,,,3.90%,,2.60%,1.30%,32.47%,,,2.60%,3.90%,,,1,,0.83,,13,,0.06,0.07
6,1,China,Beijing,57,51.12%,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,No,Observational,1/21/20,2/7/20,17,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,45,45,17,,,3.50%,40.40%,0%,0%,100%,0%,0%,91.20%,77.20%,14%,5,5,3.5,6,5,5,4,6,,,,,24.60%,14%,7.00%,5.30%,5.30%,5.30%,,1.80%,3.50%,,82.50%,,,,57.90%,14%,17.50%,,33.30%,33.30%,,1.80%,5.30%,7%,9%,,,,0%,0%,0%,0.00%,1,3.95,3.45,4.64,,,,,,189,152,245,,,,139,127,144,,,28,28,,,,,63,67,13,,,0.1,,12.7,,,,,,,,,,,,,,,,,,,,,,,,0%,,0.00%,0.00%,33.30%,,,1.80%,0.00%,,,1,,0.93,,12,,0,0
6,2,China,Beijing,20,50.00%,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,MedrXiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.13.20035436v1.full.pdf,English,No,Observational,1/21/20,2/7/20,17,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,69,69,15,,,0%,55.00%,0%,0%,100%,0%,0%,85%,50%,35%,3.5,3.5,3,4,6,6,5,7,,,,,50%,40%,10.00%,30.00%,15.00%,5%,,5%,15%,,95%,,,,80.00%,40%,0.00%,,10.00%,10.00%,,0.00%,15.00%,15%,0%,,,,0%,100%,,,1,5.92,3.68,7.59,,,,,,198,134,272,,,,137,119,148,,,32,36,,,,,68,115,55,,,0.13,,12.7,,,,,,,,,,,,,,,,,,,,,,,,15.00%,,10.00%,5.00%,30.00%,,,5.00%,15.00%,,,1,,0.5,,18.5,,0.25,0.33
7,0,China,Wuhan,36,43.26%,Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study,MedrXiv,Yang et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20036780v1.full.pdf,English,No,Observational,2/12/20,3/2/20,19,Top-level,Severe,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,69.4,69.4,21.16,,,,83.30%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,38.90%,27.80%,33.30%,19.40%,5.60%,,5.6,,8.30%,,,,,,100%,,,,,,,,,,,,,,,0%,100.00%,0,14,6.9,21.1,0.6,0.3,0.9,,,156,99.8,213,12.7,6,19.4,122.4,104.3,140.5,,,34.5,30.5,,,,10.7,83.5,,,,,,,,94.40%,,27.80%,0.00%,0.00%,,27.80%,77.80%,8.30%,80.60%,80.60%,,,,0%,100%,,61.10%,,,,,,,,19.44%,,,,,22.22%,,,,1,1,na,,,,0.64,
7,1,China,Wuhan,22,42.13%,Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study,MedrXiv,Yang et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20036780v1.full.pdf,English,No,Observational,2/12/20,3/2/20,19,Subgroup,CCRT group,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,67.5,67.5,11.4,,,,86.40%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,36.40%,27.30%,27.30%,18.20%,9.10%,,0.00%,,13.60%,,,,,,100%,,,,,,,,,,,,,,,,100.00%,0,14.3,5.8,22.8,0.6,0.3,0.9,,,159,94,203,13,5,21,126.8,108.2,145.4,,,36,43.5,,,,10.8,94.5,,,,,,,,96%,,36.40%,0.00%,0.00%,,36.40%,77.30%,9.10%,77.30%,77.30%,,,,0%,100%,,100%,,,,,,,,22.70%,,,,,22.70%,,,,1,1,,,,,0.55,
7,2,China,Wuhan,14,41.57%,Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study,MedrXiv,Yang et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20036780v1.full.pdf,English,No,Observational,2/12/20,3/2/20,19,Subgroup,Non-CCRT group,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,72.6,72.6,9.1,,,,78.60%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,42.90%,28.60%,42.90%,21.40%,0.00%,,14.30%,,,,,,,,100%,,,,,,,,,,,,,,,,100.00%,0,13.4,9,17.8,0.6,0.3,0.9,,,156,110.3,221.5,12.2,8,16.4,115.5,105,131,,,30.5,29.5,,,,10.3,72,,,,,,,,93%,,14.30%,0.00%,0.00%,,14.30%,78.60%,7.10%,85.70%,85.70%,,,,0%,100%,,0%,,,,,,,,14.30%,,,,,21.40%,,,,1,1,,,,,0.79,
8,0,Italy,Nationwide,3200,34.83%,"Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020",COVID-19 Surveillance Group,Palmieri et. al.,https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf,English,No,Observational,3/1/20,3/20/20,19,Subgroup,Severe,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,NA,78.5,80,,73,85,,70.60%,100%,0%,0%,0%,0%,,,,,,,,4,,,,,,,,98.80%,73.80%,33.90%,30.10%,13.70%,19.50%,3.70%,,20.20%,3.70%,76.00%,,,,40%,73.00%,,,,,,8.00%,,,,,,,0.00%,100.00%,0.00%,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,84%,54%,,,,,,,,,,,,,,,,,,,,96.50%,,96.50%,,,,,,10.40%,29.20%,8.50%,,,1,0.5,0,5,4,,1,1
9,0,China,Zhejiang,91,46.07%,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",QJM: An International Journal of Medicine,Qian et. al.,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,Yes,Observational,1/20/20,2/16/20,27,Top-level,General,Positive only,End-point and active,Survivors only,Both,Yes,,All,NA,50,,,36.5,57,0%,40.66%,0%,0%,100%,0%,0%,98.90%,34.07%,8.79%,,6,,,,,,,,,,,,16.48%,8.79%,,,,,,,,71.43%,,,,60.44%,3.30%,7.69%,32.97%,5.49%,43.96%,,23.08%,6.59%,25.27%,,,,,,90.10%,9.90%,,1,4.99,4.25,5.69,1.35,0.98,1.66,,,196,142,238,2.91,,,135,125,145,,40,18,21,,,,3.95,66,,6.81,,,0.02,0.3,,,100%,100%,0%,0%,,100%,100%,0%,9.89%,,,,,,,,,,,,,,,,,,,,,,,,,1,0.1,0.34,,,,0,0
9,1,China,Zhejiang,9,33.15%,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",QJM: An International Journal of Medicine,Qian et. al.,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,Yes,Observational,1/20/20,2/16/20,27,Subgroup,Severe,Positive only,End-point and active,Survivors only,Both,,,Severe/Critical Only,,66,,,54,80,0%,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,0.00%,,1,5.23,3,5.82,0.9,0.7,1.3,,,152,127,208,3.32,,,130,118,142,,,19.9,27,,,,5.19,81.5,,30.63,,,0,0.45,,,100%,100%,0%,0%,,100%,100%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
9,2,China,Zhejiang,82,33.15%,"Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series",QJM: An International Journal of Medicine,Qian et. al.,https://www.medrxiv.org/content/10.1101/2020.02.23.20026856v2.full.pdf,English,Yes,Observational,1/20/20,2/16/20,27,Subgroup,Mild Cases,Positive only,End-point and active,Survivors only,Both,,,Mild only,,49,,,35.3,56,0%,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,100.00%,,1,4.97,4.02,5.65,1.4,1.05,1.75,,,198,144,248,2.8,,,135,126,147,,,18,21,,,,3.83,66,,5.98,,,0.03,0.3,,,100%,100%,0%,0%,,100%,100%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
10,0,China,Seven hospitals,62,54.49%,"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Yes,Observational,1/10/20,1/26/20,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,41,41,,32,52,,56.50%,0.00%,0.00%,100.00%,0.00%,0.00%,37%,37%,33.90%,4,4,3,5,2,2,1,4.3,,,,,32.30%,8.10%,1.60%,,1.60%,,11.30%,1.60%,1.60%,,77.00%,,,3%,81%,3%,34%,56.50%,52%,52%,,8%,,,,,,,,,,,1,4.7,3.5,5.8,1,0.8,1.5,,,176,135.8,215.5,2.9,,,137,128.8,152.3,,,22,26,,,,,72,69,,,,0.04,0.2,,45.20%,88.70%,74.20%,0%,0%,,33.90%,35.50%,0.00%,26.00%,0.00%,,,,0%,1.61%,,0%,42%,0%,,,,2.00%,,,,,,,,,,,0.98,0.02,0.02,,,,0,
10,1,China,Seven hospitals,33,54.49%,"Clinical Findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Yes,Observational,1/10/20,1/26/20,16,Subgroup,> 10 days after onset,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,45,45,,37,54,,57.60%,0.00%,0.00%,100.00%,0.00%,0.00%,27%,27%,27.30%,3,3,3,4,6.5,6.5,5,9,,,,,39.40%,12.10%,3.00%,,3.00%,,12.10%,3.00%,0.00%,,73.00%,,,3%,82%,6%,45%,57.60%,58%,58%,,9%,,,,,,,,,,,1,4.5,3.1,6.1,1,0.7,1.4,,,172.5,128.8,202.8,2.8,,,137.5,129,149.5,,,22.5,27.5,,,,,71.5,60,,,,0.04,0.2,,48.50%,93.90%,81.00%,0.00%,0.00%,,51.50%,51.50%,0.00%,33.00%,0.00%,,,,0%,3%,,0%,33%,0%,,,,3.00%,,,,,,,,,,,0.97,0.03,0.03,,,,0,
10,2,China,Seven hospitals,29,54.49%,"Clinical Findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",BMJ,Xu et. al.,https://www.bmj.com/content/bmj/368/bmj.m606.full.pdf,English,Yes,Observational,1/10/20,1/26/20,16,Subgroup,<=10 days after onset,Positive only,Active only,Both,Non-discharged only,Yes,Both,All,Both,39,39,,31,50,,55.20%,0.00%,0.00%,100.00%,0.00%,0.00%,48%,48%,41.40%,5,5,4,7,2,2,1,2,,,,,24.10%,3.40%,0.00%,,0.00%,,10.30%,0.00%,3.40%,,83.00%,,,3%,79%,0%,21%,55.20%,45%,45%,,0%,,,,,,,,,,,1,4.9,3.9,5.7,1,0.9,1.5,,,186,149,228,2.9,,,136.5,127.3,153.8,,,22,25,,,,,71.4,71.4,,,,0.04,0.2,,41.40%,82.80%,65.00%,0.00%,0.00%,,13.80%,17.20%,0.00%,17.00%,0.00%,,,,0%,0%,,0%,51%,0%,,,,0.00%,,,,,,,,,,,1,0,0,,,,0,
11,0,China,Guangzhou,33,30.90%,Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study,Journal of Infection,Deng et. al.,https://reader.elsevier.com/reader/sd/pii/S0163445320301134?token=517FFF6E19C9C17E84812ED8214D6754AB25026D7C243B1030EA49CE191BCDD9FFAAAFB89B027FDC2CB8F9A14AA9655C,English,Yes,Observational,1/17/20,2/29/20,43,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,,43.7,,,,,49.03%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,12.24%,16.33%,14.28%,14.28%,2.06%,0.00%,8.12%,,8.12%,10.20%,,,,,,,,,,,,,,,,,,,,,32.63%,,,5.24,,,1.67,,,,,196.12,,,,,,,,,,,,,9.33,,,,,,,,,,,,61.28%,100.00%,100.00%,0.00%,0.00%,,0.00%,0.00%,0.00%,18.40%,71.48%,,32.63%,,,0.00%,,,,,,,,,,,,,,,,,,,1,,,,,,0,
11,1,China,Guangzhou,16,37.08%,Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study,Journal of Infection,Deng et. al.,https://reader.elsevier.com/reader/sd/pii/S0163445320301134?token=517FFF6E19C9C17E84812ED8214D6754AB25026D7C243B1030EA49CE191BCDD9FFAAAFB89B027FDC2CB8F9A14AA9655C,English,Yes,Observational,1/17/20,2/29/20,43,Subgroup,Combination therapy group,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,,41.8,,,,,43.80%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,12.50%,18.80%,12.50%,12.50%,0%,0%,6.20%,,6.20%,12.50%,,,,,,,,,,,,,,,,,,,,,31.20%,,0,5.34,3.52,7.16,1.83,1.01,2.65,,,194.8,139.7,249.9,,,,,,,,,,,9.23,4.26,14.2,,,,,,,,,,56.30%,100%,100%,0.00%,0.00%,,0.00%,0.00%,0.00%,6.20%,68.80%,,31.20%,,,0%,,,,,,,,,,,,,,,,,,,1,,0.94,,,,0,0
11,2,China,Guangzhou,17,37.08%,Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study,Journal of Infection,Deng et. al.,https://reader.elsevier.com/reader/sd/pii/S0163445320301134?token=517FFF6E19C9C17E84812ED8214D6754AB25026D7C243B1030EA49CE191BCDD9FFAAAFB89B027FDC2CB8F9A14AA9655C,English,Yes,Observational,1/17/20,2/9/20,23,Subgroup,Monotherapy group,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,,47.25,,,,,58.80%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,11.76%,11.70%,17.60%,17.60%,5.90%,0%,11.70%,,11.70%,5.90%,,,,,,,,,,,,,,,,,,,,,35.30%,,0,5.04,3.96,6.12,1.36,0.84,1.88,,,198.6,121.4,275.8,,,,,,,,,,,9.51,4.65,14.37,,,,,,,,,,70.60%,100%,100%,0.00%,0.00%,,0.00%,0.00%,0.00%,41.20%,76.50%,,35.30%,,,0%,,,,,,,,,,,,,,,,,,,1,,0.53,,,,0,0
12,0,China,Jiangsu,620,58.99%,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet Preprint Serve,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,No,Observational,1/10/20,2/18/20,39,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,NA,,44.48,17.16,,,,52.60%,0%,0%,100%,0%,0%,89.84%,35.00%,41.50%,6.91,6.91,,,,4.23,,,4.03%,4.84%,,,,15.48%,6.45%,2.10%,,1.10%,0.50%,,0.60%,1.00%,65.97%,37.05,,,55.32%,2.58%,,26.61%,,,,8.56%,,1.90%,,,,,15.65%,75.81%,5.30%,3.20%,0,5.21,3.24,7.18,1.36,0.72,2,616.07,427.15,190.47,127.4,253.54,3.36,1.6,5.16,135.33,115.86,154.8,0.4,41.25,31.03,32.26,10.59,3.94,17.24,4.19,67.91,127.44,21.25,,0.32,,0.52,12.44,53.55%,92.90%,,,,,,,,22.90%,25.20%,34.80%,2.90%,,5.30%,0.80%,0.00%,0.00%,81.00%,23.10%,,,8.55%,,,,0.32%,,,,,,,,1,0.03,0.41,,,,0,0
12,1,China,Jiangsu,97,58.99%,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet Preprint Serve,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,No,Observational,1/10/20,2/18/20,39,Subgroup,Asymptomatic/Mild,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,,35.96,19.88,,,,45.40%,0%,0%,100%,0%,0%,96.90%,24.70%,59.80%,4.49,4.49,,,,4.38,,,6.20%,5.20%,,,,11.30%,9.30%,3.10%,,0.00%,0%,,0%,2.90%,23.70%,36.77,,,29.90%,1.00%,,12.40%,,,,4.10%,,1.00%,,,,,100.00%,0.00%,0.00%,0.00%,0,5.68,3.8,7.56,1.76,1.04,2.48,805.05,656.73,218.88,142.36,295.4,3.38,1.96,4.8,136.26,118.06,154.46,0.41,43.46,26.78,27.31,11.78,3.73,19.83,4.47,64.57,173.73,8.94,,0.39,,0.52,12.29,15.50%,85.60%,,,,,,,,7.20%,9.30%,16.50%,0.00%,,0.00%,0.00%,0.00%,0.00%,90.70%,11.30%,,,0.00%,,,,0.00%,,,,,,,,1,0,0.36,,,,0,0
12,2,China,Jiangsu,470,58.99%,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet Preprint Serve,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,No,Observational,1/10/20,2/18/20,39,Subgroup,Moderate,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Both,,44.47,15.62,,,,52.60%,0%,0%,100%,0%,0%,88.90%,36.60%,39.40%,5.1,5.1,,,,4.19,,,4.00%,4.10%,,,,14.30%,4.90%,1.30%,,1.30%,0.40%,,0.60%,5.70%,72.60%,37.09,,,58.90%,2.70%,,24.70%,,,,9.20%,,2.30%,,,,,0.00%,100.00%,0.00%,0.00%,0,5.07,3.35,6.79,1.35,0.78,1.92,594.17,385.96,186.82,129.11,244.53,3.26,1.74,4.78,135.55,115.62,155.48,0.4,41.07,31.19,32.32,10.19,3.98,16.4,4.07,68.03,120.52,20.25,,0.33,,0.46,12.44,56.80%,93.60%,,,,,,,,18.90%,23.00%,34.00%,0.90%,,1.30%,0.00%,0.00%,0.00%,80.20%,21.30%,,,0.00%,,,,0.00%,,,,,,,,1,0.02,0.44,,,,0,0
12,3,China,Jiangsu,53,58.99%,"Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China",Lancet Preprint Serve,Liu et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548753,English,No,Observational,1/10/20,2/18/20,39,Subgroup,Severe/Critical,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,,60.09,13.86,,,,66.00%,0%,0%,100%,0%,0%,84.90%,39.60%,26.40%,4.44,4.44,,,,4.42,,,0.00%,1.90%,,,,34.00%,15.10%,7.50%,,1.90%,1.90%,,1.90%,4.80%,84.90%,37.2,,,69.80%,11.30%,,41.50%,,,,11.30%,,0%,,,,,0.00%,0.00%,62.26%,37.74%,0,5.46,1.89,9.03,0.7,0.38,1.02,364.5,231,160.95,104.91,216.99,4.19,0.59,7.79,131.24,113.51,148.97,0.39,38.13,39.32,42.86,11.73,4.68,18.78,4.78,73.71,90.09,58.09,,0.04,,1.09,12.7,94.30%,100.00%,,,,,,,,86.80%,73.60%,75.50%,26.40%,,50.90%,9.40%,0.00%,0.00%,69.80%,60.40%,,,100.00%,,,,3.80%,,,,,,,,1,0.19,0.17,,,,0,0
13,0,China,Nationwide,1099,52.25%,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,Yes,Observational,12/11/19,1/29/20,49,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,47,,,35,58,,58.10%,0%,0%,100%,0%,0%,,31.30%,,,4,2,7,,,1,,12.60%,,,,,15%,7.40%,2.50%,1.10%,0.90%,,1.40%,0.70%,,88.70%,,38.3,,67.80%,18.70%,13.60%,33.70%,14.90%,38.10%,4.80%,3.80%,5%,,13.90%,11.50%,,,,84.30%,15.70%,,,4.7,3.5,6,1,0.7,1.3,,,168,132,207,,,,134,119,148,,,,,,,,,,,,,,,,,58%,35.80%,0.00%,0.00%,35.80%,,0.00%,0.00%,0.00%,18.60%,13.10%,,41.30%,,5.10%,2.30%,0.50%,0.80%,,,,,,3.40%,,,1.10%,,,,0.50%,,,,1,0.05,0.05,,12,,0.01,0.22
13,1,China,Nationwide,926,50.56%,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,Yes,Observational,12/11/19,1/29/20,49,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,Yes,Both,Mild only,Non-ventilation only,45,,,34,57,,58.20%,0%,0%,100%,0%,0%,,31.60%,,,4,2.8,7,,,,,11.80%,,,,,13.40%,5.70%,1.80%,0.60%,0.80%,,1.20%,0.50%,,88.10%,,38.3,,67.30%,15.10%,13.40%,33.40%,14.50%,37.80%,5.10%,3.50%,4.60%,,14%,10.80%,,,,,,,,4.9,3.8,6,1,0.8,1.4,,,172,139,212,,,,135,120,148,,,,,,,,,,,,,,,,,53.80%,33.80%,0.00%,0.00%,33.80%,,0.00%,0.00%,0.00%,13.70%,9.30%,,35.70%,,0%,0%,0%,0%,,,,,,1.10%,,,0.10%,,,,0.10%,,,,1,0.02,0.05,,11,,0,0.02
13,2,China,Nationwide,173,50.56%,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,Yes,Observational,12/11/19,1/29/20,49,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,52,,,40,60,,57.80%,0%,0%,100%,0%,0%,,30.00%,,,4,2,7,,,,,16.90%,,,,,23.70%,16.20%,5.80%,3.50%,1.70%,,2.30%,1.70%,,92%,,38.5,,70.50%,37.60%,15%,35.30%,17.30%,39.90%,3.50%,5.80%,6.90%,,13.30%,15%,,,,,,,,3.7,3,6.2,0.8,0.6,1,,,137.5,99,179.5,,,,128,112,141,,,,,,,,,,,,,,,,,80.30%,46.20%,0.00%,0.00%,46.20%,,0.00%,0.00%,0.00%,44.50%,33.50%,,71.10%,,32.40%,14.50%,2.90%,5.20%,,,,,,15.60%,,,6.40%,,,,2.90%,,,,1,0.19,0.03,,13,,0.08,0.74
13,3,China,Nationwide,67,50.56%,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,Yes,Observational,12/11/19,1/29/20,49,Subgroup,ICU/Venitlation/Death,Positive and Negative/Unconfirmed,End-point and active,Both,Both,Yes,Both,All,Both,63,,,53,71,,67.20%,0%,0%,100%,0%,0%,,35.70%,,,4,1,7.5,,,,,25.80%,,,,,35.80%,26.90%,9.00%,10.40%,1.50%,,6.00%,3.00%,,88.10%,,38.5,,68.70%,53.70%,12%,29.90%,9.00%,32.80%,3.00%,6.00%,4.50%,,9%,11.90%,,,,,,,,6.1,4.9,11.1,0.7,0.6,0.9,,,156.5,114.2,195,,,,125,105,140,,,,,,,,,,,,,,,,,89.60%,53.70%,0.00%,0.00%,53.70%,,0.00%,0.00%,0.00%,52.20%,40.30%,,88.10%,,43.30%,37.30%,7.50%,11.90%,,,,,,40.30%,,,13.40%,,,,40.30%,,,,1,0.82,0.02,,14.5,,0.22,0.94
13,4,China,Nationwide,1032,50.56%,Clinical Characteristics of Coronavirus Disease 2019 in China,NEJM,Guan et al.,https://www.nejm.org/doi/full/10.1056/NEJMoa2002032,English,Yes,Observational,12/11/19,1/29/20,49,Subgroup,Not (ICU/Ventilation/Death),Positive and Negative/Unconfirmed,End-point and active,Survivors only,Both,Yes,Non-ICU only,All,Both,46,,,35,57,,57.50%,0%,0%,100%,0%,0%,,31.10%,,,4,2,7,,,,,11.80%,,,,,13.70%,6.10%,2.00%,0.50%,0.90%,,1.10%,0.60%,,88.80%,,38.3,,67.70%,16.40%,14%,33.90%,15.30%,38.50%,4.90%,3.70%,5.00%,,14.20%,11.40%,,,,,,,,4.7,3.5,5.9,1,0.7,1.3,,,169,133,207,,,,134,120,148,,,,,,,,,,,,,,,,,55.90%,34.60%,0.00%,0.00%,34.60%,,0.00%,0.00%,0.00%,16.40%,11.30%,,38.30%,,2.60%,0.00%,0.00%,0.10%,,,,,,1.00%,,,0.30%,,,,1.00%,,,,1,0,0.05,,12,,0,0
16,0,China,Wuhan,41,56.74%,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,Yes,Observational,12/16/19,1/2/20,17,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,49,,,41,58,,73%,0%,0%,100%,0%,0%,66%,66%,,,,,,,7,4,8,7%,,,,32%,15%,20%,15%,2%,2%,2%,,,2%,98%,,,29%,76%,55%,,28%,44%,44%,,3%,,,,,,,,,,,1,6.2,4.1,10.5,0.8,0.6,1.1,,,164.5,131.5,263,5,,,126,118,140,,31.4,32,34,11.7,9.5,13.9,,74.2,132.5,,,,0.1,0.5,11.1,100%,93%,0%,0%,93%,,0%,0%,0%,22%,,66%,24%,,24%,5%,5%,7%,,,,29%,,29%,,12%,,,,,7%,10%,,,1,0.32,0.68,,,,0.15,0.18
16,1,China,Wuhan,13,56.74%,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,Yes,Observational,12/16/19,1/2/20,17,Subgroup,ICU,Positive only,End-point and active,Both,Both,Yes,ICU only,All,Both,49,,,41,61,,85%,0%,0%,100%,0%,0%,69%,69%,,,,,,,7,4,8,0%,,,,38%,15%,8%,23%,8%,0%,0%,,,0%,100%,,,62%,85%,92%,,38%,54%,54%,,0%,,,,,,,,,,,1,11.3,5.8,12.1,0.4,0.2,0.8,,,196,165,263,10.6,,,122,111,128,,27.9,49,44,14,11.9,32.9,,79,132,,,,0.1,2.4,12.2,100%,92%,0%,0%,92%,,0%,0%,0%,46%,,8%,62%,,62%,15%,15%,23%,,,,85%,,85%,,31%,,,,,23%,31%,,,1,1,0.54,,,,0.38,0.41
16,2,China,Wuhan,28,56.74%,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.",The Lancet,Huang et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext?fbclid=IwAR21v_Wz-pmaEN9TwZd1aVhOLMU6YesDciWbVkZYZAvhrX5Eru23uYA_jLk,English,Yes,Observational,12/16/19,1/2/20,17,Subgroup,Non-ICU,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,All,Both,49,,,41,57.5,,68%,0%,0%,100%,0%,0%,64%,64%,,,,,,,7,4,8.5,11%,,,,29%,14%,25%,11%,0%,4%,4%,,,4%,96%,,,14%,71%,37%,,23%,39%,39%,,4%,,,,,,,,,,,1,5.7,3.1,7.6,1,0.7,1.1,,,149,131,263,4.4,,,130.5,120,140,,34.7,27,34,10.8,9.4,12.3,,73.3,133,,,,0.1,0.5,10.7,100%,93%,0%,0%,93%,,0%,0%,0%,11%,,93%,7%,,7%,0%,0%,0%,,,,4%,,4%,,4%,,,,,0%,0%,,,1,0,0.75,,,,0.04,0.05
17,0,China,Wuhan,99,52.25%,"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study",The Lancet,Chen et al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext?from=Qikan_Academic_Index,English,Yes,Observational,1/1/20,1/20/20,19,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,55.5,13.1,,,,68%,0%,0%,100%,0%,0%,49%,,,,,,,,,,,,,,,33%,,12%,,1%,1%,,,,17%,83%,,,,82%,31%,8%,,11%,,,2%,1%,,5%,,,,,,,,1,7.5,3.9,11.1,0.9,0.4,1.4,,,213.5,,,5,,,129.8,111.5,144.6,,31.6,39,34,15.1,7.8,22.4,5.9,75.6,85,51.4,,7.9,0.5,0.9,11.3,71%,76%,76%,0%,76%,,0%,0%,0%,19%,27%,76%,,,13%,4%,3%,9%,0%,0%,,,,17%,,,4%,,,,3%,,,,1,0.23,0.31,,,,0.11,0.26
18,1,China,Zhejiang,26,25.28%,The Clinical Characteristics of Myocardial injury 1 in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease,Journal of Infection,Zhou et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301493,English,Yes,Observational,2/5/20,2/13/20,8,Subgroup,Severe,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,63,,,58,69,,46.15%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,0%,,,,,,,,,,100%,,,,,,,,,,,,,,,,0%,100%,0%,0,5.93,4.77,7.45,,,,,,,,,,,,,,,,,34,32,,,,,64.2,88,18.87,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,,
18,2,China,Zhejiang,8,25.28%,The Clinical Characteristics of Myocardial injury 1 in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease,Journal of Infection,Zhou et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301493,English,Yes,Observational,2/5/20,2/13/20,8,Subgroup,Critical,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,67,,,66,75,,62.50%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,0%,,,,,,,,,,100%,,,,,,,,,,,,,,,,0%,0%,100%,0.00%,9.32,6.37,10.99,,,,,,,,,,,,,,,,,49,44,,,,,82.6,199,73,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,,
19,0,China,Wuhan,138,62.92%,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,Yes,Observational,1/1/20,2/3/20,33,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,56,56,,42,68,29%,54.30%,0%,0%,100%,0%,0%,8.70%,8.70%,,,,,,7,7,4,8,,,,,46.40%,31.20%,10.10%,14.50%,2.90%,7.20%,2.90%,5.10%,2.90%,1.40%,98.60%,,,,59.40%,31.20%,6.50%,26.80%,34.80%,69.60%,,10.10%,10.10%,39.90%,,,,,0%,26%,0%,26.08%,1,4.5,3.3,6.2,0.8,0.6,1.1,,,163,121,191,3,2,4.9,,,,,,24,31,9.8,8.4,14.1,4.4,72,92,,,,49,203,13,64.40%,89.90%,0.00%,0%,89.90%,,0.00%,0.00%,0.00%,44.90%,0.00%,76.81%,,,10.90%,12.32%,2.90%,1.45%,,,,19.60%,,19.60%,,,8.70%,,,7.20%,3.60%,,,,1,0.26,0.34,10,10,,0.04,0.11
19,1,China,Wuhan,36,61.80%,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,Yes,Observational,1/1/20,2/3/20,33,Subgroup,Non-ICU,Positive only,End-point and active,Survivors only,Both,Yes,ICU only,All,Both,66,66,,57,78,2.80%,61.10%,0%,0%,100%,0%,0%,13.90%,13.90%,,,,,,8,8,4.5,10,,,,,72.20%,58.30%,22.20%,25%,8.30%,11.10%,0.00%,16.70%,5.60%,0%,100.00%,,,,58.30%,63.90%,8.30%,22.20%,33.30%,80.60%,,16.70%,11.10%,66.70%,,,,,0%,0%,0%,0%,1,6.6,3.6,9.8,0.8,0.5,0.9,,,142,119,202,4.6,2.6,7.9,,,,,,35,52,11.5,9.6,18.6,5.9,80,102,,,,27,414,13.2,,94.40%,0%,0%,94.40%,,0%,0%,0%,72.20%,0%,11.11%,,,42%,47%,11.10%,5.56%,,,,61.10%,,61.10%,,,30.60%,,,22.20%,8.30%,,,,1,1,0.25,10,,,0.17,0.4
19,2,China,Wuhan,102,61.80%,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China",JAMA,Wang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761044,English,Yes,Observational,1/1/20,2/3/20,33,Subgroup,ICU,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Severe/Critical Only,Non-ventilation only,51,51,,37,62,38.20%,52%,0%,0%,100%,0%,0%,6.90%,6.90%,,,,,,6,6,3,7,,,,,37.30%,21.60%,5.90%,10.80%,1%,5.90%,4%,1%,2%,2%,98.00%,,,,59.80%,19.60%,5.90%,28.40%,35.30%,65.70%,,7.80%,9.80%,30.40%,,,,,0%,100%,0%,100%,1,4.3,3.3,5.4,0.9,0.6,1.2,,,165,125,188,2.7,1.9,3.9,,,,,,23,39,9.3,8.2,12.8,4,71,87,,,,22,166,12.9,,88.20%,0%,0%,88.20%,,0%,0%,0%,35.30%,0%,100%,,,0%,0%,0%,0%,,,,4.90%,,4.90%,,,1.00%,,,2%,2.00%,,,,1,0,0.37,,10,,0,0
20,0,China,Beijing,13,33.71%,"Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China",JAMA,Chang et al.,https://jamanetwork.com/journals/jama/fullarticle/2761043,English,Yes,Observational,1/16/20,2/4/20,19,Top-level,General,Positive only,Active only,Survivors only,Both,No,ΝΑ,Mild only,NA,34,,,34,48,,77%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,92.31%,,38.4,,46.30%,,23.10%,,23.10%,,61.50%,7.70%,,,,,,,,,0%,0%,0,5.83,3.51,8.15,1.58,0.93,2.23,,,199,126.5,271.5,3.67,,,147,134.9,159.1,43.2,,,,,,,,,,14.7,,,0.19,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
21,0,China,Beijing,51,30.90%,Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia,Radiology,Song et al.,https://pubs.rsna.org/doi/pdf/10.1148/radiol.2020200274,English,Yes,Observational,1/20/20,1/27/20,7,Top-level,General,Positive only,Active only,Survivors only,Discharged only,No,ΝΑ,Mild only,NA,,49,16,,,,49%,0%,0%,100%,0%,0%,98%,,,,,,,,4,,,7%,,,,22%,10%,6%,2%,0%,0%,2%,,0%,4%,96%,,,,47%,14%,16%,,16.50%,16.50%,,10%,6%,,,,,,,0%,0%,0%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,na,,,,,
22,0,China,Northeast Chongqing,135,55.06%,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,Yes,Observational,1/23/20,2/8/20,16,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,47,,,36,55,,53.40%,0%,0%,100%,0%,0%,88.90%,,17.00%,,,,,,,,,6.70%,,,,31.90%,9.60%,8.90%,5.20%,0%,3%,1.50%,,,,88.90%,,,,76.50%,13.30%,32.50%,8.80%,32.50%,32.50%,,13.30%,3%,,,,,,,70%,30%,,1,5.4,4.1,7.8,1.1,0.7,1.5,,,158,131,230,3.5,,,133,122,147,,40.5,26,33.4,8.6,5.9,13.7,,66,82.2,10.5,,,0.11,0.4,,43.70%,100%,100%,0%,0%,,0%,0%,0%,26.70%,,,,,25.20%,0.70%,0%,3.70%,100.00%,,,,,15.60%,,,0.70%,,,7.40%,3.70%,5.20%,,,0.89,,0.11,,,,0.01,0.06
22,1,China,Northeast Chongqing,95,53.93%,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,Yes,Observational,1/23/20,2/8/20,16,Subgroup,Mild,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Both,44,,,33,49,,54.70%,0%,0%,100%,0%,0%,90.50%,,18.90%,,,,,,,,,8.40%,,,,16.30%,9.40%,3.10%,1%,0%,1%,1%,,,,90.10%,,,,70.50%,9.50%,24.20%,5.30%,26.30%,26.30%,,5.30%,4.20%,,,,,,,,,,1,5.5,4,8,1.2,0.8,1.6,,,170,136,234,3.6,,,134,124,147,,49.9,21.7,22.4,8.6,5.6,14,,66,57,7.7,,,0.04,0.3,,25%,100%,100%,0%,0%,,0%,0%,0%,15.80%,,,,,7.40%,0%,0%,1%,100%,,,,,1.10%,,,0%,,,8.40%,4%,0%,,,0.9,,0.11,,,,0,0
22,2,China,Northeast Chongqing,40,53.93%,Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing,JMV,Wan et al.,https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25783,English,Yes,Observational,1/23/20,2/8/20,16,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,56,,,52,73,,52.50%,0%,0%,100%,0%,0%,85.00%,,12.50%,,,,,,,,,2.50%,,,,70%,10%,22.50%,15%,10%,7.50%,2.50%,,,,85.00%,,,,87.50%,18.90%,27.50%,17.50%,47.50%,47.50%,,32.50%,0%,,,,,,,,,,1,5.2,4.9,6.9,0.8,0.6,1,,,147,118,213,4.1,,,130,130,143,,36,26.6,33.6,9.8,7.8,15.6,,63.5,82,91,,,0.11,0.6,,87.50%,100%,100%,0.00%,0.00%,,0.00%,0.00%,0.00%,52.50%,,,,,67.50%,2.50%,0%,10%,100%,,,,,50%,,,2.50%,,,5%,2.50%,2.50%,,,0.88,,0.13,,,,0.03,0.17
23,0,China,Wuhan,17,42.70%,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,No,Observational,1/22/20,2/10/20,19,Top-level,General,Positive only,End-point and active,Survivors only,Both,No,ΝΑ,All,NA,,45.1,12.8,,,,53%,0%,0%,100%,0%,0%,65%,,,,,,,,,,,18%,18%,25,,18%,6%,0%,0%,0%,0%,,,0%,18%,71%,,,,77%,,,17.60%,24%,47%,,12%,,,,,,,,,,,1,6.2,3.7,8.7,1.1,0.6,1.6,,,227.1,115.5,338.7,4.6,1.8,7.4,140.5,127.4,153.6,,,,,17.7,4.2,31.2,,65.8,114.9,32.1,,,0.06,217.4,11.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.29,,8.4,,0,0
23,1,China,Wuhan,5,42.70%,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,No,Observational,1/22/20,2/10/20,19,Subgroup,Discharged,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,NA,,34.8,9.2,,,,80%,0%,0%,100%,0%,0%,100%,,,,,,,,,,,40%,20%,24.1,,40%,0%,0%,0%,0%,0%,,,0%,40%,80%,,,,60%,,,0%,60%,60%,,0%,,,,,,,,,,,1,6.3,4.8,7.8,1.7,1.3,2.1,,,295,149.3,440.7,3.9,2.3,5.5,146.3,139.6,153,,,,,12.2,7.4,17,,70.5,93.3,28.6,,,0.05,105.7,11.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,8.6,,0,0
23,2,China,Wuhan,12,41.57%,"Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China",MedRxiv,Li et. al.,https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1.full.pdf,English,No,Observational,1/22/20,2/10/20,19,Subgroup,Non-Discharged,Positive only,Active only,Survivors only,Non-discharged only,No,ΝΑ,All,NA,,49.4,11.7,,,,41.70%,0%,0%,100%,0%,0%,50%,,,,,,,,,,,8.30%,16.70%,25.3,,8.30%,8.30%,0%,0%,0%,0%,,,0%,8.30%,66.70%,,,,83.30%,,,25%,16.70%,41.70%,,16.70%,,,,,,,,,,,1,6.1,3.2,9,0.9,0.5,1.3,,,202,109.5,294.5,4.9,1.7,8.1,138.5,124.1,152.9,,,,,19.3,4.5,34.1,,64.1,122.7,33.4,,,0.07,250.9,11.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,0,
24,0,China,Wuhan,48,37.64%,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,No,Observational,12/25/19,2/15/20,52,Top-level,General,Positive and Negative/Unconfirmed,End-point and active,Both,Both,Yes,Both,All,NA,,70.58,13.38,,,,68.70%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,66.70%,20.80%,27.10%,,,,,10.40%,14.60%,70.80%,,,,,,,,,,,,,,,,,,,54.20%,45.80%,,0,6.49,4.15,8.83,0.99,0.62,1.31,,,167,116,217.5,4.6,,,122.92,101.9,143.94,,,21,32,,,,,80,85,43.2,,,,0.63,,95.80%,97.90%,,,,,,,,45.80%,12.50%,60.40%,,,37.50%,2.10%,,,,,,,,,,,,,,,,,,,1,,0.65,,,,0.35,0.35
24,1,China,Wuhan,17,37.64%,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,No,Observational,12/25/19,2/15/20,52,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,Both,Severe/Critical Only,NA,,78.61,8.31,,,,70.60%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,70.60%,29.40%,23.50%,,,,,29.40%,17.60%,70.60%,,,,,,,,,,,,,,,,,,,23.50%,76.50%,,0,8.84,5.46,9.67,0.92,0.51,1.29,,,119,88.5,212.5,3.9,,,111.35,87.39,135.31,,,19,33,,,,,96,104.5,65.5,,,,2.3,,100.00%,100.00%,,,,,,,,47.10%,23.50%,11.80%,,,82.40%,5.90%,,,,,,,,,,,,,,,,,,,1,,0,,,,1,1
24,2,China,Wuhan,31,37.08%,"Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study",medRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040121v1.full.pdf,English,No,Observational,12/25/19,2/15/20,52,Subgroup,Survivors,Positive and Negative/Unconfirmed,End-point and active,Survivors only,Both,Yes,Both,All,NA,,66.16,13.66,,,,67.70%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,64.50%,16.10%,29.00%,,,,,0.00%,12.90%,71.00%,,,,,,,,,,,,,,,,,,,71.00%,29.00%,,0,5.74,4.14,7.39,1.08,0.66,1.33,,,181,146,220,4.9,,,29.26,112.86,145.66,,,23,32,,,,,79,83,23.8,,,,0.57,,93.50%,96.80%,,,,,,,,45.20%,6.50%,87.10%,,,12.90%,0.00%,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
25,0,USA,Washington,21,28.65%,Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State,JAMA,Arentz et al.,https://jamanetwork.com/journals/jama/fullarticle/2763485,English,Yes,Observational,2/20/20,3/5/20,14,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ICU only,All,NA,,70,,,,,52%,,,,,,,,,,,,,,,,,,,,,86%,,33.30%,,33.30%,,,,47.60%,42.90%,52%,37.6,39.2,,48%,76%,,,,,,,,,,,,,,,,,1,9.37,,,0.89,,,,,215,,,,,,114,,,,,26.5,34,,,,,,95,,,,,,,,,,,,,,,,,,,4.80%,,19%,71%,,,,,,,,,,,,14.30%,,,19.10%,19.10%,,,1,1,0.1,,,,0.67,0.88
26,0,Singapore,Singapore,18,43.26%,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,Yes,Observational,1/23/20,2/25/20,33,Top-level,General,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,47,,,31,73,0%,50%,0%,0%,100%,0%,0%,100%,100%,,,,,,,,,,,,,,28%,28%,11%,,,,,,,,72%,37.7,39.6,,83%,11%,,,,,,17.00%,22.20%,,61%,,,,,,,,1,4.6,1.7,6.3,1.2,0.8,1.7,,,159,116,217,2.7,,,135,11.7,17.2,,,,,,,,,,,16.3,,,,,,27.78%,27.78%,27.78%,0%,27.78%,,0%,0%,0%,0%,,,,33%,6%,,,,,,,,,,,,,,,,,,,,1,0.11,1,0.67,18,12.5,0,0
26,1,Singapore,Singapore,12,42.70%,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,Yes,Observational,1/23/20,2/25/20,33,Subgroup,Did not require supplemental oxygen,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,37,,,31,56,0%,58%,0%,0%,100%,0%,0%,100%,100%,,,,,,,,,,,,,,8%,8%,8.30%,,,,,,,,58%,38.3,39.6,,83%,8%,,,,,,25.00%,,,67.00%,,,,,,,,1,4.6,1.7,6.3,1.2,0.8,1.6,,,159,128,213,2.8,,,139,11.7,17.2,,,,,,,,,,,11.1,,,,,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,,,,0%,6%,,,,,,,,,,,,,,,,,,,,1,0,1,0,19.5,14.5,0,0
26,2,Singapore,Singapore,6,43.26%,Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore,JAMA,Young et al.,https://jamanetwork.com/journals/jama/fullarticle/2762688,English,Yes,Observational,1/23/20,2/25/20,33,Subgroup,Required supplemental oxygen,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,56,,,47,73,0%,33%,0%,0%,100%,0%,0%,100%,100%,,,,,,,,,,,,,,67%,67%,16.70%,,,,,,,,100%,37.3,38.1,,83%,17%,,,,,,0.00%,,,50%,,,,,,,,1,3.4,2.6,5.8,1.1,0.8,1.7,,,156,116,217,1.8,,,132,11.7,14,,,,,,,,,,,65.6,,,,,,83.33%,83.33%,83.33%,0%,83.33%,,0%,0%,0%,0%,,,,100%,6%,,,,,,,,33.33%,,,,,,,,,,,,1,0.33,1,2,14.5,10.5,0,0
27,0,Italy,Nationwide,355,23.60%,Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy,JAMA,Onder et al.,https://jamanetwork.com/journals/jama/fullarticle/2763667?appId=scweb,English,Yes,Observational,2/15/20,3/17/20,31,Top-level,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,80,79.5,,,,,70%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,98.20%,,35.50%,30%,24.50%,20.30%,,,,10%,,,,,,,,,,,,,,,,,,,0%,100%,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.5,0,,,,1,1
28,0,China,Wuhan,201,51.69%,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,Yes,Observational,12/25/19,1/26/20,32,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,51,,,43,60,,63.70%,0%,0%,100%,0%,0%,49.30%,49.30%,,,,,,,,,,,,,,,19.40%,10.90%,4%,2.50%,0.50%,4%,,1%,7%,93.50%,38.8,,,81.10%,,,,32.30%,32.30%,,,,,,,,,,,,,0,5.94,3.37,7.18,0.91,0.6,1.29,353,236,180,137,241.5,4.47,,,,,,,32.75,31,33,11.45,9,14.75,4.8,72.2,,42.4,,6.98,,0.61,11.1,97.50%,84.60%,14.90%,0%,66.70%,,0%,0%,0%,0%,34.80%,48.72%,,,30.34%,2.51%,0.50%,0.00%,10.90%,,,,,41.80%,,,,,,,,,,,1,0.26,0.72,,13,,0.22,0.23
28,1,China,Wuhan,84,44.94%,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,Yes,Observational,12/25/19,1/26/20,32,Subgroup,ARDS,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Ventilation only,58.5,,,50,69,,71.40%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,27.40%,19%,6%,,,,,,,92.90%,39,,,81%,,,,32.10%,32.10%,,,,,,,,,,,,,0,5.02,3.37,7.18,1.08,0.72,1.45,371,234,178,140,239.5,3.06,,,,,,,33.7,27,30,10.5,8.6,13.65,4.3,68.7,,23.4,,6.29,,0.52,10.6,98.80%,76.20%,,0%,,,0%,0%,0%,0%,,20.20%,,,72.60%,6%,1.20%,0%,,,,,,100%,,,,,,,,,,,1,0.63,0.17,,,,0.52,0.76
28,2,China,Wuhan,117,44.94%,"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China",JAMA,Wu et al.,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184,English,Yes,Observational,12/25/19,1/26/20,32,Subgroup,Non-ARDS,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Non-ventilation only,48,,,40,54,,58.10%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,13.70%,5.10%,2.60%,,,,,,,94.00%,38.6,,,82.20%,,,,32.50%,32.50%,,,,,,,,,,,,,0,8.32,5.07,11.2,0.67,0.49,0.99,241,157.5,187,124.5,252.5,7.04,,,,,,,30.4,35,38,12.9,9.5,17.05,5.8,74.6,,83,,7.39,,1.16,11.7,96.60%,90.60%,,0%,,,0%,0%,0%,0%,,69.20%,,,0%,0%,0%,0%,,,,,,0%,,,,,,,,,,,1,0,1,,,,0,0
30,1,China,Xi'an,17,34.83%,"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial",medRxiv,Bian et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,English,No,Unknown,2/3/20,2/10/20,7,Subgroup,Meplazumab,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,51,,,49,67,,64.70%,0%,0%,100%,0%,0%,,58.80%,5.90%,,,,,,,,,5.90%,,,,52.90%,35.30%,17.60%,5.90%,5.90%,,,,,,94.10%,,37.7,41.20%,52.90%,58.80%,,5.90%,58.80%,58.80%,,11.80%,,,,,,,,23.50%,35.30%,41.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,100%,0.00%,0.00%,,0.00%,0.00%,0.00%,94.10%,0%,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0.76,,,,,
30,2,China,Xi'an,11,34.83%,"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial",medRxiv,Bian et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,English,No,Unknown,2/3/20,2/10/20,7,Subgroup,No meplazumab,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,64,,,43,67,,45.50%,0%,0%,100%,0%,0%,,36.40%,18.20%,,,,,,,,,9.10%,,,,36.40%,27.30%,0%,18.20%,0,,,,,,100%,,37.7,45.50%,63.60%,63.60%,,18.20%,45.50%,45.50%,,9.10%,,,,,,,,36.40%,36.40%,27.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,90.90%,100%,100%,0.00%,0.00%,,0.00%,0.00%,0.00%,63.60%,0%,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0.36,,,,,
31,0,China and outside China,,507,19.66%,Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population- level observational study,Lancet,Sun et al.,https://www.thelancet.com/action/showPdf?pii=S2589-7500%2820%2930026-1,English,Yes,Observational,1/20/20,1/31/20,11,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,46,,35,60,,55%,0%,0%,100%,0%,0%,,,,4.5,4.8,3,6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,0.08,
32,0,China,Beijing,262,23.03%,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,Yes,Observational,1/20/20,2/10/20,21,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,47.5,,,,,,48.50%,0%,0%,100%,0%,0%,92%,40.50%,49.20%,,6.7,,,,,,,,,,,,,,,,,,,,,82.10%,,37.7,,45.80%,6.90%,6.50%,,,26.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.82,,0.17,,,,0.01,0.05
32,1,China,Beijing,46,23.03%,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,Yes,Observational,1/20/20,2/10/20,21,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,61.4,,,,,,56.50%,0%,0%,100%,0%,0%,89.10%,28.30%,56.50%,,7.5,,,,,,,,,,,,,,,,,,,,,80.40%,,37.7,,54.30%,32.60%,6.50%,,,32.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.89,,0.04,,,,0.07,0.6
32,2,China,Beijing,216,23.03%,Characteristics of COVID-19 infection in Beijing,Journal of Infection,Tian et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301018,English,Yes,Observational,1/20/20,2/10/20,21,Subgroup,Common,Positive only,End-point and active,Survivors only,Both,No,ΝΑ,Mild only,NA,44.5,,,,,,46.80%,0%,0%,100%,0%,0%,92.60%,43.10%,47.70%,,6.5,,,,,,,,,,,,,,,,,,,,,82.40%,,37.7,,44.00%,1.40%,6.50%,,,25.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.8,,0.2,,,,0,0
35,1,China,Anhui,6,21.35%,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,Yes,Observational,1/21/20,2/3/20,13,Subgroup,Mild,Positive only,End-point and active,,Both,Yes,,Mild only,,,29.2,10.9,,,,50%,0%,0%,100%,0%,0%,,67%,33%,,,,,,,,,,,,,,,,,,,,,,,83%,,,,67%,,0%,17%,,67%,,,,0,11%,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
35,2,China,Anhui,43,21.35%,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,Yes,Observational,1/21/20,2/3/20,13,Subgroup,Common,Positive only,End-point and active,,Both,Yes,,Mild only,,,33.4,12.2,,,,65%,0%,0%,100%,0%,0%,,67%,28%,,,,,,,,,,,,,,,,,,,,,,,93%,,,,84%,,11%,51%,,72%,,,,19%,7%,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
35,3,China,Anhui,21,21.35%,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,Yes,Observational,1/21/20,2/3/20,13,Subgroup,Severe,Positive only,End-point and active,,Both,Yes,,Severe/Critical Only,,,44.2,12,,,,48%,0%,0%,100%,0%,0%,,85%,10%,,,,,,,,,,,,,,,,,,,,,,,95%,,,,86%,,10%,67%,,81%,,,,43%,10%,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
35,4,China,Anhui,3,20.79%,CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity,European Journal of Radiology,Liu et al.,https://www.sciencedirect.com/science/article/pii/S0720048X20301303,English,Yes,Observational,1/21/20,2/3/20,13,Subgroup,Critical,Positive only,End-point and active,,Both,Yes,,Severe/Critical Only,,,63,21.2,,,,0%,0%,0%,100%,0%,0%,,100%,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,67%,,33%,67%,,100%,,,,100%,0%,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
37,1,China,Beijing,9,20.22%,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,Yes,Observational,1/1/20,2/21/20,51,Subgroup,Mild,Positive only,Active only,Both,Both,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,78%,0%,0%,100%,0%,0%,,89%,11%,,,,,,,,,,,,,,,,,,,,,,,67%,,,,33%,,,11%,0%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
37,2,China,Beijing,28,20.22%,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,Yes,Observational,1/1/20,2/21/20,51,Subgroup,Moderate,Positive only,Active only,Both,Both,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,54%,0%,0%,100%,0%,0%,,57%,39%,,,,,,,,,,,,,,,,,,,,,,,96%,,,,39%,,,14%,14%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
37,3,China,Beijing,10,20.22%,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,Yes,Observational,1/1/20,2/21/20,51,Subgroup,Severe,Positive only,Active only,Both,Both,No,Non-ICU only,Severe/Critical Only,Non-ventilation only,,,,,,,70%,0%,0%,100%,0%,0%,,60%,40%,,,,,,,,,,,,,,,,,,,,,,,80%,,,,40%,,,10%,30%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
37,4,China,Beijing,3,20.22%,Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2,Journal of Infection,Xu et al.,https://www.sciencedirect.com/science/article/pii/S0163445320301006,English,Yes,Observational,1/1/20,2/21/20,51,Subgroup,Critically Severe,Positive only,Active only,Both,Both,No,ICU only,Severe/Critical Only,Both,,,,,,,0%,0%,0%,100%,0%,0%,,0%,67%,,,,,,,,,,,,,,,,,,,,,,,67%,,,,67%,,,33%,33%,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0,
38,0,China,Shanghai,249,43.26%,"Clinical progression of patients with COVID-19 in Shanghai, China",Journal of Infection,Chen et al. ,https://www.sciencedirect.com/science/article/pii/S0163445320301195,English,Yes,Observational,1/20/20,2/6/20,17,Top-level,General,Positive only,End-point and active,Both,Both,No,Both,All,NA,51,51,,36,64,,50.60%,0%,0%,100%,0%,0%,,,,,,,,4,4,2,7,,,,,36.10%,21.70%,,,,0.40%,,,,16.40%,87.10%,,,,36.50%,7.60%,11.20%,,,15.70%,,3.20%,,3.20%,6.40%,,,,2.80%,10%,5%,5%,1,4.71,3.8,5.86,1.12,0.79,1.49,431,256.54,,,,,,,,,,,40.8,23,25,,,,,12,,12,,,,,,,,,0%,0%,,,,0%,12.90%,,,,,,,,,,,,,,3.20%,,,,,,,,,,,1,0.09,0.86,31,16,11,0.01,0.01
39,1,China,Zhejiang,72,50.56%,"Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings",Intl Journal of Infectious Disease,Zhang et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301727,English,Yes,Observational,1/17/20,2/8/20,22,Subgroup,Normal Imaging Findings,Positive only,Active only,Both,Both,Yes,ΝΑ,All,NA,,34.9,14.2,,,,45.80%,0%,0%,100%,0%,0%,,91.70%,8.30%,,,,,,,,,,,,,16.70%,5.60%,5.60%,0%,0%,0%,,,0%,4.20%,66.70%,,,,45.80%,0,2.80%,23.60%,7%,12.50%,,11.10%,,,23.60%,,,,,,,,1,5.42,3.42,7.42,1.39,0.78,2,,,198.44,140,256.88,3.48,,,141.04,125.42,156.66,,42.53,25.53,26.67,9.11,4.25,13.97,3.9,65.54,62.5,2.3,6.57,,0.05,,,,77.80%,,0%,0%,,,,0%,0%,,11.10%,,,0,0,0%,0%,,0%,,,,0%,,,,8.30%,,,0%,,,,1,0,na,,,,,
39,2,China,Zhejiang,573,50.56%,"Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings",Intl Journal of Infectious Disease,Zhang et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301727,English,Yes,Observational,1/17/20,2/8/20,22,Subgroup,Abnormal Imaging Findings,Positive only,Active only,Both,Both,Yes,ΝΑ,All,NA,,46.65,13.82,,,,51.50%,0%,0%,100%,0%,0%,,81.00%,19%,,,,,,,,,,,,,28.80%,16.80%,7.70%,1%,0%,1%,,,1%,6.50%,85.90%,,,,68.40%,4.50%,11.30%,36%,11.50%,19%,,7.90%,,,14%,,,,,,,,1,5.01,3.14,6.88,1.23,0.71,1.75,,,185.22,122.8,247.64,3.29,,,138.09,121.62,154.56,,41.02,29.37,30.08,11.26,3.22,19.3,4.04,69.17,73,8.8,6.62,,0.05,,,,85.20%,,0%,0%,,,,0%,13.40%,,43.60%,,,1.60%,1.60%,0%,0%,,0%,,,,2.40%,,,,13.10%,,,0.30%,,,,1,0.01,na,,,,,
40,1,China,Changzhou,15,40.45%,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,Intl Journal of Innfectious Diseases,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,English,Yes,Observational,1/23/20,2/18/20,26,Subgroup,Imported contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,35,,,29,51,,66.70%,0%,0%,100%,0%,0%,,,,,8,4,10,,,,,,,,,0%,,0%,0%,0%,,0%,,0%,0%,73.30%,,,,33.30%,13.30%,,20%,26.70%,6.70%,,13.30%,,,,,,,,100%,,,1,5.2,4.6,6.3,1.5,0.9,2.1,399,287,,,,,,,,,,,,22.9,19,,,,,,,4.4,,,,,,,100%,0%,0%,0%,,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,14,14,0,0
40,2,China,Changzhou,17,40.45%,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,Intl Journal of Innfectious Diseases,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,English,Yes,Observational,1/23/20,2/18/20,26,Subgroup,Secondary contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,37,,,24,47.5,,41.20%,0%,0%,100%,0%,0%,,,,,8,4,11,,,,,,,,,23.50%,,5.90%,11.80%,0%,,0.00%,,5.90%,0%,58.80%,,,,52.90%,5.90%,,35.30%,11.80%,0%,,5.90%,,,,,,,,100%,,,1,4.8,3.4,6.2,1.1,1,1.9,375,267,,,,,,,,,,,,13.5,17,,,,,,,2.2,,,,,,,100%,0%,0%,0%,,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,14,14,0,0
40,3,China,Changzhou,19,40.45%,Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19,Intl Journal of Innfectious Diseases,Xu et al.,https://www.sciencedirect.com/science/article/pii/S1201971220301417,English,Yes,Observational,1/23/20,2/18/20,26,Subgroup,Terciary contact,Positive only,End-point only,Both,Both,No,ΝΑ,Mild only,NA,53,,,35,65,,42.10%,0%,0%,100%,0%,0%,,,,,12,9,14,,,,,,,,,42.10%,,15.80%,15.80%,5.30%,,5%,,0%,5.30%,68.40%,,,,47.40%,5.30%,,21.10%,10.50%,10.50%,,10.50%,,,,,,,,100%,,,1,3.9,3.1,5.7,1.3,0.9,1.6,374,303,,,,,,,,,,,,25.2,22,,,,,,,7,,,,,,,100%,0%,0%,0%,,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,11,11,0,0
41,0,China,Xiaogan,114,27.53%,Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area,COVID-19) in the Xiaogan area,Wang et al.,https://www.sciencedirect.com/science/article/pii/S000992602030088X,English,Yes,Observational,1/25/20,2/9/20,15,Top-level,General,Positive only,Active only,Both,Both,No,ΝΑ,Mild only,NA,53,,,23,78,,50.90%,0%,0%,100%,0%,0%,78.90%,,,,,,,,,,,,,,,52.60%,28.90%,13.20%,6.10%,4.40%,0.90%,,,,5.30%,93.90%,,38.6,,79.80%,23.70%,,7.90%,,,,2.70%,,,5.30%,,,,,100.00%,0.00%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,,
42,0,China,Shandong,537,14.61%,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,,1/19/20,2/15/20,27,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,,,,,,,,55.70%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,87.90%,,,,35.90%,,,,,8.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,
42,1,China,Shandong,509,12.36%,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,,1/19/20,2/15/20,27,Subgroup,Common,Positive only,End-point and active,Both,Both,Yes,Both,Mild only,,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.32,,,,,
42,2,China,Shandong,16,13.48%,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,,1/19/20,2/15/20,27,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,,,,,,,,62.50%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,68.80%,98.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,3,China,Shandong,12,12.36%,山东省新型冠状病毒肺炎患者 537 例临床特征与救治效果,山东大学学报(医学版),周生余，王春亭，张伟，王锡明，董亮,,Chinese,,,1/19/20,2/15/20,27,Subgroup,Critical,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,,,,,,,,41.67%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
43,0,China,Hubei,49,14.61%,湖北省十堰市新型冠状病毒肺炎 49 例临床分析,第三军医大学学报,赵琴，雷旭，刘龙，占国清，李儒贵，李金科，李芳，杜卫星，李健，杨靖， 谭华炳,DOI：10.16016/j.1000-5404.202002107,Chinese,,,1/23/20,2/9/20,17,Top-level,General,Positive only,,,,,,,,48,,,,,,51.02%,0%,0%,100%,0%,0%,,91.80%,,,,,,,,,,,,,,36.73%,,,,,,,,,,87.76%,,,,65.31%,12.24%,24.49%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,0,China,Hubei,463,30.34%,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,,1/1/20,2/6/20,36,Top-level,Survivors,Positive only,Active only,Survivors only,Discharged only,Yes,Both,All,,51,,,,,,52.70%,0%,0%,100%,0%,0%,,,,,9,7,12.5,,,,,,,,,44.28%,23.11%,8.64%,6.05%,,,,,,,89.63%,38.5,40.5,,77.06%,41.90%,13.17%,31.53%,,28.08%,,,,,,,,,,,,,,5.44,4.09,7.52,1.07,0.76,1.46,,,212,155,285,,,,126,114,126,,,,,,,,,,,,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12,,0,
44,1,China,Hubei,282,30.34%,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,,1/1/20,2/6/20,36,Subgroup,Common,Positive only,Active only,Survivors only,Discharged only,Yes,Both,Mild only,,49,,,42,58,,51.42%,0%,0%,100%,0%,0%,,,,,10,7,13,,,,,,,,,40.43%,19.15%,7.09%,4.26%,,,,,,,86.88%,38.4,,,74.82%,39.72%,5.32%,29.08%,,28.72%,,,,,,,,,,,,,,5.17,4.08,,1.18,0.87,1.61,,,214,165,285,,,,6.71,115,138,,,,,,,,,,,,,,,,,100%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11,,0,
44,2,China,Hubei,181,29.21%,普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析,上海医学,程克斌，魏明，沈虹，吴超民，陈德昌，熊维宁，周新，张定宇，郑军华,,Chinese,,,1/1/20,2/6/20,36,Subgroup,Severe,Positive only,Active only,Survivors only,Discharged only,Yes,Both,Severe/Critical Only,,54,,,46,64,,54.70%,0%,0%,100%,0%,0%,,,,,8,7,12,,,,,,,,,50.28%,29.28%,11.05%,8.84%,,,,,,,93.92%,38.9,,,80.11%,45.30%,5.52%,35.36%,,27.07%,,,,,,,,,,,,,,5.92,4.13,,0.95,0.63,1.3,,,204,142,275,,,,8.26,107,136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13,,0,
46,0,China,Henan,524,20.22%,河南省524例新型冠状病毒肺炎患者临床特征及中医证候分布,中医杂志,李建生，李素云，谢洋，赵虎雷，冯贞贞，春柳，王佳佳，孙博倩,,Chinese,,,2/1/20,2/20/20,19,Top-level,General,Positive only,,,,Yes,,All,,45,,,33,55,,58.00%,0%,0%,100%,0%,0%,,54.80%,62.20%,,10,6,15,,,,,,,,,,,,,,,,,,,47.30%,,,,12.79%,26.34%,5.53%,11.07%,5.15%,31.30%,,2.67%,4.20%,,16.79%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,0,China,Chongqing,223,34.83%,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,,1/24/20,2/23/20,30,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,Both,,46.5,,30.4,62.6,,47.10%,0%,0%,100%,0%,0%,,28.70%,34.10%,,,,,5,,,,15.70%,,,,24.20%,11.20%,8.10%,0.40%,0.40%,,,,,4%,53.40%,,,3.10%,50.70%,6.70%,4.90%,12.10%,5.40%,5.40%,,5.40%,,,,,,,,,,,,,,,1.5,,,,,199.8,,,,,,135.1,,,,,20,30,18.8,,,,69.4,,,,,,,,,100%,,,,,,,,7.60%,,58.30%,,,5.40%,1.30%,,,,,,,,,,,,,,,,,,,,,0.5,,14,11.9,0,0
47,1,China,Chongqing,192,34.83%,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,,1/24/20,2/23/20,30,Subgroup,Common,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,Both,,44.9,,28.9,60.9,,45.30%,0%,0%,100%,0%,0%,,27.60%,37.50%,,,,,4,,,,15.60%,,,,20.80%,10.90%,5.20%,0.50%,0.50%,,,,,3.60%,47.90%,,,1.00%,49.50%,0,5.20%,10.40%,5.20%,5.20%,,6.30%,,,,,,,,,,,,,,,1.5,,,,,197.8,,,,,,135.9,,,,,20,26,19.2,,,,69.5,,,,,,,,,100%,,,,,,,,9%,,63.50%,,,0,0,,,,,,,,,,,,,,,,,,,,,0.53,,13.8,11.7,0,0
47,2,China,Chongqing,31,34.83%,重庆市223例新型冠状病毒肺炎患者的临床特征分析,西南大学学报(自然科学版),袁婧，孙艳雨，左玉洁，陈婷颖，曹齐，袁国丹，杨梅，张维，彭安周，陈 耀凯,,Chinese,,,1/24/20,2/23/20,30,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,Both,,56.4,,44,68.8,,58.10%,0%,0%,100%,0%,0%,,35.50%,12.90%,,,,,6,,,,16.10%,,,,45.20%,12.90%,25.80%,0,0,,,,,6.50%,87.10%,,,16.10%,58.10%,48.40%,3.20%,22.60%,6.50%,6.50%,,0,,,,,,,,,,,,,,,1,,,,,211.8,,,,,,130.1,,,,,34,60,17.5,,,,68.2,,,,,,,,,100%,,,,,,,,54.80%,,25.80%,,,38.70%,9.70%,,,,,,,,,,,,,,,,,,,,,0.36,,16.4,13.9,0,0
48,0,China,Jiangxi,49,24.72%,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,,1/21/20,1/27/20,6,Top-level,General,Positive only,,,,,,All,,,42.9,,,,,67.32%,0%,0%,100%,0%,0%,93.89%,,,4.7,,,,6.7,,,,6.12%,,,,28.60%,12.20%,4.10%,,,,,,,12.20%,78.70%,37.1,39.1,,38.80%,,12.20%,,,18.40%,,4.10%,,,14.90%,16.30%,,,,81.63%,,,,5.52,,,,,,312.16,174.74,,,,3.84,,,,,,,,22.7,27.4,,,,,,,27.77,,,,,,,15.38%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,1,China,Jiangxi,40,22.47%,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,,1/21/20,1/27/20,6,Subgroup,Common,Positive only,,,,,,Mild only,,,40.6,,,,,62.50%,0%,0%,100%,0%,0%,97.50%,,,4.7,,,,,,,,7.50%,,,,,5.00%,0,,,,,,,15%,80.00%,37.2,,,32.50%,,10.00%,7.50%,,15.00%,,5.00%,,,17.50%,12.50%,,,,,,,,4.61,,,,,,352.75,201,,,,2.96,,,,,,,,20.7,25.1,,,,,,,16.05,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,2,China,Jiangxi,9,21.91%,江西地区 49 例新型冠状病毒肺炎患者临床特征分析,中国呼吸与危重监护杂志,向天新，刘家明，许飞，程娜，刘洋，钱克俭，张伟,,Chinese,,,1/21/20,1/27/20,6,Subgroup,Severe/Critical,Positive only,,,,,,Severe/Critical Only,,,53,,,,,88.90%,0%,0%,100%,0%,0%,77.78%,,,4.5,,,,,,,,0,,,,,44.44%,22.22%,,,,,,,,66.67%,36.9,,,66.67%,,22.22%,44.44%,,33.33%,,0,,,0,33.33%,,,,,,,,9.56,,,,,,221.32,145.35,,,,7.76,,,,,,,,32,38.1,,,,,,,79.86,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
50,0,China,,308,17.42%,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,,1/25/20,2/20/20,26,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,,,52.95,,38.74,,,47.81%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,82.00%,,,,95.00%,,,,,67.90%,,10.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.22,,0.05,
50,1,China,,34,15.73%,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,,1/25/20,2/20/20,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,,,65.1,,51.8,78.4,,54.54%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.41,,0.36,
50,2,China,,87,15.73%,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,,1/25/20,2/20/20,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,,,58.4,,43.1,73.7,,54.02%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,95.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19.43,,0.05,
50,3,China,,98,15.73%,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,,1/25/20,2/20/20,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,,,45.8,,31.9,59.7,,43.88%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,99.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16.4,,0,
50,4,China,,90,15.73%,308 例新型冠状病毒肺炎病例回顾性分析及抗疫强身功运动处方的临床应用 方案,上海中医药杂志,方磊，朱清广，程伟，占超，方晓明，郭超阳，李振瑞，姚斐，房敏,10.16305/j.1007-1334.2020.05.095,Chinese,,,1/25/20,2/20/20,26,Subgroup,,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,,,50.3,,36.6,64,,43%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,94.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.7,,0,
51,0,China,Hunan,697,12.36%,湖南省 697 例新型冠状病毒肺炎确诊病例就诊及诊断分析,实用预防医学,刘子言，高立冬，胡世雄，罗垲炜，肖洁华，赵善露，曾舸，戴志辉，杨浩， 孙倩莱，张恒娇，邓志红,,Chinese,,,12/21/19,2/13/20,54,Top-level,General,Positive only,Active only,Both,Both,No,Both,All,Both,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
53,0,China,Guangdong,188,18.54%,Evidence and characteristics of human-to-human transmission of 2019-nCoV,MedRxiv,Kang et. al.,https://www.medrxiv.org/content/medrxiv/early/2020/02/06/2020.02.03.20019141.full.pdf,English,No,Observational,1/1/20,1/27/20,26,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,48.8,,,,,49.50%,0%,0%,100%,0%,0%,,75%,,5.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,84.50%,12.20%,3.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,
53,1,China,Guangdong,37,25.28%,Evidence and characteristics of human-to-human transmission of 2019-nCoV,MedRxiv,Kang et. al.,https://www.medrxiv.org/content/medrxiv/early/2020/02/06/2020.02.03.20019141.full.pdf,English,No,Observational,1/1/20,1/27/20,26,Subgroup,13 Family clusters,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,58,54.65,16.3,48,78,,48.60%,0%,0%,100%,0%,0%,100.00%,0.7568,24.32%,,,,,,,,,,,,,,,,,,,,,,,56.70%,,,,45.90%,,,,,0.189,,,,,,,,,,38%,0.27027027,0.081081081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.38,0.08,0.03,,,,0,0
54,0,China,Various,9,29.21%,Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China,JAMA,Wei et. al.,https://doi.org/10.1001/jama.2020.2131,English,Yes,Observational,12/8/19,2/6/20,60,Top-level,General,Positive only,End-point and active,Survivors only,,No,Non-ICU only,Mild only,Non-ventilation only,0.58,0.56,,0.33,0.75,,22%,0%,0%,100%,0%,0%,87.50%,,,,,,,,,,,,,,,,,,,,,,,,,44%,,,,22%,,,11%,,,,,,,11%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,1,0,na,,,,0,
55,0,China,Wuhan,1,34.27%,A new coronavirus associated with human respiratory disease in China,Nature,Wu et. al,https://www.nature.com/articles/s41586-020-2008-3?fbclid=IwAR10YjXQeW795Vke_56S0Qz-eZzCXSosAAYpF6vuWjWH8vnGIUKWJr1BkoI,English,Yes,Observational,12/26/19,1/7/20,12,Top-level,General,Positive only,Active only,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,41,41,,,,,100%,0%,0%,100%,0%,0%,100%,100%,,,,,,6,,,,,,,,,,,,,,,,,,100%,,38.4,,100%,100%,,100%,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,41.4,,,,,,100%,100%,0%,0%,100%,,0%,0%,0%,100%,0%,0%,0%,0%,0%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,1,1,na,3,,,,
56,0,China,Wuhan,10,38.20%,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,No,Observational,1/1/20,2/11/20,41,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,60%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,4.3,3.5,5.1,0.7,0.6,0.9,,,165,135,219,2.8,,,138,121,151,,,24,26,,,,,65,94,12.1,,17,0.1,0.5,12.3,100%,60%,60%,0%,60%,,0%,0%,0%,50%,0%,0%,100%,100%,,,,,0%,0%,,,,,,,,,,,,,,,1,,0.6,,,,0.2,0.25
56,1,China,Wuhan,8,37.64%,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,No,Observational,1/1/20,2/11/20,41,Subgroup,Survivors,Positive only,End-point and active,Survivors only,Both,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,4.2,3.2,5,0.8,0.7,0.9,,,167,150,221,2.6,,,138,126,150,,,21,23,,,,,59,92,10.1,,13,0.1,0.5,12.6,100%,75%,75%,0%,75.00%,,0%,0%,0%,37.50%,0%,0%,100%,100%,,,,,0%,0%,,,,,,,,,,,,,,,1,,0.75,,,,0,0
56,2,China,Wuhan,2,37.64%,Dynamic profile of severe or critical COVID-19 cases,MedRxiv,Xu,https://www.medrxiv.org/content/10.1101/2020.03.18.20038513v1,English,No,Observational,1/1/20,2/11/20,41,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,ΝΑ,Severe/Critical Only,NA,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,4.6,3.5,5.7,0.7,0.6,0.8,,,170,121,219,4.3,,,137,128,146,,,28,30,,,,,103,120,25.5,,21,0.2,2.4,18.1,100%,0%,0%,0%,0%,,0%,0%,0%,100%,0%,0%,100%,100%,,,,,0%,0%,,,,,,,,,,,,,,,1,,0,,,,1,1
57,0,China,Guizhou,162,16.85%,"Epidemiologic Characteristics of COVID-19 in Guizhou, China",MedRxiv,Ping et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20028944v1.full.pdf,English,No,Observational,1/21/20,2/16/20,26,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,37,,,,,,50.62%,0%,0%,100%,0%,0%,91.35%,51.85%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,na,,,,,
58,0,China,Shanghai,148,29.21%,Clinical Features of COVID-19-Related Liver Damage,MedRxiv,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,No,Observational,1/20/20,1/31/20,11,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,50.5,,,36,64,,49.30%,0%,0%,100%,0%,0%,,,,,,,,,5,3,7,,,,,,,,,,,,,,,70.30%,,,,45.30%,,,26.70%,,,,4.10%,2%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16%,39.20%,21%,0%,18.26%,,,8.77%,0%,0%,0%,,,,,,,,,,,,,,,,,44.60%,,,,,,,1,,0.63,,12,,0.01,0.01
58,1,China,Shanghai,75,28.65%,Clinical Features of COVID-19-Related Liver Damage,MedRxiv,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,No,Observational,1/20/20,1/31/20,11,Subgroup,Abnormal liver,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,62.67%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,76%,,,,46.67%,,,22.67%,,,,,,,,,,,,,,,,4.99,3.74,5.72,0.93,0.64,1.73,336,201,,,,,,,,,,,,,,,,,,,,24.7,,,0.06,,,22.67%,45.33%,31.00%,0%,22.70%,,,8%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,1,,0.59,,15.14,,,
58,2,China,Shanghai,73,28.65%,Clinical Features of COVID-19-Related Liver Damage,MedRxiv,Fan et. al,https://www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf,English,No,Observational,1/20/20,1/31/20,11,Subgroup,Normal liver,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,38.36%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,64%,,,,43.84%,,,27.34%,,,,,,,,,,,,,,,,4.4,5.66,27.5,1.32,0.96,1.57,492,273,,,,,,,,,,,,,,,,,,,,6.23,,,0.02,,,9.59%,32.88%,11%,0%,13.70%,,,9.56%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,1,,0.81,,12.67,,,
59,0,China,Wuhan,82,50.56%,Clinical characteristics of 82 death cases with COVID-19,MedRxiv,Zhang et. al.,https://www.medrxiv.org/content/10.1101/2020.02.26.20028191v1.full.pdf,English,No,Observational,1/11/20,2/10/20,30,Top-level,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,Both,Severe/Critical Only,Both,72.5,,,65,80,,65.90%,0%,0%,100%,0%,0%,,,,,7,4,10,10,10,7,15,,,,,76.80%,56.10%,18.30%,20.70%,14.60%,7.30%,2.40%,12.20%,7.30%,12.20%,78%,38.8,,,64.60%,63.40%,,,,46.30%,,12.20%,2.30%,,4.90%,,,,,,,100%,,,,,0.5,0.3,0.8,,,148.5,102,206,6.8,,,,,,,33.1,26,72,13.6,10,22.9,8.6,78,107.5,11.7,,,0.3,5.1,13.2,100%,100%,,,,,,,,35.30%,,,100%,,36.60%,4.80%,,,,,28%,,100%,,,24.60%,,,,,,,,,1,0.17,0,,5,,1,1
60,0,China,Jiangxi,11,26.97%,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,No,Observational,2/12/20,3/19/20,36,Top-level,Survivors,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,,,,,,,36.40%,0%,0%,100%,0%,0%,18.20%,,9.10%,,,,,,,,,,,,,18.20%,18.20%,,,,,,,,,36.40%,,,,36.40%,63.60%,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,81.81%,0%,0%,,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,17.81,7,0,0
60,1,China,Jiangxi,2,28.09%,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,No,Observational,2/12/20,3/19/20,36,Subgroup,Naive,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,31,,,18,44,,50.00%,0%,0%,100%,0%,0%,50.00%,,,,,,,,,,,,,,,0.00%,0.00%,,,,,,,,,0.00%,,,,50.00%,50.00%,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,8,3,0,0
60,2,China,Jiangxi,9,28.65%,First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf,English,No,Observational,2/12/20,3/19/20,36,Subgroup,Experienced,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,NA,44,,,18,66,,33.30%,0%,0%,100%,0%,0%,11.10%,,11.10%,,,,,,,,,,,,,22.20%,22.20%,,,,,,,,,44.40%,,,,33.30%,66.60%,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,0%,0%,,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,20,13,0,0
61,1,China,Two provinces,62,47.75%,A comparative multi­center study on the clinical and imaging features of confirmed and unconfirmed patients with COVID­19,MedRxiv,Miao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040782v1.full.pdf,English,No,Observational,1/12/20,2/13/20,32,Subgroup,Confirmed,Positive only,Active only,Survivors only,Non-discharged only,Yes,Both,All,Both,43.8,,,,,,51.60%,0%,0%,100%,0%,0%,,71%,38.60%,7,7,3.5,9,,,,,24.80%,16.80%,,,,13.90%,5%,2%,3%,1%,3%,1%,0%,,79%,,,,59.70%,4.80%,8.10%,16.10%,24.20%,24.20%,4.80%,11.30%,,,8.10%,,,,4.80%,,,6.50%,1,5.3,4,6.7,1.3,0.9,1.8,,,178,130.5,215.5,2.9,3.7,6.6,138.8,122.1,155.5,,,22,25.5,9.7,7.4,13.1,,68,67,9.9,,,0.05,0.37,11.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,0,
62,0,China,Chongqing,167,21.91%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,,,,,,,0%,0%,100%,0%,0%,,32.20%,49.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,74.80%,13.10%,0%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,0,,,,1,0,1,,16.68,,0,0
62,1,China,Chongqing,2,34.83%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Asymptomatic 0-14,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,0%,0%,100%,0%,0%,,0.00%,100.00%,9,,,,,,,,0.00%,,,,,,,,,,0%,,0%,,0%,,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,,100.00%,0.00%,0%,0%,0,4.66,3.81,5.5,2.93,1.91,3.94,811,561,140.5,30,251,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,1,0,1,,16.5,,0,0
62,2,China,Chongqing,2,32.58%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Asymptomatic 15-29,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,0%,0%,100%,0%,0%,,50.00%,50.00%,8.5,,,,,,,,0.00%,,,,,,,,,,0%,,0%,,0%,,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,,100.00%,0.00%,0%,0%,0,3.9,,,1.63,1.21,2.05,691,537,166,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,1,0,1,,10.5,,0,0
62,3,China,Chongqing,2,34.27%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Asymptomatic 30-39,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,0%,0%,100%,0%,0%,,50.00%,0.00%,20.5,,,,,,,,50.00%,,,,,,,,,,0%,,0%,,0%,,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,,100.00%,0.00%,0%,0%,0,7.11,5.11,9.1,2.14,1.31,2.96,420,,229,221,237,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,1,0,1,,16,,0,0
62,4,China,Chongqing,6,34.83%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Asymptomatic 40-49,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,0%,0%,100%,0%,0%,,0.00%,66.70%,8.8,,,,,,,,33.30%,,,,,,,,,,0%,,0%,,0%,,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,,100.00%,0.00%,0%,0%,0,5.9,4.11,6.27,1.3,0.96,1.99,433,370,183,87,328,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,16.70%,,0.00%,,,0,,,,1,0,1,,12.2,,0,0
62,5,China,Chongqing,5,34.27%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Asymptomatic 50-59,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,0%,0%,100%,0%,0%,,0.00%,80.00%,7,,,,,,,,40.00%,,,,,,,,,,0%,,0%,,0%,,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,,100.00%,0.00%,0%,0%,0,6.42,6.68,9.4,2.04,2.03,3,253,,197,192,198,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,1,0,1,,11.6,,0,0
62,6,China,Chongqing,3,32.58%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Asymptomatic 70+,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,,,,,,,,0%,0%,100%,0%,0%,,0.00%,100.00%,13.7,,,,,,,,0.00%,,,,,,,,,,0%,,0%,,0%,,,,0.00%,0.00%,0.00%,,,0%,,,,,,,,,100.00%,0.00%,0%,0%,0,5.19,5.17,8.05,0.83,0.78,2.57,273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0.00%,,,0,,,,1,0,1,,19,,0,0
62,7,China,Chongqing,7,34.27%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Severe 30-39,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,0%,0%,100%,0%,0%,,71.40%,28.60%,9.1,,,,,,,,28.60%,,,,,,,,,,14.30%,,0%,,100%,,,,71.40%,14.30%,57.10%,,,57.10%,,,,,,,,,0.00%,0.00%,100%,0%,0,5.29,4.1,8.2,2.19,0.67,2.97,399,342,205.5,133,503,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,14.30%,,,0,,,,1,,1,,18.3,,0,0
62,8,China,Chongqing,3,34.27%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Severe 40-49,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,0%,0%,100%,0%,0%,,66.70%,33.30%,8.3,,,,,,,,0.00%,,,,,,,,,,0%,,0%,,66.70%,,,,66.70%,33.30%,0,,,0%,,,,,,,,,0.00%,0.00%,100%,0%,0,3.3,3.26,3.34,0.86,0.75,0.96,393,304,186,174,233,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0,,,0,,,,1,,1,,17,,0,0
62,9,China,Chongqing,5,34.27%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Severe 50-59,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,0%,0%,100%,0%,0%,,80.00%,20.00%,12.3,,,,,,,,20%,,,,,,,,,,20%,,0%,,80%,,,,60%,60%,20%,,,20%,,,,,,,,,0.00%,0.00%,100%,0%,0,5.17,3.2,6.07,0.78,0.75,1.07,167,235,77,68,86,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,20%,,,0,,,,1,,1,,26.5,,0,0
62,10,China,Chongqing,3,33.71%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Severe 60-69,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,0%,0%,100%,0%,0%,,0.00%,33.30%,,,,,,,,,66.70%,,,,,,,,,,0%,,0%,,33.30%,,,,66.70%,66.70%,100%,,,100%,,,,,,,,,0.00%,0.00%,100%,0%,0,6.34,5.43,6.68,0.69,0.63,1.43,117,121,158,131,356,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,0,,,0,,,,1,,1,,15.7,,0,0
62,11,China,Chongqing,4,34.27%,"High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China",MedRxiv,Tao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.16.20037259v1.full.pdf,English,No,Observational,1/1/20,3/1/20,60,Subgroup,Severe 70-79,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,,,,,,,,0%,0%,100%,0%,0%,,50.00%,50.00%,10.3,,,,,,,,25%,,,,,,,,,,25%,,0%,,50%,,,,75%,100%,50%,,,50%,,,,,,,,,0.00%,0.00%,100%,0%,0,3.05,2.25,3.85,0.5,0.4,0.97,121,111,130.5,121,140,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,,25%,,,0,,,,1,,1,,21.25,,0,0
63,0,China,Wuhan,403,50.56%,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf,English,No,Observational,1/30/20,2/25/20,26,Top-level,General,Positive only,End-point only,Both,Both,Yes,Both,All,NA,,56,,39,68,,47.90%,0%,0%,100%,0%,0%,,,,,,,,,,,,7.20%,10.20%,,,43.40%,28%,14.10%,8.90%,6.90%,,,9.70%,1.70%,9.70%,79.20%,,,,10.20%,2%,,,0.50%,3.50%,,1.00%,0.50%,,2%,,,,,,,,1,5.5,4.11,7.3,1.06,0.75,1.49,,,192,148,251,3.57,,,126.9,109.2,144.6,,37.4,,,12.8,10,17.5,,69,,25.5,,,0.06,0.73,,86.60%,97.80%,,0%,30.50%,,,80.40%,0%,41.20%,49.10%,,26.30%,,13.90%,5.70%,,,17.90%,,,35.50%,,,,,,21.60%,,20.60%,14.10%,19.20%,,,1,,0.75,,,,0.25,0.25
63,1,China,Wuhan,100,50.56%,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf ,English,No,Observational,1/30/20,2/25/20,26,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,Both,Severe/Critical Only,NA,,71,,65,80,,57%,0%,0%,100%,0%,0%,,,,,,,,,,,,9%,10%,,,77%,60%,25%,16%,17%,,,22%,3%,22%,87%,,,,4%,2%,,,0%,2%,,1.00%,0%,,0%,,,,,,,,1,8.58,5.13,12.34,0.73,0.46,0.92,,,169,121,219,7.09,,,125,105.4,144.6,,33.2,,,17.4,12.7,24.7,,82,,95,,,0.2,5.38,,99%,96%,,0%,21%,,,66%,0%,74%,66%,,74%,,48%,16%,,,8%,,,90%,,,,,,71%,,65%,43%,58%,,,1,,0,,,,1,1
63,2,China,Wuhan,303,50.56%,"Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China",MedRxiv,Luo et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20033175v1.full.pdf,English,No,Observational,1/30/20,2/25/20,26,Subgroup,Discharged,Positive only,End-point only,Both,Discharged only,Yes,Both,All,NA,,49,,37,62,,44.90%,0%,0%,100%,0%,0%,,,,,,,,,,,,6.60%,10.20%,,,32.30%,17.50%,10.60%,6.60%,3.60%,,,5.60%,1.30%,5.60%,76.60%,,,,12.20%,2%,,,0.70%,4%,,1.00%,0.70%,,2.60%,,,,,,,,1,5.03,3.98,6.5,1.18,0.9,1.62,,,205,153,264,3.1,,,127.5,110.4,144.6,,38.5,,,11.9,9.5,15.4,,68,,23.8,,,0.04,0.5,,82.90%,98.30%,,0%,30%,,,85.10%,0%,30.40%,43.60%,,10.60%,,2.60%,2.30%,,,21.10%,,,17.50%,,,,,,5.30%,,5.90%,4.60%,6.30%,,,1,,1,,,,0,0
64,0,China,Qingdao/Wuhan,74,34.83%,Epidemiological and Clinical Characteristics of Children with Coronavirus Disease 2019,MedRxiv,Wu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.19.20027078v1.full.pdf,English,No,Observational,1/20/20,2/27/20,38,Top-level,General,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,NA,,6,,0.1,15.08,,59.46%,0%,0%,100%,0%,0%,,,95.59%,,,,,,,,,0%,0%,,,0%,,,,,,,,,,27.03%,38.6,40.1,,32.43%,2.70%,2.70%,2.70%,0%,6.76%,,4.05%,,4.05%,,,,,40.54%,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.9,,,0.1,,,35.52%,,0%,0%,,,,,,1.30%,,,0%,,1.30%,0%,0%,0%,,,,,,,,,,,,,,,,,1,,1,,11,,0,0
65,0,Japan (Diamond Princess),International,104,20.79%,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,No,Observational,2/11/20,2/26/20,15,Top-level,General,Positive only,,Survivors only,Both,,,All,,68,,,46.75,75,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,50%,,6.70%,,,3.80%,,,,,28.80%,,,,27.90%,6.70%,9.60%,,,,,7.70%,,,15.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13.50%,0%,1%,,,,,,,,,,,,,,,,,,,,,na,,,,,
65,1,Japan (Diamond Princess),International,76,17.42%,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,No,Observational,2/11/20,2/26/20,15,Subgroup,"Non-severe (asymptomatic, mild)",Positive only,,Survivors only,Both,,,Mild only,,66.5,,,44.75,74,,,0%,0%,100%,0%,0%,,,,,,,,,,,,14.50%,,,,44.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,na,,,,,
65,2,Japan (Diamond Princess),International,28,17.42%,Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 2 “Diamond Princess” in Japan,MedRxiv,Tabata et. al.,https://www.medrxiv.org/content/10.1101/2020.03.18.20038125v1.full.pdf,English,No,Observational,2/11/20,2/26/20,15,Subgroup,Severe,Positive only,,Survivors only,Both,,,Severe/Critical Only,,72.5,,,55.25,76.5,,,0%,0%,100%,0%,0%,,,,,,,,,,,,25%,,,,64.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50%,0%,3.57%,,,,,,,,,,,,,,,,,,,,,na,,,,,
66,0,South Korea,Nationwide,7755,14.04%,"Coronavirus disease-19: The First 7,755 Cases in the Republic of Korea",MedRxiv,KCDC,https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1,English,,,2/11/20,2/26/20,15,Top-level,General,Positive only,,Both,Both,No,,All,NA,,,,,,,38%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0.01,
66,1,South Korea,Nationwide,66,20.79%,"Coronavirus disease-19: The First 7,755 Cases in the Republic of Korea",MedRxiv,KCDC,https://www.medrxiv.org/content/10.1101/2020.03.15.20036368v1,English,,,2/11/20,2/26/20,15,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,,Severe/Critical Only,NA,77,,,45,84,,56%,0%,0%,100%,0%,0%,,,,,,,,,4.5,0,11,,,,,97%,,,15.90%,,11.10%,,,7.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,1,1
67,0,China,Wuhan,82,41.01%,"The clinical and epidemiological features and hints of 82 confirmed COVID-19 pediatric cases aged 0-16 in Wuhan, China",MedRxiv,Yu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.15.20036319v1.full.pdf,English,,,2/1/20,2/20/20,19,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,4,3.39,,0,6,0,62.20%,0%,0%,100%,0%,0%,,100%,,,,,,,,,,0%,0%,,,9%,,,,,,,,,9%,62.19%,,,,62.19%,2.44%,,,,,,,,,,,,,9.76%,,,,0,8.76,,,,,,,,248,,,,,,125,,,,38.07,34.57,44.43,,,,12.52,16.13,,18.22,64.97,30.66,1.47,,10.82,85.37%,100%,,,,,,,,3.66%,3.66%,6.10%,,,2.44%,2.44%,,,,,0%,1.22%,1.22%,0%,0%,1.22%,2.44%,0%,,,,,,,1,0.1,0.73,,11.2,,0,0
69,0,China,Shenzhen,6,50.00%,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Yes,Observational,1/10/20,1/24/20,14,Top-level,General,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,All,Non-ventilation only,50,46.17,17.98436475,36,65,0%,50%,0%,0%,100%,0%,0%,33%,0%,33%,4.5,4.5,3,6,7.8,7,7,9,,,,,66.67%,33.33%,16.67%,0%,0%,16.67%,,,0%,16.67%,83.33%,37.7,,,83.33%,,,,50%,50%,16.67%,33.33%,,,16.67%,,,,,16.67%,16.67%,0%,1,5.2,4.3,6.5,1.7,0.7,2.7,,,196.5,166.75,201,4.05,,,148,131,152,,44.45,19.23,24.18,7.9,6.15,9.2,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,0.83,0,0,0,,,0,
69,1,China,Shenzhen,1,47.75%,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Yes,Observational,1/10/20,1/24/20,14,Subgroup,Patient 1,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,65,65,,65,65,0%,0%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,7,7,7,7,,,,,100%,100%,0%,0%,0%,100%,,,0%,0%,100%,39,,,100.00%,,,,100%,100%,0%,0%,,,0%,,,,,0%,0%,0%,1,4.8,4.8,4.8,0.6,0.6,0.6,,,157,157,157,4,,,131,131,131,,39.4,14.2,20.5,6.9,6.9,6.9,3.5,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,1,0,0,0,,,0,
69,2,China,Shenzhen,1,47.75%,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Yes,Observational,1/10/20,1/24/20,14,Subgroup,Patient 2,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Severe/Critical Only,Non-ventilation only,66,66,,66,66,0%,100%,0%,0%,100%,0%,0%,0%,0%,0%,,,,,6,6,6,6,,,,,100%,100%,0%,0%,0%,0%,,,0%,0%,100%,39,,,100.00%,,,,100%,100%,0%,0%,,,0%,,,,,100%,100%,0%,1,4.2,4.2,4.2,0.7,0.7,0.7,,,118,118,118,3.2,,,156,156,156,,38.5,13.9,23.3,5.9,5.9,5.9,5.7,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,1,0,0,0,,,0,
69,3,China,Shenzhen,1,47.75%,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Yes,Observational,1/10/20,1/24/20,14,Subgroup,Patient 3,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,37,37,,37,37,0%,0%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,9,9,9,9,,,,,0%,0%,0%,0%,0%,0%,,,0%,0%,100%,36.2,,,100.00%,,,,0%,0%,100%,100%,,,100%,,,,,0%,0%,0%,1,5.6,5.6,5.6,2.2,2.2,2.2,,,224,224,224,3.1,,,150,150,150,,50.4,25.9,27.4,9.3,9.3,9.3,3.1,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,1,0,0,0,,,0,
69,4,China,Shenzhen,1,47.75%,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Yes,Observational,1/10/20,1/24/20,14,Subgroup,Patient 4,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,36,36,,36,36,0%,100%,0%,0%,100%,0%,0%,0%,0%,0%,,,,,10,10,10,10,,,,,100%,0%,0%,0%,0%,0%,,,0%,100%,100%,36.5,,,100%,,,,0%,0%,0%,100%,,,0%,,,,,0%,0%,0%,1,11.4,11.4,11.4,2.7,2.7,2.7,,,196,196,196,8.1,,,152,152,152,,48.1,20.2,18.1,8.9,8.9,8.9,5.2,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,1,0,0,0,,,0,
69,5,China,Shenzhen,1,45.51%,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Yes,Observational,1/10/20,1/24/20,14,Subgroup,Patient 5,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,10,10,,10,10,0%,100%,0%,0%,100%,0%,0%,0%,0%,0%,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,,,0%,0%,0%,36.5,,,0%,,,,0%,0%,0%,0%,,,0%,,,,,0%,0%,0%,1,6.5,6.5,6.5,2.8,2.8,2.8,,,197,197,197,3.2,,,146,146,146,,49.1,23.9,28.2,3.6,3.6,3.6,5.6,,,,,,,,,,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,0,0,0,0,,,0,
69,6,China,Shenzhen,1,47.75%,A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,Lancet,Chan et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30154-9/fulltext,English,Yes,Observational,1/10/20,1/24/20,14,Subgroup,Patient 6,Positive only,Active only,Survivors only,Non-discharged only,No,Non-ICU only,Mild only,Non-ventilation only,63,63,,63,63,0%,0%,0%,0%,100%,0%,0%,0%,0%,0%,,,,,7,7,7,7,,,,,100%,0%,100%,0%,,0%,,,0%,0%,100%,39,,,100%,,,,100%,100%,0%,0%,,,0%,,,,,0%,0%,0%,1,4.3,4.3,4.3,1.2,1.2,1.2,,,205,205,205,2.7,,,130,130,130,,41.2,17.3,27.6,10.4,10.4,10.4,4.9,,,,,,,,,100%,,,,,,,,,,,,,,0%,0%,,,,,,,,,,,,,,,,,,,1,0,0,0,,,0,
70,0,China,Wuhan,101,60.11%,"Clinical characteristics of 101 non-survivors hospitalized with COVID-19—A single center, retrospective study",Lancet,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550014,English,No,Observational,1/1/20,2/15/20,45,Top-level,General,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,,Severe/Critical Only,Both,71,,,60,80,,59.41%,0%,0%,100%,0%,0%,100%,100%,,,,,,,,,,,,,,82%,58.42%,21.78%,24%,13.86%,7%,18%,12.87%,11%,0%,81.19%,,,,55.45%,58.42%,4.95%,,6%,35.64%,,10%,3%,,,,,,0%,0%,0%,100%,1,9.7,9.04,10.36,0.76,0.68,0.84,197.9,130.4,178.2,167.37,189.03,8.47,,,,,,,33.14,55.99,116.8,25.01,18.32,31.7,11.94,139.8,,107.9,,,1.3,15.31,15.35,98%,96%,0%,0%,0%,,0%,96%,0%,43.56%,0%,0%,77.23%,77.23%,40.59%,13.86%,0%,4.95%,0%,0.00%,,,99.01%,,,52.48%,,17.82%,13.86%,52.48%,22.77%,,,,1,,0,,4,,1,1
70,1,China,Wuhan,48,59.55%,"Clinical characteristics of 101 non-survivors hospitalized with COVID-19—A single center, retrospective study",Lancet,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550014,English,No,Observational,1/1/20,2/15/20,45,Subgroup,<= 3 day course of disease group,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,,Severe/Critical Only,Both,72,,,59,78,,58%,0%,0%,100%,0%,0%,100%,100%,,,,,,,,,,,,,,77%,54%,19%,18.75%,8%,6%,19%,8%,4%,0%,79%,,,,48%,58%,2%,,2%,40%,,8%,2%,,,,,,0%,0%,0%,100%,1,12.36,11.11,13.61,0.7,0.62,0.78,203.3,120.7,185.2,163.95,206.45,11.23,,,,,,,32.32,88.64,219.2,28.94,16.95,40.93,15.2,172.5,,123.4,,,2.26,21.28,18.73,98%,97.92%,0%,0%,0%,,0%,97.92%,0%,35.42%,0%,0%,72.92%,72.92%,22.92%,16.67%,0%,4.17%,0.00%,0.00%,,,97.92%,,,58.33%,,18.75%,8.33%,,25%,,,,1,,0,,2,,1,1
70,2,China,Wuhan,53,59.55%,"Clinical characteristics of 101 non-survivors hospitalized with COVID-19—A single center, retrospective study",Lancet,Shi et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550014,English,No,Observational,1/1/20,2/15/20,45,Subgroup,> 3 day course of disease group,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,,Severe/Critical Only,Both,71,,,59,81,,60%,0%,0%,100%,0%,0%,100%,100%,,,,,,,,,,,,,,85%,62%,25%,28.30%,19%,8%,17%,17%,17%,0%,83%,,,,62%,58%,9%,,9%,32%,,11%,8%,,,,,,0%,0%,0%,100%,1,7.72,7.21,8.23,0.69,0.64,0.74,195.6,151,173,162.5,183.5,6.48,,,,,,,33.75,34.15,46.15,22.38,14.61,30.15,10.08,116.5,,94.1,,,0.58,11.47,13.22,98%,94.34%,0%,0%,0%,,0%,94.34%,0%,50.94%,0%,0%,81.13%,81.13%,56.60%,11.32%,0%,5.66%,0.00%,0.00%,,,100%,,,47.17%,,16.98%,18.87%,,20.75%,,,,1,,0,,7,,1,1
71,1,China,Wuhan,55,50.00%,"Clinical Characteristics of 55 Cases of Deaths with COVID-19 Pneumonia in Wuhan, China: Retrospective Case Series",Lancet,Yao et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550019,English,No,Observational,1/26/20,2/18/20,23,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,,Severe/Critical Only,Both,65,70.7,,60,80,0%,67%,0%,0%,100%,0%,0%,100%,100%,,,,,,,,,,,,,,73%,60%,26%,,22%,7%,6%,22%,9%,0%,96%,,,,62%,96%,4%,,93%,93%,,4%,4%,,,,,,0%,0%,0%,100%,1,7.85,4.84,12.79,0.55,0.41,0.8,,,160.5,93.3,227.7,7.58,3.44,11.72,125,105,145,,34.2,25,43,14.1,8.6,19.9,8.34,80,,84.9,44,,0.4,3.31,13.1,96%,,,,,,,,,,,,,,21.80%,,,7.30%,,,,,,,,,,,,,,,,,1,,0,,,,1,1
72,0,China,Wuhan,140,37.64%,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Yes,Observational,1/16/20,2/3/20,18,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,57,,,30,75,2.10%,50.70%,0%,0%,100%,0%,0%,10.70%,0%,0%,,,,,8,8,7,10,1.40%,,,,64.30%,30%,12.10%,5.00%,1.40%,,5.70%,,,10%,91.70%,,,,75%,36.70%,,,,75%,36.70%,12.90%,17.30%,12.20%,,,,,,41.40%,,,1,4.7,3.7,6.7,0.8,0.7,1,,,,,,,,,,,,,,,,,,,,,72.5,34.2,,,0.07,0.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,,
72,1,China,Wuhan,82,37.64%,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Yes,Observational,1/16/20,2/3/20,18,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,NA,51.5,,,31,71,3.70%,46.30%,0%,0%,100%,0%,0%,13.40%,0%,0%,,,,,8,8,6,10,0%,,,,53.70%,24.40%,11.00%,3.70%,0%,,5%,,,10%,88.10%,,,,76.10%,29.90%,,,,76.10%,29.90%,11.00%,23.20%,11.00%,,,,,,0%,,,1,4.5,3.5,5.9,0.8,0.7,1.1,,,,,,,,,,,,,,,,,,,,,83,28.7,,,0.05,0.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,,
72,2,China,Wuhan,58,37.64%,"Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China",Epidemiology and Genetics,Zhang et. al.,https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238,English,Yes,Observational,1/16/20,2/3/20,18,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,NA,64,,,33,77,0%,56.90%,0%,0%,100%,0%,0%,6.90%,0%,0%,,,,,7,7,6,10,3.40%,,,,79.30%,37.90%,13.80%,6.90%,3.40%,,6.90%,,,10%,96.20%,,,,73.60%,45.30%,,,,73.60%,45.30%,15.80%,8.80%,14.00%,,,,,,100%,,,1,5.3,4,9,0.7,0.6,0.9,,,,,,,,,,,,,,,,,,,,,66,47.6,,,0.1,0.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,,
73,0,China,Wuhan,36,53.93%,"Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China",MedRxiv,Huang et. al.,https://www.medrxiv.org/content/medrxiv/early/2020/03/05/2020.02.27.20029009.full.pdf,English,No,Observational,1/21/20,2/14/20,24,Top-level,General,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,ΝΑ,Severe/Critical Only,NA,69.22,69.22,18.890544,62.8844,75.5556,,69.44%,0%,0%,100%,0%,0%,,,,,,,,,,,,11.11%,,,,,58.33%,19.44%,13.89%,11.11%,2.78%,,22.22%,8.33%,,94.44%,,,,77.78%,58.33%,,22.22%,2.78%,47.22%,,8.33%,,,,,,,,0%,100%,0%,0,7.67,4.1,10.97,0.67,0.45,0.89,,,167.21,115.4,219.02,6.64,,,123.74,111.14,136.34,,30.18,26,43,11.21,7.5,19.2,7.8,83,,106.2,,100.6,0.61,8.64,,100%,97.22%,97.22%,0%,97.22%,,97.22%,97.22%,0%,69.44%,55.56%,,97.22%,,52.78%,25%,,,16.67%,,,100%,,100%,,,,,,,2.78%,,,,1,,0,,,,1,1
74,0,Chile,Chile,922,19.10%,SITUACIÓN EPIDEMIOLÓGICA COVID-19. CHILE al 23 de marzo de 2020,Departamento de Epidemiología. Ministerio de Salud de Chile,Departamento de Epidemiología. Ministerio de Salud de Chile,https://www.dropbox.com/s/cj3p12oncrewh72/Informe_10_COVID_19_Chile.pdf.pdf.pdf?dl=0,Spanish,No,Observational,3/1/20,3/23/20,22,Top-level,General,Positive only,End-point and active,Both,,,,,,34,,,29,47,,49%,0%,0%,0%,100%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,9%,,,,52%,57%,52%,,4%,,,,47%,,45%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.07,,na,,,,0,
75,0,USA,Nationwide,12,34.83%,First 12 patients with coronavirus disease 2019 (COVID-19) in the United States,MedRxiv,The COVID-19 Investigation Team,10.1101/2020.03.09.20032896,English,No,Observational,1/20/20,2/22/20,33,Top-level,General,Positive only,End-point and active,Both,Both,No,Both,All,Both,53,,,,,,67%,,,,,,100%,75%,17%,,,,,1,1,0,3,8.33%,,,,16.67%,16.67%,8.33%,16.67%,8.33%,0.00%,8%,,0%,33.33%,58.33%,,,,66.67%,8.33%,25%,,,41.67%,,8.33%,,,8.33%,8.33%,,,0%,58.33%,50%,8.33%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,,0%,0%,,,,,,,,0.58,0.08,0.92,4,12.71,29,0,0
75,1,USA,Nationwide,7,38.76%,First 12 patients with coronavirus disease 2019 (COVID-19) in the United States,MedRxiv,The COVID-19 Investigation Team,10.1101/2020.03.09.20032896,English,No,Observational,1/20/20,2/22/20,33,Subgroup,Hospitalized,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,55,,,,,,71.40%,,,,,,100%,,,,,,,2,1,1,3,14.28%,,,,57.14%,14.28%,14.28%,14.28%,14.28%,0%,,,0%,28.57%,85.27%,,38.544,,85.71%,14.28%,14.28%,,,28.57%,,14.28%,,,,,,,0%,100%,85.72%,14.28%,1,3.65,3.3,3.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71.42%,42.85%,0%,0%,,,,,,0%,0%,,14.28%,,,,,,,,0%,,,,,0%,0%,,,,,,,,1,0.14,0.86,4,12.71,32,0,0
77,0,China,Wuhan,109,41.01%,Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome,MedRxiv,Liu et al. ,10.1101/2020.02.17.20024166,English,No,Observational,1/2/20,2/12/20,41,Top-level,General,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,Both,55,,,43,66,,54.10%,0%,0%,100%,0%,0%,,,,,,,,5,5,3,7,,,,,,33.90%,11%,,3.70%,,,5.50%,9.20%,,82.60%,,,,61.50%,,,,,56.90%,,11%,,,,,,,0%,,,,,5.2,4,7,0.9,0.5,1.2,,,,,,3.6,2.8,5.6,,,,,,23,30,9,6.5,13.4,4.3,65,91,31,,,0.1,600,,97.20%,98.20%,,,,,,,,,,,25.70%,,,0.00%,,,,,,,,48.60%,,,,,,,,,,,1,,0.72,,15,,0.28,0.28
77,1,China,Wuhan,56,41.01%,Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome,MedRxiv,Liu et al.,10.1101/2020.02.17.20024166,English,No,Observational,1/2/20,2/12/20,41,Subgroup,Non-ARDS,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,Both,49,,,37,59,,55.40%,0%,0%,100%,0%,0%,,,,,,,,4,4,2,6,,,,,,28.60%,1.80%,,3.60%,,,0.00%,3.60%,,85.70%,,,,64.30%,,,,,46.40%,,10.70%,,,,,,,0%,,,,,4.9,3.8,6.2,1,0.8,1.4,,,,,,3.2,2.4,4.2,,,,,,23,29,8.3,6.8,11.7,3.5,64,100,20,,,0.1,370,,94.60%,98.20%,,,,,,,,,,,3.60%,,,0.00%,,,,,,,,0%,,,,,,,,,,,1,,0.91,,15,,0.09,0.09
77,2,China,Wuhan,53,45.51%,Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome,MedRxiv,Liu et al.,10.1101/2020.02.17.20024166,English,No,Observational,1/2/20,2/12/20,41,Subgroup,ARDS,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,All,Both,61,,,52,70,,52.80%,0%,0%,100%,0%,0%,,,,,,,,7,7,5,9,,,,,,39.60%,20.80%,,3.80%,,,11.30%,15.10%,,79.20%,,,,58.50%,,,,,67.90%,,11.30%,,,,,,,0%,,,,,5.4,4.5,8,0.7,0.4,1.1,,,,,,4.1,3.1,7.1,,,,,,24,31,10.5,6.2,14.8,5.5,67,83,49,,,0.1,940,,100%,98.10%,86.80%,0%,26.40%,,11.30%,11.30%,0%,69.80%,54.70%,,49.10%,,,0.00%,,,,,,,,100%,,,,,,,,,,,1,,0.51,,16,,0.49,0.49
78,0,China,Nanjing,24,35.39%,"Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China",Science China Life Sciences,Hu et. al.,10.1101/2020.02.20.20025619,English,Yes,Observational,1/28/20,2/18/20,21,Top-level,General,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,32.5,,,19,57,,33.30%,0%,0%,100%,0%,0%,,33.30%,,,8,6,9,,,,,4.20%,,,,,8.30%,8.30%,4.20%,0%,0%,,4.20%,4.20%,,20.80%,,,,8.30%,,,,,8.30%,4.20%,,,,,,,,,,,,1,,,,,,,,,,,,,,,132,120,144,,,,,,,,,,,,,,,,,4.20%,87.50%,,,,,,,,0%,12.50%,,,,0%,0%,,,100%,,0%,,,,,,,,,,,,,,1,0,0.38,,,9.5,0,0
78,1,China,Nanjing,5,34.83%,"Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China",Science China Life Sciences,Hu et. al.,10.1101/2020.02.20.20025619,English,Yes,Observational,1/28/20,2/18/20,21,Subgroup,Symptomatic,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,53,,,23,65,,0%,0%,0%,100%,0%,0%,,60%,,,8,6,9,,,,,0%,,,,,0%,0%,0%,0%,0%,,0%,20%,,100%,,,,40%,,,,,40%,20%,,,,,,,,,,,,1,,,,,,,,,,,,,,,124,123,129,,,,,,,,,,,,,,,,,0%,100%,,,,,,,,0%,40%,,,,0%,0%,,,100%,,0%,,,,,,,,,,,,,,1,0,0,,,12,0,
78,2,China,Nanjing,19,33.71%,"Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China",Science China Life Sciences,Hu et. al.,10.1101/2020.02.20.20025619,English,Yes,Observational,1/28/20,2/18/20,21,Subgroup,Asymptomatic,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,32,,,15,57,,42.10%,0%,0%,100%,0%,0%,,26.30%,,,,,,,,,,5.30%,,,,,10.50%,10.50%,5.30%,0%,0%,,5.30%,0%,,0%,,,,0%,,,,,0%,0%,,,,,,,,,,,,1,,,,,,,,,,,,,,,134.5,120,152,,,,,,,,,,,,,,,,,5.30%,84.20%,,,,,,,,0%,5.30%,,,,0%,0%,,,100%,,0%,,,,,,,,,,,,,,1,0,0.5,,,6,0,0
79,0,China,Wuhan,25,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025239,English,No,Observational,1/14/20,2/13/20,30,Top-level,General,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,73,71.88,24.35,62,78,,40.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,64%,36%,36%,8%,16%,0%,0%,0%,36%,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,10.56,,1,1
79,1,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025240,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 1,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,55,55,0,55,55,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,100.00%,0.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,4.39,4.39,4.39,0.35,,,,,,,,,,,,,,,,,,,,,,,,14.1,,,0.02,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,17,,1,1
79,2,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025241,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 2,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,62,62,0,62,62,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,100.00%,0.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,7.27,7.27,7.27,0.32,,,,,,,,,,,,,,,,,,,,,,,,83.5,,,1.42,0.01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,11,,1,1
79,3,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025242,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 3,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,81,81,0,81,81,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,100.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,1,1.29,1.29,1.29,0.49,,,,,,,,,,,,,,,,,,,,,,,,52.9,,,0.13,0.07,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,17,,1,1
79,4,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025243,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 4,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,72,72,0,72,72,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,100.00%,100.00%,100%,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,8.9,8.9,8.9,0.9,,,,,,,,,,,,,,,,,,,,,,,,211,,,0.89,0.08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,10,,1,1
79,5,China,Wuhan,1,29.78%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025244,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 5,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,83,83,0,83,83,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,100.00%,100.00%,0%,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,4.07,4.07,4.07,0.2,,,,,,,,,,,,,,,,,,,,,,,,76.1,,,,0.54,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,7,,1,1
79,6,China,Wuhan,1,29.21%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025245,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 6,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,70,70,0,70,70,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,7.95,7.95,7.95,0.51,,,,,,,,,,,,,,,,,,,,,,,,201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,8,,1,1
79,7,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025246,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 7,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,73,73,0,73,73,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,0.00%,100.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,9,,1,1
79,8,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025247,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 8,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,74,74,0,74,74,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,0.00%,100.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,8,,1,1
79,9,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025248,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 9,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,82,82,0,82,82,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,100.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,7,,1,1
79,10,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025249,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 10,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,78,78,0,78,78,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,0%,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,10,,1,1
79,11,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025250,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 11,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,78,78,0,78,78,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,9,,1,1
79,12,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025251,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 12,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,67,67,0,67,67,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,100.00%,0.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,7,,1,1
79,13,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025252,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 13,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,94,94,0,94,94,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,100.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,1,3.7,3.7,3.7,1.4,,,,,,,,,,,,,,,,,,,,,,,,58,,,0.07,0.18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,14,,1,1
79,14,China,Wuhan,1,29.78%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025253,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 14,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,69,69,0,69,69,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,0.00%,0.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,4.74,4.74,4.74,0.84,,,,,,,,,,,,,,,,,,,,,,,,19.9,,,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,13,,1,1
79,15,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025254,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 15,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,90,90,0,90,90,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,0%,0%,0%,100%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,9,,1,1
79,16,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025255,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 16,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,75,75,0,75,75,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,100.00%,0.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,11.52,11.52,11.52,0.92,,,,,,,,,,,,,,,,,,,,,,,,39,,,0.12,0.34,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,7,,1,1
79,17,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025256,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 17,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,56,56,0,56,56,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,0.00%,0.00%,0%,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,14.49,14.49,14.49,1.2,,,,,,,,,,,,,,,,,,,,,,,,56.8,,,0.24,0.01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,7,,1,1
79,18,China,Wuhan,1,29.78%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025257,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 18,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,59,59,0,59,59,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,100.00%,0.00%,0%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,2.5,2.5,2.5,0.54,,,,,,,,,,,,,,,,,,,,,,,,7.6,,,0.08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,11,,1,1
79,19,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025258,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 19,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,56,56,0,56,56,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,100.00%,0.00%,0%,0%,0%,100%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,2.89,2.89,2.89,0.7,,,,,,,,,,,,,,,,,,,,,,,,4.9,,,0.11,0.06,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,17,,1,1
79,20,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025259,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 20,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,74,74,0,74,74,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,0%,0%,0%,100%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,8,,1,1
79,21,China,Wuhan,1,30.34%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025260,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 21,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,55,55,0,55,55,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,0.00%,0.00%,0%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,2.02,2.02,2.02,0.76,,,,,,,,,,,,,,,,,,,,,,,,31.8,,,0.07,0.01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,10,,1,1
79,22,China,Wuhan,1,29.78%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025261,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 22,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,64,64,0,64,64,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,0.00%,0.00%,0%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,9.08,9.08,9.08,0.06,,,,,,,,,,,,,,,,,,,,,,,,52,,,0.09,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,20,,1,1
79,23,China,Wuhan,1,29.78%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025262,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 23,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,74,74,0,74,74,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,0.00%,0%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,0,8.88,8.88,8.88,0.26,,,,,,,,,,,,,,,,,,,,,,,,19.2,,,0.13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,19,,1,1
79,24,China,Wuhan,1,28.65%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025263,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 24,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,56,56,0,56,56,,0.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,100.00%,0.00%,100.00%,0%,100%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,8.08,8.08,8.08,1.07,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,5,,1,1
79,25,China,Wuhan,1,26.40%,"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China",MedRxiv,Li et. al.,10.1101/2020.02.19.20025264,English,No,Observational,1/14/20,2/13/20,30,Subgroup,Patient 25,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,100,100,0,100,100,,100.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,100%,0.00%,100.00%,100.00%,100%,0%,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,4,,1,1
80,0,China,Chongqing,51,49.44%,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China",MedRxiv,Liu et al.,10.1101/2020.02.20.20025536,English,No,Observational,1/20/20,2/11/20,22,Top-level,General,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,All,Both,45,,,34,51,,62.70%,0%,0%,100%,0%,0%,92.30%,84.30%,,,,,,,,,,,,,,,7.80%,7.80%,,,,,,,,84.30%,,,,74.50%,21.60%,9.80%,31.40%,11.80%,43.10%,,7.80%,5.90%,,,,,,,,,,1,5.4,4.1,7.6,1.1,0.7,1.6,,,189,134,235,3.7,2.5,6,136,123,152,,40,18,21,,,,4.1,67,52,10.5,,0,0.04,0.28,,21.60%,100%,100%,0%,13.70%,,0%,0%,0%,19.60%,7.80%,,15.70%,,11.80%,2%,,,100%,94.10%,,,,,,,,,,,,,,,1,,0.98,,12,,0.02,0.02
80,1,China,Chongqing,44,47.19%,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China",MedRxiv,Liu et al.,10.1101/2020.02.20.20025536,English,No,Observational,1/20/20,2/11/20,22,Subgroup,Non-severe,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,Non-ventilation only,44,,,33,49,,63.70%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,6.80%,0%,,,,,,,,84.10%,,,,72.70%,11.40%,11.40%,31.80%,11.40%,36.40%,,9.10%,6.80%,,,,,,,,,,1,5.2,4.1,7.6,1.3,0.9,1.7,,,192,139,237,3.5,2.4,5.6,136,123,152,,41,18,21,,,,4.1,68,59,7.5,,0,0.04,0.28,,9%,100%,100%,0%,6.80%,,0%,0%,0%,,0%,,4.50%,,0%,0%,,,100%,95.50%,,,,,,,,,,,,,,,1,,1,,,,0,0
80,2,China,Chongqing,7,47.19%,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China",MedRxiv,Liu et al.,10.1101/2020.02.20.20025536,English,No,Observational,1/20/20,2/11/20,22,Subgroup,Severe,Positive only,End-point only,Both,Discharged only,Yes,ΝΑ,Severe/Critical Only,Both,52,,,44,60,,57.10%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,14.30%,57.10%,,,,,,,,85.70%,,,,85.70%,85.70%,0%,28.60%,14.30%,85.70%,,0%,0%,,,,,,,,,,1,5.7,3.5,10.7,0.37,0.3,0.6,,,150,116,225,5.2,3.2,9.9,132,121,152,,35,26,29,,,,5.1,67,42,135.7,,4.6,0.1,0.6,,100%,100%,100%,0%,57%,,0%,0%,0%,,57.10%,,85.70%,,85.70%,14.30%,,,100%,85.70%,,,,,,,,,,,,,,,1,,0.86,,,,0.14,0.14
81,0,China,Wuhan,110,38.76%,"Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China",MedRxiv,Wang et. al.,10.1101/2020.03.02.20029306,English,No,Observational,1/1/20,2/10/20,40,Top-level,Patients with pneumonia,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,All,NA,45,,,,,,43.63%,0%,0%,100%,0%,0%,,,,,,,,,,,,23.63%,20.91%,,,,20.91%,13.63%,6.36%,5.46%,,,6.36%,,,81.82%,,,,61.82%,32.73%,,,,37.28%,,,,,,,,,0%,65.45%,34.55%,0%,0,5.21,4.04,6.68,1,0.55,1.45,,,167.41,137.59,206.2,3.68,2.51,5.1,131.55,114.33,148.76,,39.01,20.49,25.8,,,,4.3,62.18,,20.61,,,0.07,0.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,0,
81,1,China,Wuhan,38,38.76%,"Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China",MedRxiv,Wang et. al.,10.1101/2020.03.02.20029307,English,No,Observational,1/1/20,2/10/20,40,Subgroup,Severe pneumonia,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,Severe/Critical Only,NA,70,,,,,,63.16%,0%,0%,100%,0%,0%,,,,,,,,,,,,23.68%,10.53%,,,,39.47%,21.05%,7.89%,10.53%,,,7.89%,,,86.84%,,,,55.26%,39.47%,,,,26.32%,,,,,,,,,0%,0%,100%,0%,0,5.2,3.9,6.46,0.6,0.29,0.91,,,144.5,110.75,167.75,4.26,2.84,4.84,129.87,110.48,149.26,,35.3,21.9,36.8,,,,4.99,74.75,,49.8,,,0.12,1.11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,0,
81,2,China,Wuhan,72,38.76%,"Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China",MedRxiv,Wang et. al.,10.1101/2020.03.02.20029308,English,No,Observational,1/1/20,2/10/20,40,Subgroup,Non-severe pneumonia,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,All,NA,35,,,,,,33.33%,0%,0%,100%,0%,0%,,,,,,,,,,,,23.61%,26.39%,,,,11.11%,9.72%,5.56%,2.78%,,,5.56%,,,79.17%,,,,65.28%,29.17%,,,,43.06%,,,,,,,,,0%,100%,0%,0%,0,5.21,4.11,6.8,1.21,0.68,1.74,,,179.5,151.75,226.5,3.38,2.33,5.24,132.43,116.36,148.5,,40.97,19.75,20,,,,3.93,55.55,,5.2,,,0.05,0.37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,0,
82,0,China,Chongqing,46,56.18%,Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults,MedRxiv,Liao et al.,10.1101/2020.03.10.20032136,English,No,Observational,1/25/20,2/23/20,29,Top-level,General,Positive only,End-point and active,Survivors only,Both,Yes,ΝΑ,All,NA,26.2,,,,,,52.20%,0%,0%,100%,0%,0%,95.60%,47.80%,47.80%,7.2,,,,,,,,10.90%,28.90%,,37%,13%,,,,,,,,,,69.10%,,,,81%,2.40%,19.10%,38.10%,7.10%,19.10%,7.10%,4.80%,2.40%,9.50%,,,7.10%,,8.70%,,89.10%,2.20%,1,5,4.1,6.7,1.3,1,1.8,,,192.5,156,237,3.4,2.5,4.4,139.5,130,151,,,17.9,18.3,8.7,5.9,14.6,3.4,61.5,57,26,,,0.03,0.3,11,,100%,,,,,,,,,,,84.80%,84.80%,,,,,93.50%,,0%,0,0%,0%,,0,0,0,0,0,6.50%,0,0,0,1,,0.78,,,12.6,0,0
82,1,China,Chongqing,14,56.18%,Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults,MedRxiv,Liao et al.,10.1101/2020.03.10.20032136,English,No,Observational,1/25/20,2/23/20,29,Subgroup,Adolescents (10-24 yrs),Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,17.5,,,,,,50%,0%,0%,100%,0%,0%,100%,64.30%,35.70%,,,,,,,,,7.10%,21.40%,,28.60%,7.10%,,,,,,,,,,58.30%,,,,91.70%,0%,16.70%,50%,8.30%,16.70%,16.70%,16.70%,0%,0%,,,8.30%,,14.30%,,85.70%,0%,1,5.4,4.5,6.7,1.4,1.1,2.3,,,183,156,227,3.8,3.1,5.6,147,133,151,,,16.3,16.6,9,5.9,24.8,3.9,62.5,53,32,,,0.04,0.2,11.25,,100%,,,,,,,,,,,64.30%,64.30%,,,,,92.90%,,0%,0,0%,0%,,0,0,0,0,0,7.10%,0,0,0,1,0,0.86,,,12.6,0,0
82,2,China,Chongqing,32,55.62%,Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults,MedRxiv,Liao et al.,10.1101/2020.03.10.20032136,English,No,Observational,1/25/20,2/23/20,29,Subgroup,Young Adults (25-35 yrs),Positive only,End-point and active,Survivors only,Both,Yes,ΝΑ,All,NA,30,,,,,,53.10%,0%,0%,100%,0%,0%,93.70%,40.50%,53.10%,,,,,,,,,12.50%,32.30%,,40.60%,15.60%,,,,,,,,,,73.30%,,,,76.70%,6.70%,20%,33.30%,6.70%,20%,3.30%,0%,3.30%,13.30%,,,6.70%,,6.30%,,90.60%,3.10%,1,4.8,3.9,6.7,1.3,0.9,1.8,,,194.5,152,248,3.2,2.4,4.4,137.5,128.5,150.5,,,20,19.3,8.3,6.1,13.5,3.15,61.5,57.6,30,,,0.03,0.3,11,,100%,,,,,,,,,,,93.80%,93.80%,,,,,93.80%,,0%,0,0%,0%,,0,0,0,0,0,6.30%,0,0,0,1,,0.75,,,12.5,0,0
83,0,China,,64,53.37%,"Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis",MedRxiv,Liu et. al.,10.1101/2020.03.09.20033118,English,No,Observational,1/16/20,2/24/20,39,Top-level,General,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,All,Non-ventilation only,35,,,29,43,100%,36%,0%,0%,100%,0%,0%,23.40%,,23.40%,,,,,,8.5,4.3,15,2%,,21.4,,13%,5%,2%,,,,,,,3%,67%,,,,47%,16%,13%,13%,22%,34%,,5%,,6%,25%,5%,3%,,,98%,2%,,1,4.7,3.6,5.7,1.4,0.9,1.8,,,188,148,211,56.9,51.4,66.3,130,119,141,,,17.5,21.5,10,8.2,13.5,3.9,66.6,60,,,4.4,,0.2,,86.00%,100%,,,,,,,,11%,36%,50%,,53%,,,,,,52%,,,,,,,,,,,,,,,1,0,0.53,0,12.5,,0,0
83,1,China,,37,53.37%,"Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis",MedRxiv,Liu et. al.,10.1101/2020.03.09.20033119,English,No,Observational,1/16/20,2/24/20,39,Subgroup,Symptoms < 10 days,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,All,Non-ventilation only,37,,,32,44,100%,46%,0%,0%,100%,0%,0%,29.70%,,29.70%,,,,,,5,3,7,3%,,21.9,,16%,3%,3%,,,,,,,5%,68%,,,,46%,19%,8%,14%,22%,38%,,3%,,5%,32%,3%,5%,,,97%,2.70%,,1,4,3.4,5,1.3,0.9,1.6,,,160,130,201,56.3,50.3,66,133,124,142,,,20,23,9.5,7.9,12.5,3.9,68.3,62,,,4.7,,0.2,,100%,100%,,,,,,,,14%,49%,59%,,64%,,,,,,54%,,,,,,,,,,,,,,,1,0,0.51,0,18,,0,0
83,2,China,,25,52.81%,"Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis",MedRxiv,Liu et. al.,10.1101/2020.03.09.20033120,English,No,Observational,1/16/20,2/24/20,39,Subgroup,Symptoms >= 10 days,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,All,Non-ventilation only,30,,,27,36,100%,24%,0%,0%,100%,0%,0%,16%,,16%,,,,,,18,14,24,0%,,21.3,,8%,8%,0%,,,,,,,,68%,,,,52%,12%,20%,12%,20%,24%,,8%,,8%,16%,8%,0%,,,100%,0%,,1,5.7,4.7,6.6,1.6,1.1,2.2,,,195,178,247,57.5,51.5,65.1,125,119,136,,,15,17,12,8.2,14.5,4,65.8,60,,,3.3,,0.2,,68%,100%,,,,,,,,8%,20%,40%,,40%,,,,,,48%,,,,,,,,,,,,,,,1,0,0.52,0,9,,0,0
84,0,China,Wuhan,48,27.53%,Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O,MedRxiv,Xu et al.,10.1101/2020.02.26.20028084,English,No,Observational,1/6/20,1/31/20,25,Top-level,General,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,Both,Severe/Critical Only,NA,,39.08,13.88,,,,27.10%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,58.30%,,,,33.30%,2.10%,6.30%,,10.40%,12.50%,,8.30%,,4.20%,2.10%,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,39%,0%,0%,0%,,0%,39%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,0.13,0.02,0,,,,0,
84,1,China,Wuhan,42,27.53%,Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O,MedRxiv,Xu et al.,10.1101/2020.02.26.20028084,English,No,Observational,1/6/20,1/31/20,25,Subgroup,Non-hospitalized,Positive only,End-point and active,Survivors only,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,,36.93,11.57,,,,23.80%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,52.40%,,,,31%,2.40%,7.10%,,11.90%,11.90%,,9.50%,,4.80%,2.40%,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,0%,0%,,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,0,,,,0,
84,2,China,Wuhan,6,27.53%,Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O,MedRxiv,Xu et al.,10.1101/2020.02.26.20028084,English,No,Observational,1/6/20,1/31/20,25,Subgroup,Hospitalized,Positive only,End-point and active,Survivors only,Both,Yes,Both,Severe/Critical Only,NA,,54,18.61,,,,50%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,50%,0%,0%,,0%,16.70%,,0%,,0%,0%,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,0%,100%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.17,0,,,,0,
85,0,China,Wuhan,104,51.12%,"Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China",MedRxiv,Qiu et al.,10.1101/2020.03.04.20026005,English,No,Observational,1/22/20,2/12/20,21,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,43,7.54,,,,47.12%,0%,0%,100%,0%,0%,89.42%,46%,,,6,,,6,,,,3.85%,1.92%,,,,14.42%,11.54%,6.73%,0.96%,,,,,,63.46%,,,,75.96%,14.42%,,37.50%,19.23%,31.73%,,1.92%,,,,,,,,,15.38%,,1,5.04,4.13,7.06,0.97,0.71,1.47,,,197.1,130.85,263.35,,,,137.74,121.1,154.38,,37.35,20,26,10.9,7.55,16.65,,66.09,71,11.75,,,0.04,0.47,,20.19%,99.04%,82.69%,0%,0.00%,,,63.46%,0.00%,8.65%,13.46%,,,,,,,,93.27%,8.65%,,,,11.54%,,,,4.81%,,2.14%,1.92%,,,,1,0.09,0.38,,10.45,,0.01,0.02
85,1,China,Wuhan,48,48.88%,"Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China",MedRxiv,Qiu et al.,10.1101/2020.03.04.20026005,English,No,Observational,1/22/20,2/12/20,21,Subgroup,Imported,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,,40,10.67,,,,45.83%,0%,0%,100%,0%,0%,,100%,,,5.5,,,6,,,,2.08%,2.08%,,,,12.50%,14.58%,2.08%,0%,,,,,,75%,,,,75%,18.75%,,29.17%,27.08%,33.33%,,0%,,,,,,,,,16.67%,,1,4.99,4.16,5.94,0.85,0.66,1.09,,,198.27,128.46,268.08,,,,138.52,123.7,153.34,,37.43,19.75,25.65,11.04,7.6,19.62,,64.17,71.5,11.35,,,0.03,0.45,,22.92%,100%,,0%,0.00%,,,,0.00%,10.42%,20.83%,,,,,,,,,8.33%,,,,10.42%,,,,6.25%,,0%,0%,,,,1,0.06,0.52,,11.16,,0,0
85,2,China,Wuhan,56,48.88%,"Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China",MedRxiv,Qiu et al.,10.1101/2020.03.04.20026005,English,No,Observational,1/22/20,2/12/20,21,Subgroup,Indigenous,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,44,19.76,,,,48.21%,0%,0%,100%,0%,0%,,0%,,,6,,,6,,,,5.36%,1.79%,,,,16.07%,8.93%,10.71%,1.79%,,,,,,53.57%,,,,76.79%,10.71%,,44.64%,12.50%,30.36%,,3.57%,,,,,,,,,14.28%,,1,5.14,4.09,7.5,1.08,0.76,1.64,,,196.04,132.52,259.56,,,,14.82,0,33.06,,37.29,20.5,26.5,7.26,7.26,14.01,,67.81,69.5,11.95,,,0.04,0.51,,17.86%,98.21%,,0%,0.00%,,,,0.00%,7.14%,7.14%,,,,,,,,,8.93%,,,,12.50%,,,,3.57%,,5.36%,3.57%,,,,1,0.11,0.27,,9.27,,0.02,0.06
86,0,Scotland,,1,67.42%,The index case of SARS-CoV-2 in Scotland: a case report,Journal of Infection,Hill et. al.,https://doi.org/10.1016/j.jinf.2020.03.022,English,Yes,Observational,1/3/20,9/3/20,7,Top-level,General,Positive only,End-point only,Both,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,51,51,,51,51,0%,100%,100%,0%,0%,0%,0%,100%,0%,100%,7,7,7,7,3,3,3,3,0%,,,,,100%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,,100%,0%,0%,100%,100%,100%,,0%,0%,0%,100%,0%,,,0%,100%,0%,0%,0,4.9,4.9,4.9,1.6,1.6,1.6,,,239,239,239,2.5,,,,,,,,,,,,,,,,4,,,,,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,1,0,1,,8,8,0,0
87,0,UK,England,2,65.17%,Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission,Journal of Infection,Lillie et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30102-X/fulltext,English,Yes,Observational,1/23/20,2/6/20,14,Top-level,General,Positive only,End-point only,Both,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,36.5,36.5,,23,50,,50%,100%,0%,0%,0%,0%,100%,50%,50%,4,4,4,4,4,4,3,5,,,,,,0%,0%,0%,0%,0%,,,0%,0%,50%,37.3,37.3,,50%,0%,0%,0%,50%,0%,0%,0%,0%,0%,50%,0%,,,0%,100%,0%,0%,0,6.95,3.4,10.5,0.85,0.6,1.1,,,,,,5.54,2.4,8.67,,,,,,61,56,,,,,,,27.5,,,,,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,50%,0%,0%,0%,1,0,1,,6.5,8.5,0,0
87,1,UK,England,1,65.17%,Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission,Journal of Infection,Lillie et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30102-X/fulltext,English,Yes,Observational,1/23/20,2/6/20,14,Subgroup,Patient 1,Positive only,End-point only,Both,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,50,50,,50,50,,0%,100%,0%,0%,0%,0%,100%,100%,0%,4,4,4,4,5,5,5,5,,,,,,0%,0%,0%,0%,0%,,,0%,0%,100%,37.6,37.6,,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,0%,100%,0%,0%,0,3.4,3.4,3.4,0.6,0.6,0.6,,,,,,2.4,2.4,2.4,,,,,,47,46,,,,,,,15,,,,,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,0%,0%,0%,0%,1,0,1,,4,7,0,0
87,2,UK,England,1,65.17%,Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission,Journal of Infection,Lillie et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30102-X/fulltext,English,Yes,Observational,1/23/20,2/6/20,14,Subgroup,Patient 2,Positive only,End-point only,Both,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,23,23,,23,23,,100%,100%,0%,0%,0%,0%,100%,0%,100%,4,4,4,4,3,3,3,3,,,,,,0%,0%,0%,0%,0%,,,0%,0%,0%,37,37,,0%,0%,0%,0%,100%,0%,0%,0%,0%,0%,100%,0%,,,0%,100%,0%,0%,0,10.5,10.5,10.5,1.1,1.1,1.1,,,,,,8.67,8.67,8.67,,,,,,75,66,,,,,,,40,,,,,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,,,0%,0%,0%,0%,,0%,0%,0%,0%,0%,100%,0%,0%,0%,1,0,1,,9,10,0,0
88,0,USA,Illinois,2,26.40%,First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.,The Lancet,Ghinai et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30607-3/fulltext,English,Yes,Observational,1/23/20,2/18/20,26,Top-level,General,Positive only,End-point only,Survivors only,Discharged only,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,50%,,,,,,100%,50%,50%,,,,,8,8,8,8,,,,,,,,,50%,,,,,,100%,,,,100%,,50%,,,100%,,,100%,,,,50%,,,,,,,3.2,3.2,3.2,0.75,0.75,0.75,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,17,32,0,
88,1,USA,Illinois,1,26.40%,First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.,The Lancet,Ghinai et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30607-3/fulltext,English,Yes,Observational,1/23/20,2/18/20,26,Subgroup,Patient 1,Positive only,End-point only,Survivors only,Discharged only,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,0%,,,,,,100%,100%,0%,,,,,6,6,6,6,,,,,,,,,0%,,,,,,100%,,,,100%,,0%,,,100%,,,100%,,,,100%,,,,,,,3,3,3,0.7,0.7,0.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,14,33,0,
88,2,USA,Illinois,1,26.40%,First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.,The Lancet,Ghinai et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30607-3/fulltext,English,Yes,Observational,1/23/20,2/18/20,26,Subgroup,Patient 2,Positive only,End-point only,Survivors only,Discharged only,No,Non-ICU only,Mild only,Non-ventilation only,,,,,,,100%,,,,,,100%,0%,100%,,,,,10,10,10,10,,,,,,,,,100%,,,,,,100%,,,,100%,,100%,,,100%,,,100%,,,,0%,,,,,,,3.4,3.4,3.4,0.8,0.8,0.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,20,31,0,
89,0,South Korea,Nationwide,28,23.60%,Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea,Osong Public Health and Research Perspectives,Osong Public Health Dept,https://ophrp.org/journal/view.php?doi=10.24171/j.phrp.2020.11.1.03,English,Yes,Observational,1/20/20,2/14/20,25,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,,42.6,,,,,53.60%,0%,0%,100%,0%,0%,,57%,36%,4.1,,,,,,,,,,,,35.70%,,,,,3.60%,,,,,32.10%,,,,17.90%,,,17.90%,14.30%,,,,,,32.10%,17.90%,,,11%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.25,,12.7,,,
90,0,Australia,Nationwide,295,16.85%,"COVID-19, Australia: Epidemiology Report 7 (Reporting week ending 19:00 AEDT 14 March 2020).",COVID-19 National Surveillance Team,COVID-19 National Surveillance Team,https://www1.health.gov.au/internet/main/publishing.nsf/Content/1D03BCB527F40C8BCA258503000302EB/$File/covid_19_australia_epidemiology_report_7_reporting_week_ending_19_00_aedt_14_march_2020.pdf,English,No,Observational,1/12/20,3/14/20,62,Top-level,General,Positive only,End-point and active,Both,,,,,,47,47,,,,,50%,,,,,,86%,,,,,,,,,,,,,,,,,,,,,,,,,36.60%,,,,28.50%,18.60%,10.50%,,7.50%,,,16.30%,11.50%,,24.40%,,3.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.27,,,,,,0.01,
91,0,China,Zhejiang,651,60.11%,"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms",Gut,Jin et. al.,https://gut.bmj.com/content/gutjnl/early/2020/03/24/gutjnl-2020-320926.full.pdf,English,Yes,Observational,1/27/20,2/8/20,12,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,45.20935484,45.20935484,14.42044547,30.78890937,59.62980031,,50.84%,0%,0%,100%,0%,0%,99.39%,59.14%,40.24%,,,,,,,,,6.32%,,,,27.35%,15.36%,7.38%,0.77%,0.15%,0.92%,3.84%,,0.92%,0.61%,83.72%,,,,66.82%,4.15%,,34.87%,,18.28%,,44.32%,44.32%,,,,,,,9.83%,,,1,4.72,3.76,5.95,1.17,0.88,1.57,,,177.68,145.43,217.77,2.93,2.18,4,137.72,127.89,150.81,40.37,41.34,21.9,24.96,9.65,7.02,13.18,3.75,66,66,8.79,5.82,,0.05,,,42.55%,83.87%,83.87%,0%,0%,,83.87%,83.87%,0%,11.37%,0%,,,,0%,2.61%,0%,0%,83.87%,0%,0.30%,2.61%,2.61%,2.61%,,0%,0.30%,9.83%,,,,,,,1,0.03,,,,,0,
91,1,China,Zhejiang,74,60.11%,"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms",Gut,Jin et. al.,https://gut.bmj.com/content/gutjnl/early/2020/03/24/gutjnl-2020-320926.full.pdf,English,Yes,Observational,1/27/20,2/8/20,12,Subgroup,GI Symptoms,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,46.14,46.14,14.19,31.95,60.33,,50%,0%,0%,100%,0%,0%,94.59%,51.35%,43.24%,,,,,,,,,4.23%,,,,33.78%,16.22%,9.46%,1.35%,0%,0%,11%,,0%,0%,85.14%,,,,71.62%,10.81%,,39.19%,,31.08%,,0%,0%,,,,,,,22.97%,,,1,4.85,3.8,6.34,0.97,0.73,1.3,,,183,141,216,3.14,2.6,4.7,135.5,127,149.3,39.4,40.13,25,29.35,10,7.15,13.8,3.35,66,73,15.69,5.95,,0.06,,,41.89%,89.19%,89.19%,0%,0%,,89.19%,89.19%,0%,14.86%,0%,,,,0%,6.76%,0%,0%,89.19%,0%,1.35%,6.76%,6.76%,6.76%,,0%,1.35%,17.57%,,,,,,,1,0.07,,,,,0,
91,2,China,Zhejiang,577,60.11%,"Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms",Gut,Jin et. al.,https://gut.bmj.com/content/gutjnl/early/2020/03/24/gutjnl-2020-320926.full.pdf,English,Yes,Observational,1/27/20,2/8/20,12,Subgroup,No GI Symptoms,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,45.09,45.09,14.45,30.64,59.54,,50.95%,0%,0%,100%,0%,0%,100.00%,60.14%,39.86%,,,,,,,,,6.59%,,,,26.52%,15.25%,7.11%,0.69%,0.17%,1.04%,2.95%,,1.04%,0.69%,83.54%,,,,66.20%,3.30%,,34.32%,,16.64%,,50%,50%,,,,,,,8.14%,,,1,4.7,3.76,5.9,1.2,0.9,1.6,,,177,146,218,2.9,2.13,3.91,138,128,151,40.5,41.5,21.5,24.4,9.6,7,13.1,3.8,66,70,7.9,5.8,,0.05,,,42.63%,83.19%,83.19%,0%,0%,,83.19%,83.19%,0%,10.92%,0%,,,,0%,2.08%,0%,0%,83.19%,0%,0.17%,2.08%,2.08%,2.08%,,0%,0.17%,8.84%,,,,,,,1,0.02,,,,,0,
92,0,China,Hunan,10,44.94%,Short-Term Moderate-Dose Corticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy,preprints.org,Zhou et. al.,https://www.preprints.org/manuscript/202003.0065/v2,English,No,Observational,1/17/20,2/27/20,41,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,,Both,51.6,,,29,68,0,80%,0%,0%,100%,0%,0%,100%,40%,60%,,,,,5.4,5.4,2,15,,,,,40%,30%,,10%,,,,,,,90%,37.59,,,60%,60%,30%,40%,,10%,,30%,10%,,,,10%,,,,,,0,,,,0.59,0.41,0.77,,,,,,,,,,,,,30.27,34.27,51.6,13.88,7.67,20.09,6.83,61.14,317.12,,,,,,,90%,100%,,,,,,,,100%,100%,70%,60%,100%,30%,10%,0%,10%,,,,,,10%,,,,80%,,,60%,40%,,,1,,0.4,,,,0.1,
93,0,China,Shenzhen,5,46.63%,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,Yes,Observational,1/20/20,3/25/20,65,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,65,59,29.71880544,55,65,,60%,0%,0%,100%,0%,0%,,,,6.6,7,3,7,2.6,2,2,3,0%,,,,20%,20%,0%,0%,0%,0%,0%,0%,0%,0%,100%,37.552,38.5,,,,,,,,,,,,,,,,,100%,0%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,160.06,,147.9,1.8,,,,100%,80%,40%,0%,,0%,0%,0%,0%,0%,,,100%,0%,100%,20%,,80%,,,100%,,100%,,,,,,20%,,,,,1,1,0.6,,53,,0,0
93,1,China,Shenzhen,1,45.51%,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,Yes,Observational,1/20/20,3/25/20,65,Subgroup,Patient 1,Positive only,Active only,Both,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,75,75,0,75,75,,100%,0%,0%,100%,0%,0%,,,,1,1,1,1,2,2,2,2,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,38,38.6,,,,,,,,,,,,,,,,,100%,0%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,163.4,,70.5,1.2,,,,100%,100%,100%,0%,,0%,0%,0%,0%,0%,,,100%,0%,100%,0%,,100%,,,100%,,100%,,,,,,0%,,,,,1,1,0,,,,0,
93,2,China,Shenzhen,1,45.51%,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,Yes,Observational,1/21/20,3/26/20,65,Subgroup,Patient 2,Positive only,Active only,Both,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,65,65,0,65,65,,100.00%,0%,0%,100%,0%,0%,,,,7,7,7,7,4,4,4,4,0%,,,,100%,100%,0%,100%,0%,0%,0%,0%,0%,0%,100.00%,37.28,39,,,,,,,,,,,,,,,,,100%,0%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,242.8,,438.2,7.3,,,,100%,100%,0%,0%,,0%,0%,0%,0%,0%,,,100%,0%,100%,100%,,0%,,,100%,,100%,,,,,,100%,,,,,1,1,0,,,,0,
93,3,China,Shenzhen,1,46.63%,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,Yes,Observational,1/22/20,3/27/20,65,Subgroup,Patient 3,Positive only,End-point only,Both,Discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,55,55,0,55,55,,0.00%,0%,0%,100%,0%,0%,,,,3,3,3,3,2,2,2,2,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100.00%,37.08,37.6,,,,,,,,,,,,,,,,,100%,0%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,65,,63.9,0.1,,,,100%,100%,0%,0%,,0%,0%,0%,0%,0%,,,100%,0%,100%,0%,,100%,,,100%,,100%,,,,,,0%,,,,,1,1,1,,53,,0,0
93,4,China,Shenzhen,1,46.63%,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,Yes,Observational,1/23/20,3/28/20,65,Subgroup,Patient 4,Positive only,End-point only,Both,Discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,35,35,0,35,35,,0.00%,0%,0%,100%,0%,0%,,,,7,7,7,7,2,2,2,2,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100.00%,37.5,38.3,,,,,,,,,,,,,,,,,100%,0%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,156,,79.1,0.2,,,,100%,0%,100%,0%,,0%,0%,0%,0%,0%,,,100%,0%,100%,0%,,100%,,,100%,,100%,,,,,,0%,,,,,1,1,1,,51,,0,0
93,5,China,Shenzhen,1,46.63%,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,JAMA,Shen et. al.,doi:10.1001/jama.2020.4783,English,Yes,Observational,1/24/20,3/29/20,65,Subgroup,Patient 5,Positive only,End-point only,Both,Discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,65,65,0,65,65,,100.00%,0%,0%,100%,0%,0%,,,,15,15,15,15,3,3,3,3,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100.00%,37.9,39,,,,,,,,,,,,,,,,,100%,0%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,173.1,,87.8,0.2,,,,100%,100%,0%,0%,,0%,0%,0%,0%,0%,,,100%,0%,100%,0%,,100%,,,100%,,100%,,,,,,0%,,,,,1,1,1,,55,,0,0
94,0,Netherlands,Nationwide,86,21.35%,SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020,MedRxiv,Kluytmans et. al.,https://www.medrxiv.org/content/10.1101/2020.03.23.20041913v1,English,No,Observational,2/27/20,,,Top-level,General,Positive only,End-point and active,Survivors only,Both,No,Non-ICU only,All,NA,49,,,,,100%,17.40%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,53.50%,,,,75.60%,38.40%,57%,,64%,,,18.60%,17.40%,17.40%,39.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.02,,,,,8,0,
94,1,Netherlands,Nationwide,32,21.35%,SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020,MedRxiv,Kluytmans et. al.,https://www.medrxiv.org/content/10.1101/2020.03.23.20041913v1,English,No,Observational,2/27/20,,,Top-level,General,Positive only,End-point and active,Survivors only,Both,No,Non-ICU only,All,NA,47,,,,,100%,18.80%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,62.50%,,,,65.60%,18.80%,56.30%,,65.60%,,,15.60%,3.10%,3.10%,34.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,5,0,
94,2,Netherlands,Nationwide,54,21.35%,SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020,MedRxiv,Kluytmans et. al.,https://www.medrxiv.org/content/10.1101/2020.03.23.20041913v1,English,No,Observational,2/27/20,,,Top-level,General,Positive only,End-point and active,Survivors only,Both,No,Non-ICU only,All,NA,49,,,,,100%,16.70%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,48.10%,,,,81.50%,42.60%,57.40%,,81.50%,,,20.40%,25.90%,25.90%,50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.04,,,,,9,0,
95,0,China,Hangzhou,10,39.89%,Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression,,Liu et. al.,https://doi.org/10.1016/j.ijid.2020.03.013,English,Yes,Observational,1/22/20,2/11/20,20,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Non-ventilation only,42,,,34,50,,50%,0%,0%,100%,0%,0%,100%,60%,40%,,5,3,7,,,,,,,,,,10%,0%,10%,,0%,10%,,10%,,70%,,,10%,80%,0%,30%,40%,,,10%,0%,30%,,40%,,,,,,10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50%,100%,100%,0%,0%,,20%,20%,0%,30%,50%,90%,90%,,,,,,90%,,,,20%,,,,,,,0%,0%,,,,1,0.3,0.7,,13,,,
96,0,China,Wuhan,183,19.10%,Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.,J Thromb Haemost,Tang et. al.,https://www.ncbi.nlm.nih.gov/pubmed/32073213,English,Yes,Observational,1/1/20,2/3/20,34,Top-level,General,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,,54.1,16.2,,,,53.55%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,41%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.66,13.7,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0.11,
96,1,China,Wuhan,162,19.10%,Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.,J Thromb Haemost,Tang et. al.,https://www.ncbi.nlm.nih.gov/pubmed/32073213,English,Yes,Observational,1/1/20,2/3/20,34,Subgroup,Survivors,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,NA,,52.4,15.6,,,,50.62%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,38.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.61,13.6,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
96,2,China,Wuhan,21,19.10%,Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.,J Thromb Haemost,Tang et. al.,https://www.ncbi.nlm.nih.gov/pubmed/32073213,English,Yes,Observational,1/1/20,2/3/20,34,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,NA,,64,20.7,,,,76.19%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,57.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.12,15.5,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,1,
97,0,United Kingdom,Nationwide,775,24.72%,ICNARC report on COVID-19 in critical care,ICARNAC,ICARNAC,https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b,English,No,Observational,2/29/20,3/26/20,27,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,61,60.2,13.6,51,71,,70.50%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,0.10%,1.20%,4.70%,0.40%,,2.70%,37.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.70%,,,,,,,,,,,,,,,,,,,,1,1,0.11,4,,,0.1,0.48
97,1,United Kingdom,Nationwide,86,19.10%,ICNARC report on COVID-19 in critical care,ICARNAC,ICARNAC,https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b,English,No,Observational,2/29/20,3/26/20,27,Subgroup,COVID-19 - discharged alive from critical care,Positive only,End-point only,Survivors only,Discharged only,Yes,ICU only,Severe/Critical Only,Both,60,,,50,69,,59.30%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,8.14%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,38.37%,,,,,,,,,,,,,,,,,,,,1,1,,,,,0,
97,2,United Kingdom,Nationwide,79,20.22%,ICNARC report on COVID-19 in critical care,ICARNAC,ICARNAC,https://www.icnarc.org/DataServices/Attachments/Download/b5f59585-5870-ea11-9124-00505601089b,English,No,Observational,2/29/20,3/26/20,27,Subgroup,COVID-19 - died in critical care,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,ICU only,Severe/Critical Only,Both,70,,,65,80,,73.42%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,12.66%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,82.28%,,,,,,,,,,,,,,,,,,,,1,1,0,,,,1,1
98,0,China,Sichuan,81,50.56%,"Critical Care for Patients with Severe Covid-19 in Sichuan Province, China——A Provincial Cohort Study",MedRxiv,Liao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20041277v2.full.pdf,English,No,Observational,1/16/20,3/15/20,59,Top-level,General,Positive only,End-point only,Both,Both,Yes,ΝΑ,All,Both,50,,,39,65,,63%,0%,0%,100%,0%,0%,76.50%,45.70%,,,,,,,,,,3.70%,,24,,53.10%,18.50%,22.20%,6.20%,13.60%,0%,,6.20%,3.70%,42%,48.20%,,,,49.40%,30.90%,,,,37%,,,,,,,,,,,,,,6.2,4.5,7.8,0.8,0.6,1.1,,,166,136,217,5,0.6,1.1,,,,,,,,11.7,6.9,18.4,,67.8,,40.6,,,,0.78,,71.60%,,87.70%,0%,0%,,0%,30.90%,0%,54.30%,18.50%,63%,9.90%,96%,16%,0%,0%,6.20%,70.40%,0.00%,1.20%,37.70%,,37.70%,,,,,,,7.40%,,,,1,,0.88,,,,0.12,0.12
98,1,China,Sichuan,53,52.25%,"Critical Care for Patients with Severe Covid-19 in Sichuan Province, China——A Provincial Cohort Study",MedRxiv,Liao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20041277v2.full.pdf,English,No,Observational,1/16/20,3/15/20,59,Subgroup,Rapid Recovery,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,Both,49,,,39,63,,64.10%,0%,0%,100%,0%,0%,79.30%,49.10%,,,,,,,,,,1.90%,,24.5,,43.40%,17%,15.10%,3.80%,9.40%,0%,,3.80%,1.90%,34%,47.20%,,,,54.70%,32.10%,,,,37.70%,,,,,,,,,,65.43%,0%,0%,,6.3,4.9,8.2,0.8,0.6,1.1,,,178,139,237,4.6,0.6,1.1,,,,,,,,12.6,9,17.5,,62.1,,39.4,,,,0.74,,73.60%,,88.70%,0%,0%,,0%,24.50%,0%,50.90%,18.90%,64.20%,9.40%,98.10%,15.10%,0%,0%,0%,60%,0%,0%,37.70%,,37.70%,,,,,,,5.70%,,,,1,,1,,,,0,0
98,2,China,Sichuan,10,52.25%,"Critical Care for Patients with Severe Covid-19 in Sichuan Province, China——A Provincial Cohort Study",MedRxiv,Liao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20041277v2.full.pdf,English,No,Observational,1/16/20,3/15/20,59,Subgroup,No Recovery,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,ΝΑ,Severe/Critical Only,Both,76,,,64,80,,40%,0%,0%,100%,0%,0%,60%,30%,,,,,,,,,,10%,,25.2,,100%,40%,30%,30%,30%,0%,,30%,20%,90%,50%,,,,30%,30%,,,,20%,,,,,,,,,,0%,0%,12.35%,,6.7,4.9,7.4,0.4,0.3,1.1,,,124,111,147,5.4,0.3,1.1,,,,,,,,7.9,3.5,19.5,,80,,99.5,,,,1.34,,80%,,60%,0%,0%,,0%,50%,0%,60%,20%,70%,0%,80%,20%,0%,0%,50%,90%,0%,10%,40%,,40%,,,,,,,30%,,,,1,,0,,,,1,1
98,3,China,Sichuan,18,52.25%,"Critical Care for Patients with Severe Covid-19 in Sichuan Province, China——A Provincial Cohort Study",MedRxiv,Liao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20041277v2.full.pdf,English,No,Observational,1/16/20,3/15/20,59,Subgroup,Pronged Recovery,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Severe/Critical Only,Both,48,,,37,60,,72.20%,0%,0%,100%,0%,0%,77.80%,44.40%,,,,,,,,,,5.60%,,23.2,,55.60%,11.10%,38.90%,0%,16.70%,0%,,0%,0%,38.90%,50%,,,,61.10%,27.80%,,,,44.40%,,,,,,,,,,0%,22.22%,0%,,5.9,3.9,9.5,0.8,0.6,1.1,,,169.5,150,202,4.2,0.6,1.1,,,,,,,,10.8,6.2,19.7,,73.2,,33,,,,0.62,,61.10%,,100%,0%,0%,,0%,38.90%,0%,61.10%,16.70%,55.60%,16.70%,100.00%,16.70%,0%,0%,0%,89%,0%,0%,33.30%,,33.30%,,,,,,,0%,,,,1,,1,,,,0,0
99,0,China,Shenzhen,391,28.65%,"Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v3.full.pdf,English,No,Observational,1/14/20,2/12/20,27,Top-level,General,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,49,,,,,,47.80%,0%,0%,100%,0%,0%,96.93%,0%,22.25%,,,,,,,,,,,,,,,,,,,,,,,84.40%,,,,39.10%,3.10%,16.10%,,19.40%,13.60%,,0.80%,1%,,6.60%,5.60%,3.30%,,6.40%,84.70%,9%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.58,,20.8,20.8,0.01,0.01
99,1,China,Shenzhen,87,26.40%,"Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v3.full.pdf,English,No,Observational,1/14/20,2/12/20,27,Subgroup,Contact based,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,39,,,,,,27.60%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,3.2,,,,,,,,,,,,,,,,,,71.30%,,,,23%,8.30%,11.50%,,6.90%,8%,,1.10%,0%,,4.60%,2.30%,2.30%,,19.50%,77.10%,3.40%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
99,2,China,Shenzhen,292,26.40%,"Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v3.full.pdf,English,No,Observational,1/14/20,2/12/20,27,Subgroup,Symptom based,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,45,,,,,,55.10%,0%,0%,100%,0%,0%,100%,0%,0%,,,,,5.5,,,,,,,,,,,,,,,,,,88.40%,,,,43.50%,3.80%,17.50%,,23.60%,15.40%,,0.70%,1%,,6.50%,6.80%,3.80%,,2.70%,87.00%,10.30%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
99,3,China,Shenzhen,12,25.84%,"Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v3.full.pdf,English,No,Observational,1/14/20,2/12/20,27,Subgroup,Uknown,Positive only,End-point only,Both,Both,No,ΝΑ,All,NA,59,,,,,,16.70%,0%,0%,100%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,83.30%,,,,50%,0%,16.70%,,8.30%,8.30%,,0%,0%,,25%,0%,0%,,0%,83.40%,16.70%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
100,0,China,Wuhan,120,42.13%,Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection,MedRxiv,Yan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040832v1.full.pdf,English,No,Observational,1/31/20,3/9/20,38,Top-level,General,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,All,Both,52,,,35,63,,45%,0%,0%,100%,0%,0%,,,,,,,,,,,,10%,,,,,26.70%,8.30%,5.80%,1.60%,5.80%,,,0.80%,2.50%,,,,,,,,,,,,,,,,,,,0%,25.87%,25.03%,0.84%,,5.65,4.14,7.33,1.14,0.81,1.55,,,195,144,269,,,,,,,,,,31,,,,,61,,,,,,,,85%,65%,65%,0%,0%,,0%,0%,0%,45%,0%,0%,17.50%,,1.70%,0.80%,0%,0%,,,,,,,,,,,,,,,,,1,0,1,,21,23,0,0
100,1,China,Wuhan,78,35.96%,Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection,MedRxiv,Yan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040832v1.full.pdf,English,No,Observational,1/31/20,3/9/20,38,Subgroup,LPV/r group,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,All,Both,50,,,34,61,,44.90%,0%,0%,100%,0%,0%,,,,,,,,,,,,10.30%,,,,,24.40%,10.30%,6.40%,1.30%,5.10%,,,1.30%,2.60%,,,,,,,,,,,,,,,,,,,0%,32.10%,32.10%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,93.60%,100%,100%,0%,0%,,0%,0%,0%,56.40%,0%,0%,21.80%,,1.30%,1.30%,0%,0%,,,,,,,,,,,,,,,,,1,0,1,,23,22,0,0
100,2,China,Wuhan,42,35.96%,Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection,MedRxiv,Yan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040832v1.full.pdf,English,No,Observational,1/31/20,3/9/20,38,Subgroup,No LPV/r group,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,All,Both,57,,,36.5,66,,45.20%,0%,0%,100%,0%,0%,,,,,,,,,,,,9.50%,,,,,31%,4.80%,4.80%,2.40%,7.10%,,,0%,2.40%,,,,,,,,,,,,,,,,,,,0%,14.30%,11.90%,2.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71.40%,0%,0%,0%,0%,,0%,0%,0%,23.80%,0%,0%,9.50%,,2.40%,0%,0%,0%,,,,,,,,,,,,,,,,,1,0,1,,18.5,28.5,0,0
101,0,France,Marseille,80,35.39%,Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study,MedRxiv,Gautret et. al.,https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf,English,No,Observational,3/3/20,3/21/20,18,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,52.5,52.5,,42,62,,52.50%,100%,0%,0%,0%,0%,,,,,,,,4.8,4.8,0,10.4,,,,5%,,16.30%,11.20%,7.50%,10%,6.30%,,,,7.50%,15%,38.6,38.8,,58.80%,,,,,,,,,,16.30%,,,,5%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22.50%,100%,0%,0%,0%,,0%,0%,100%,,,,15%,,,,,,,,,,,,,,,,,,,,,,1,0.04,0.81,,4.6,4.1,0.01,0.01
102,0,China,Wuhan,236,34.83%,Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2.full.pdf,English,No,RCT,2/20/20,3/12/20,21,Top-level,General,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,51.52542373,51.52542373,,,,,46.61%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,27.96%,11.44%,,,,,,,24.57%,52.96%,,,,56.78%,5.51%,,10.17%,2.12%,28.39%,,15.68%,,,11.02%,,,,0%,11.44%,11.44%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,23.99%,100%,0%,49.15%,0%,,0%,50.85%,0%,6.35%,0%,0%,0%,,,,0%,0%,,,,2.09%,2.09%,,,,,,,,,,,,1,,0.56,,,,0,0
102,1,China,Wuhan,116,34.83%,Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2.full.pdf,English,No,RCT,2/20/20,3/12/20,21,Subgroup,Favipiravir group,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,50,50,,,,,50.86%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,31.03%,12.07%,,,,,,,18.96%,55.17%,,,,60.34%,7.76%,,11.21%,1.72%,34.48%,,18.97%,,,7.76%,,,,0%,15.52%,15.52%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.33%,100%,0%,100%,0%,,0%,0%,0%,4.30%,0%,0%,0%,,,,0%,0%,,,,0.80%,0.80%,,,,,,,,,,,,1,,0.61,,,,0,0
102,2,China,Wuhan,120,34.83%,Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2.full.pdf,English,No,RCT,2/20/20,3/12/20,21,Subgroup,Arbidol group,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,53,53,,,,,42.50%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,25.00%,10.83%,,,,,,,30.00%,50.83%,,,,53.33%,3.33%,,9.17%,2.50%,22.50%,,12.50%,,,14.17%,,,,0%,7.50%,7.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19.80%,100%,0%,0%,0%,,0%,100%,0%,8.33%,0%,0%,0%,,,,0%,0%,,,,3.33%,3.33%,,,,,,,,,,,,1,,0.52,,,,0,0
103,0,USA,Washington,167,20.22%,"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington",NEJM,McMichael et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2005412?articleTools=true,English,Yes,Observational,2/27/20,3/18/20,20,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,72,72,,,,29.90%,32.90%,,,,,,,,,,,,,,,,,,,,30.70%,,44.30%,22.80%,40.70%,21.60%,9%,5.90%,,25.70%,25.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.4,,,,,,0.21,0.53
103,1,USA,Washington,101,20.22%,"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington",NEJM,McMichael et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2005412?articleTools=true,English,Yes,Observational,2/27/20,3/18/20,20,Subgroup,Residents,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,83,83,,,,0%,31.70%,,,,,,,,,,,,,,,,,,,,6%,,67.30%,31.70%,60.40%,31.70%,14.90%,0.00%,,40.60%,36.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.55,,,,,,0.34,0.62
103,2,USA,Washington,50,20.22%,"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington",NEJM,McMichael et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2005412?articleTools=true,English,Yes,Observational,2/27/20,3/18/20,20,Subgroup,Healthcare Personel,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,43.5,43.5,,,,100%,24%,,,,,,,,,,,,,,,,,,,,18.80%,,8%,10%,8%,4%,0%,0%,,0%,6%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.06,,,,,,0,0
103,3,USA,Washington,16,20.22%,"Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington",NEJM,McMichael et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2005412?articleTools=true,English,Yes,Observational,2/27/20,3/18/20,20,Subgroup,Visitors,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,62.5,62.5,,,,0%,68.80%,,,,,,,,,,,,,,,,,,,,22.20%,,12.50%,6.20%,18.80%,12.50%,0%,3.60%,,12.50%,18.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5,,,,,,0.06,0.12
104,0,China,Wuhan,52,48.88%,"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study",The Lancet Respiratory Medicine,Yang et. al.,https://www.sciencedirect.com/science/article/pii/S2213260020300795,English,Yes,Observational,12/24/19,1/26/20,33,Top-level,General,Positive only,End-point only,Both,,,ICU only,Severe/Critical Only,,59.7,,13.3,,,,67%,0%,0%,100%,0%,0%,52%,33%,19%,,,,,,,,,4%,,,,,,17%,10%,8%,4%,29%,14%,29%,67%,98%,,,,77%,63.50%,6%,,11.50%,,,,4%,,6%,,2%,,,,,100%,,,,,0.67,,,,,180.62,113.38,247.85,,,,128.23,111.92,144.54,,,,,17.04,8.25,25.83,,79.01,,,,,,,12.13,94%,44%,13.50%,0%,35.00%,,0%,0%,0%,58%,54%,0%,63.50%,10%,56%,42%,12%,17%,0%,0%,,67%,,,,,,29%,,23%,29%,2%,,,1,1,0.15,,,,0.62,0.76
104,1,China,Wuhan,20,48.88%,"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study",The Lancet Respiratory Medicine,Yang et. al.,https://www.sciencedirect.com/science/article/pii/S2213260020300795,English,Yes,Observational,12/24/19,1/26/20,33,Subgroup,Survivors,Positive only,End-point only,Survivors only,,,ICU only,Severe/Critical Only,,51.9,,12.9,,,,70%,0%,0%,100%,0%,0%,55%,45%,10%,,,,,,,,,10%,,,,,,10%,10%,10%,5%,30%,0%,15%,45%,100%,,,,75%,60%,5%,,10%,,,,5%,,0%,,5%,,,,,100%,,,,,0.74,0.34,1.14,,,164,90,238,,,,127,107,147,,,,,13.1,8.8,17.4,,76.3,,,,,,,10.9,95%,65%,,0%,,,0%,0%,0%,70%,45%,0%,85%,12.50%,30%,15%,5%,5%,0%,0%,,45%,,,,,,30%,,15%,15%,0%,,,1,1,0.4,,,,0,0
104,2,China,Wuhan,32,50.00%,"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study",The Lancet Respiratory Medicine,Yang et. al.,https://www.sciencedirect.com/science/article/pii/S2213260020300795,English,Yes,Observational,12/24/19,1/26/20,33,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,,ICU only,Severe/Critical Only,,64.6,,11.2,,,,66%,0%,0%,100%,0%,0%,50%,25%,25%,,,,,,,,,0%,,,,,,22%,9%,6%,3%,28.00%,22.00%,37.50%,81%,97%,,,,78%,66%,6%,,12.50%,,,,3%,,9%,,0%,,,,,100%,,,,,0.62,0.25,0.99,,,191,128,254,,,,129,115,143,,,,,19.5,7.9,31.1,,80.7,,,,,,,12.9,94%,31%,,0%,,,0%,0%,0%,50%,59%,0%,50%,11.50%,72%,59%,16.00%,25%,0%,0%,,81%,,,,,,28%,,28%,37.50%,3%,,,1,1,0,7,,,1,1
106,0,China,Wuhan,155,48.88%,"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China",Clinical Infectious Diseases,Mo et. al.,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa270/5805508,English,Yes,Observational,1/1/20,2/5/20,36,Top-level,General,Positive only,End-point and active,Both,Both,Yes,,All,Both,54,,,42,66,,55.50%,0%,0%,100%,0%,0%,23.90%,,,,,,,,,,,3.90%,,,,45.80%,23.90%,9.70%,9.70%,3.20%,4.50%,4.50%,4.50%,3.90%,,81.30%,,38.5,,62.60%,32.30%,9.80%,,61.00%,73.20%,,4.50%,3.70%,,,,3.70%,,,40.60%,35.50%,23.50%,1,4.36,3.3,6.03,0.9,0.66,1.11,,,170,127,208,2.89,1.97,4.41,,,,,38,23,32,,,,,71,93,33,,45,0.05,191,,,29.00%,17.40%,,,,,20.00%,,51.00%,5.80%,,,65.80%,23.20%,,,,19.40%,7.10%,,,,,,,,,,,,,,,1,,0.45,,,,0.14,0.2
106,1,China,Wuhan,70,44.94%,"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China",Clinical Infectious Diseases,Mo et. al.,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa270/5805509,English,Yes,Observational,1/1/20,2/5/20,36,Subgroup,General,Positive only,,,,Yes,,All,Non-ventilation only,46,,,35,56,,44.30%,0%,0%,100%,0%,0%,22.90%,,,,,,,,,,,2.90%,,,,,21.40%,4.30%,0%,0%,2.90%,2.90%,0%,2.90%,,90.00%,,38.3,,61.40%,21.40%,6.80%,,63.60%,75.00%,,2.90%,4.50%,,,,4.50%,,,61.40%,34.30%,4.30%,1,4.16,3.33,5.18,0.97,0.79,0.56,,,179,146,219,2.72,1.88,3.53,,,,,39,20,32,,,,,65,100,23,,23,0.05,178,,,25.70%,8.60%,,,,,20.00%,,34.30%,2.90%,,,42.90%,0%,,,,12.90%,0%,,,,,,,,,,,,,,,1,,,,,,,
106,2,China,Wuhan,85,44.94%,"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China",Clinical Infectious Diseases,Mo et. al.,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa270/5805510,English,Yes,Observational,1/1/20,2/5/20,36,Subgroup,Refractory patients,Positive only,,,,Yes,,All,Both,61,,,52,70,,64.70%,0%,0%,100%,0%,0%,24.70%,,,,,,,,,,,4.70%,,,,,25.90%,14.10%,16.50%,4.70%,5.90%,5.90%,8.20%,4.70%,,74.10%,,38.8,,63.50%,41.20%,13.20%,,57.90%,71.10%,,5.90%,5.30%,,,,0.00%,,,23.50%,36.50%,40%,1,4.65,3.14,6.84,0.8,0.56,1.04,,,159,119,202,3.28,1.99,5.08,,,,,36,28,37,,,,,79,89,46,,64,0.05,213,,,31.80%,24.70%,,,,,20.00%,,64.70%,8.20%,,,84.70%,84.70%,,,,24.70%,12.90%,,,,,,,,,,,,,,,1,,,,,,,
107,0,China,Wuhan,83,37.64%,"Acute gastrointestinal injury in critically ill patients with coronavirus disease 2019 in Wuhan, China",MedRxiv,Sun et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20043570v1.full.pdf,English,No,Observational,2/10/20,3/16/20,35,Subgroup,no severe comorbidities,Positive only,End-point only,Both,,Yes,,Severe/Critical Only,,70,,,60,79,,71%,0%,0%,100%,0%,0%,,,,,,,,10,10,7,15,,,23.7,,,0%,,,0%,,,,,,40%,,,,22%,0.084,,,0.036,0.072,,4%,4%,,,,10%,,,,,1,0,10.3,7.44,14,0.6,0.43,0.83,,,,,,,,,,,,,,,,,,,,,,85.9,,,0.27,8.29,,,,,,,,,,,,,,,,1,1,,1,,,,0.928,,0.928,,0.446,19.30%,0.181,,0.446,0.361,,,,1,,0.52,,12,,0.48,0.48
107,1,China,Wuhan,11,20.79%,"Acute gastrointestinal injury in critically ill patients with coronavirus disease 2019 in Wuhan, China",MedRxiv,Sun et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20043570v1.full.pdf,English,No,Observational,2/10/20,3/16/20,35,Subgroup,No AGI,Positive only,Active only,Survivors only,,,,,,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,10,7,15,,,23.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.9,6.4,11.3,0.85,0.62,1.12,,,,,,,,,,,,,,,,,,,,,,82.7,,,0.17,2.65,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,,,,,1,,,,30,,0,
107,2,China,Wuhan,30,20.79%,"Acute gastrointestinal injury in critically ill patients with coronavirus disease 2019 in Wuhan, China",MedRxiv,Sun et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20043570v1.full.pdf,English,No,Observational,2/10/20,3/16/20,35,Subgroup,AGI I,Positive only,End-point and active,Both,,,,,,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,10,6,14.3,,,23.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.7,7.2,11.8,0.66,0.43,0.82,,,,,,,,,,,,,,,,,,,,,,72.3,,,0.19,4.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.70%,,,,,,,,1,,,,13.5,,0.47,
107,3,China,Wuhan,35,20.79%,"Acute gastrointestinal injury in critically ill patients with coronavirus disease 2019 in Wuhan, China",MedRxiv,Sun et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20043570v1.full.pdf,English,No,Observational,2/10/20,3/16/20,35,Subgroup,AGI II,Positive only,End-point and active,Both,,,,,,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,10,7,15,,,23.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11.9,8.1,15.1,0.51,0.38,0.76,,,,,,,,,,,,,,,,,,,,,,99.8,,,0.29,11.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,25.70%,,,,,,,,1,,,,18,,0.54,
107,4,China,Wuhan,7,20.79%,"Acute gastrointestinal injury in critically ill patients with coronavirus disease 2019 in Wuhan, China",MedRxiv,Sun et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20043570v1.full.pdf,English,No,Observational,2/10/20,3/16/20,35,Subgroup,AGI III-IV,Positive only,End-point and active,Both,,,,,,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,15,10,21,,,22.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16.6,12.9,25.5,0.59,0.37,0.85,,,,,,,,,,,,,,,,,,,,,,120.4,,,0.41,15.51,,,,,,,,,,,,,,,,,,,,,,,,,,,,71.40%,,,,,,,,1,,,,19,,1,
108,0,China,Wuhan,2,42.70%,A special case of COVID-19 with long duration of viral shedding for 49 days,MedRxiv,Tan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040071v1.full.pdf,English,No,Observational,2/8/20,3/17/20,40,Top-level,General,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,NA,60,60,,,,,50%,0%,0%,100%,0%,0%,,,,,,,,12.5,12.5,10,15,0%,,,,50%,0%,0%,0%,0%,0%,,,0%,50%,100%,,,0%,50%,,,,,,,0%,0%,,,,0%,,,100%,,,1,6.78,6.6,5.95,1.7,1.21,2.19,,,222,,,4.26,3.61,4.91,137,137,137,,40.15,24,,,,,,84.4,,,,2.3,,90,11.8,,100%,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,27.5,,0,0
108,1,China,Wuhan,1,43.82%,A special case of COVID-19 with long duration of viral shedding for 49 days,MedRxiv,Tan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040071v1.full.pdf,English,No,Observational,2/8/20,3/17/20,40,Subgroup,Patient 1,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,NA,45,45,,45,45,,100.00%,0%,0%,100%,0%,0%,,,,,,,,15,15,15,15,0,,,,0,0.00%,0%,0.00%,0,0,,,0,0,1,,,0,0,,,,,,,0,0,,,,0,,,100%,,,1,6.6,6.6,6.6,2.19,2.19,2.19,,,222,,,3.61,3.61,3.61,137,137,137,,41.9,24,,,,,,79,,,,2.3,,90,11.8,,1,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,39,,0,0
108,2,China,Wuhan,1,38.76%,A special case of COVID-19 with long duration of viral shedding for 49 days,MedRxiv,Tan et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040071v1.full.pdf,English,No,Observational,2/9/20,2/24/20,16,Subgroup,Patient 2,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,NA,75,75,,75,75,,0%,0%,0%,100%,0%,0%,,,,,,,,10,10,10,10,0%,,,,100%,0%,0%,0%,0%,0%,,,0%,100%,100%,,,0%,100%,,,,,,,0%,0%,,,,0%,,,100%,,,1,6.95,6.95,6.95,1.21,1.21,1.21,,,,,,4.91,4.91,4.91,,,,,38.4,,,,,,,89.8,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,16,,0,0
109,0,China,Wuhan,377,30.34%,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,No,Observational,1/1/20,2/28/20,58,Top-level,Extrapolated top-level stats,Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,53.71,,38.23,69.2,,45.09%,0%,0%,100%,0%,0%,,,,7.69,,3.14,12.24,,,,,,,,,,35.23%,22.30%,5.57%,,,,,,,,,,,,,,,,,,,,,,,,,,68.97%,31.03%,,,5.05,3.95,6.71,1.01,0.77,1.35,,,,,,3.59,2.58,5.12,,,,,38.55,20.32,23,,,,4.37,64.68,,23.19,,,,1.37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
109,1,China,Wuhan,171,30.34%,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,No,Observational,1/1/20,2/28/20,58,Subgroup,Non-severe (Train),Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,49.05,,32.44,65.66,,38.60%,0%,0%,100%,0%,0%,,,,7.61,,2.89,12.33,,,,,,,,,,23.29%,17%,4.09%,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,,,5.13,3.78,6.42,1.12,0.89,1.54,,,,,,3.25,2.32,4.55,,,,,39.74,19.6,20,,,,3.78,59.3,,8.5,,,,0.45,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
109,2,China,Wuhan,79,30.34%,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,No,Observational,1/1/20,2/28/20,58,Subgroup,Severe (Train),Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,65.23,,50.23,80.23,,56.96%,0%,0%,100%,0%,0%,,,,7.15,,3.32,10.98,,,,,,,,,,62.03%,36.71%,6.33%,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,,,5.51,4,7.3,0.66,0.46,0.95,,,,,,4.24,3.01,6.31,,,,,35.84,23.7,31.6,,,,5.58,72.1,,61,,,,3.26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
109,3,China,Wuhan,89,30.34%,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,No,Observational,1/1/20,2/28/20,58,Subgroup,Non-severe (Test),Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,47,,31.71,62.29,,40.45%,0%,0%,100%,0%,0%,,,,8.24,,3.45,13.03,,,,,,,,,,25.84%,14.61%,3.37%,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,,,5.2,3.99,6.3,1.22,0.91,1.51,,,,,,3.4,2.36,4.41,,,,,40.07,17.3,19,,,,3.92,64.8,,7.4,,,,0.56,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
109,4,China,Wuhan,38,30.34%,"A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.24.20042119v1.full.pdf,English,No,Observational,1/1/20,2/28/20,58,Subgroup,Severe (Test),Positive and Negative/Unconfirmed,End-point and active,Both,Both,No,ΝΑ,All,NA,,66.47,,54.57,78.37,,60.53%,0%,0%,100%,0%,0%,,,,7.89,,3.14,12.64,,,,,,,,,,55.26%,34.21%,15.79%,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,,,3.43,4.47,7.76,0.72,0.5,0.97,,,,,,4.24,3.4,6.83,,,,,35.22,23.6,27.95,,,,5.6,73.2,,47.7,,,,3.45,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
110,0,China,Wuhan,323,44.38%,"Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China",,Hu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20037721v1.full.pdf,English,No,Observational,1/8/20,3/10/20,63,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,61,,,23,91,2.80%,51.40%,0%,0%,100%,0%,0%,,,,,,,,,9,1,60,11.80%,11.10%,,,,32.50%,14.60%,12.70%,1.90%,1.50%,1.50%,12.70%,2.20%,9%,83.90%,,,,50.80%,4.30%,0.90%,,,,,,0.30%,,,0.30%,0.90%,,,47.00%,45.00%,8%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,94.10%,71.20%,8.70%,0%,69.70%,,4.33%,64.40%,0%,60.70%,0%,,,,32.50%,10.50%,,22.30%,6.80%,0%,,4%,31%,4%,,,13.30%,,,7.40%,5.30%,,,,1,,0.78,,,,0.11,0.12
110,1,China,Wuhan,151,42.70%,"Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China",,Hu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20037721v1.full.pdf,English,No,Observational,1/8/20,3/10/20,63,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,NA,56,,,23,89,4.60%,49.70%,0%,0%,100%,0%,0%,,,,,,,,,8.5,1,30,7.90%,11.90%,,,,25.80%,9.30%,5.30%,0%,0%,2.00%,5.30%,2.60%,5.30%,86.10%,,,,49%,4%,2%,,,,,,0%,,,0.70%,0%,,,100%,0%,0%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,94.70%,74.80%,0%,0%,77.20%,,0%,65.60%,0%,57.60%,0%,,,,19.20%,1.30%,,17.20%,5.30%,0%,,0.70%,8.60%,0.70%,,,2.60%,,,1.30%,1.30%,,,,1,,,,,,,
110,2,China,Wuhan,146,42.70%,"Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China",,Hu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20037721v1.full.pdf,English,No,Observational,1/8/20,3/10/20,63,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,NA,64,,,23,87,1.40%,52.70%,0%,0%,100%,0%,0%,,,,,,,,,10,1,60,15.10%,8.20%,,,,38.40%,15.10%,15.10%,3.40%,2.70%,1.40%,15.10%,2.10%,10.30%,82.90%,,,,52.70%,4.10%,0%,,,,,,0%,,,0%,1.40%,,,0%,100%,0%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,93.80%,67.80%,0%,0%,66.40%,,0%,65.10%,0%,58.90%,0%,,,,41.10%,8.90%,,28.80%,5.50%,0%,,2.70%,44.50%,2.70%,,,15.80%,,,6.20%,3.40%,,,,1,,,,,,,
110,3,China,Wuhan,26,42.70%,"Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China",,Hu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.25.20037721v1.full.pdf,English,No,Observational,1/8/20,3/10/20,63,Subgroup,Critical,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,NA,70,,,44,91,0%,53.80%,0%,0%,100%,0%,0%,,,,,,,,,8.5,2,20,15.40%,23.10%,,,,38.50%,42.30%,42.30%,3.80%,3.80%,0%,42%,0%,23.10%,76.90%,,,,50%,7.70%,0%,,,,,,3.80%,,,0%,3.80%,,,0%,0%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,92.30%,69.20%,100%,0%,73.10%,,53.80%,53.80%,0%,88.50%,0%,,,,61.50%,73.10%,,15.40%,23.10%,0%,,30.80%,84.60%,30.80%,,,61.50%,,,50%,38.50%,,,,1,,,,,,,
111,0,China,Wuhan,187,36.52%,Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19),JAMA Cardiology,Guo et. al.,https://jamanetwork.com/journals/jamacardiology/article-abstract/2763845,English,Yes,Observational,1/23/20,2/23/20,29,Top-level,General,Positive only,End-point only,Both,Both,Yes,ΝΑ,All,Both,,58.5,14.66,,,,48.70%,0%,0%,100%,0%,0%,,,,,,,,,,,,9.60%,,,,,32.60%,15%,11.20%,2.10%,7%,,,3.20%,,,,,,,,,,,,,,,,,,,,,,,,,4.9,3.8,7.4,0.8,0.6,1.1,,,,,,3.7,2.4,6.1,,,,,,23,21,,,,,61,,,,,0.08,0.43,12.8,97.90%,88.80%,,,,,,,,56.70%,11.20%,,,,24.10%,,,,,,,,,24.60%,,5.90%,,15.40%,34.10%,,14.60%,,,,1,,0.77,,16.63,,0.23,0.23
111,1,China,Wuhan,135,36.52%,Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19),JAMA Cardiology,Guo et. al.,https://jamanetwork.com/journals/jamacardiology/article-abstract/2763845,English,Yes,Observational,1/23/20,2/23/20,29,Subgroup,TnT level normal,Positive only,End-point only,Both,Both,Yes,ΝΑ,All,Both,,53.53,13.22,,,,42.20%,0%,0%,100%,0%,0%,,,,,,,,,,,,8.10%,,,,,20.70%,8.90%,3.00%,0%,5.20%,,,0.70%,,,,,,,,,,,,,,,,,,,,,,,,,4.6,3.7,6.1,0.84,0.63,1.13,,,,,,3.1,2.4,4.9,,,,,,23,29,,,,,55.7,,,,,0.05,0.29,12.4,97%,88.90%,,,,,,,,51.10%,10.40%,,,,10.40%,,,,,,,,,11.90%,,1.50%,,16.50%,20%,,4.70%,,,,1,,0.91,,17.27,,0.09,0.09
111,2,China,Wuhan,52,36.52%,Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19),JAMA Cardiology,Guo et. al.,https://jamanetwork.com/journals/jamacardiology/article-abstract/2763845,English,Yes,Observational,1/23/20,2/23/20,29,Subgroup,TnT level elevated,Positive only,End-point only,Both,Both,Yes,ΝΑ,All,Both,,71.4,9.43,,,,65.40%,0%,0%,100%,0%,0%,,,,,,,,,,,,13.50%,,,,,63.50%,30.80%,32.70%,7.70%,11.50%,,,9.60%,,,,,,,,,,,,,,,,,,,,,,,,,7.4,4.9,11.6,0.69,0.34,1.01,,,,,,6,3.5,10.1,,,,,,28.5,39.5,,,,,69.8,,,,,0.21,3.85,13.3,100%,88.50%,,,,,,,,71.20%,13.50%,,,,59.60%,,,,,,,,,57.70%,,17.30%,,13.20%,65.80%,,36.80%,,,,1,,0.4,,14.94,,0.6,0.6
112,0,China,Wuhan,416,48.88%,"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China",JAMA Cardiology,Shi et. al.,https://jamanetwork.com/journals/jamacardiology/fullarticle/2763524,English,Yes,Observational,1/20/20,2/10/20,21,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,64,,,21,95,,49.30%,0%,0%,100%,0%,0%,,,,,,,,,10,1,30,,,,,,30.50%,14.40%,10.60%,2.90%,2.20%,1.00%,5.30%,3.40%,5.30%,80.30%,,,,34.60%,28.10%,2.20%,5.50%,4.60%,13.20%,,3.80%,,,2.90%,,3.40%,,,,,,1,5.8,4.3,8.3,0.9,0.6,1.3,,,207,153,265,,,,124,11.1,13.4,,36,28,30,,,,,59.2,,45,,,0.07,,,56.50%,96.90%,,,,,,,,73.10%,62.30%,76%,,76%,12.30%,7.70%,,0.50%,,,,,,23.30%,,,,,2.90%,,1.90%,,6.50%,,1,,0.1,,,,0.14,0.59
112,1,China,Wuhan,82,48.88%,"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China",JAMA Cardiology,Shi et. al.,https://jamanetwork.com/journals/jamacardiology/fullarticle/2763524,English,Yes,Observational,1/20/20,2/10/20,21,Subgroup,With Cardiac Injury,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,74,,,34,95,,53.70%,0%,0%,100%,0%,0%,,,,,,,,,10,1,30,,,,,,59.80%,24.40%,29.30%,7.30%,8.50%,2.40%,15.90%,6.10%,15.90%,76.80%,,,,34.10%,31.70%,2.40%,3.70%,6.10%,18.30%,,1.20%,,,4.90%,,13.40%,,,,,,1,9.4,6.9,13.8,0.6,0.4,0.9,,,172,111,215,,,,125,10.8,13.2,,32,29,40,,,,,101.7,,102,,,0.27,,,82.90%,100%,,,,,,,,87.80%,82.90%,31.70%,,31.70%,46.30%,22%,,2.40%,,,,,,58.50%,,,,,7.30%,,8.50%,,13.40%,,1,,0.02,,,,0.51,0.96
112,2,China,Wuhan,334,48.88%,"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China",JAMA Cardiology,Shi et. al.,https://jamanetwork.com/journals/jamacardiology/fullarticle/2763524,English,Yes,Observational,1/20/20,2/10/20,21,Subgroup,Without Cardiac Injury,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,NA,60,,,21,90,,48.20%,0%,0%,100%,0%,0%,,,,,,,,,10,1,28,,,,,,23.40%,2.00%,6.00%,1.80%,0.60%,0.60%,2.70%,2.70%,2.70%,81.10%,,,,34.70%,27.20%,2.10%,6.00%,4.20%,12.00%,,4.50%,,,2.40%,,0.90%,,,,,,1,5.5,4.2,7.4,1,0.8,1.4,,,216,165,273,,,,124,11.2,13.5,,37,28,29,,,,,56.6,,37,,,0.06,,,50%,96.10%,,,,,,,,69.50%,57.20%,86.80%,,86.80%,3.90%,4.20%,,0%,,,,,,14.70%,,,,,1.80%,,0.30%,,4.80%,,1,,0.23,,,,0.05,0.16
113,0,China,Wuhan,173,22.47%,Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019,MedRxiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.02.20030189v1.full.pdf,English,No,Observational,1/11/20,2/9/20,29,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,48,,,35,61,,49%,0%,0%,100%,0%,0%,,72.80%,,,,,,,,,,,,,,24%,12%,6.40%,1.80%,,,,,,,,,,,,,,,,,,,,,,,,,,81.50%,,18.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.36,,,,0.01,0.03
113,1,China,Wuhan,141,23.03%,Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019,MedRxiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.02.20030189v1.full.pdf,English,No,Observational,1/11/20,2/9/20,29,Subgroup,Non-critical,Positive only,End-point and active,Both,Both,No,ΝΑ,Mild only,Non-ventilation only,41,,,33,56,,45%,0%,0%,100%,0%,0%,,71.40%,,,,,,,,,,,,,,18%,7.80%,4.30%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,,,,,,,,,,,,,,,,,,,1,,0.38,,,,0,0
113,2,China,Wuhan,32,23.03%,Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019,MedRxiv,Zhao et. al.,https://www.medrxiv.org/content/10.1101/2020.03.02.20030189v1.full.pdf,English,No,Observational,1/11/20,2/9/20,29,Subgroup,Critical,Positive only,End-point and active,Both,Both,No,ΝΑ,Severe/Critical Only,Ventilation only,64,,,58,66,,66%,0%,0%,100%,0%,0%,,78.10%,,,,,,,,,,,,,,47%,28%,16%,9.40%,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,1,,0.25,,,,0.06,0.2
114,0,China,Guangzhou,10,43.26%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Top-level,General,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,6.625,7.543,,2.1675,13.3975,0%,60.00%,0%,0%,100%,0%,0%,100%,70.00%,30.00%,,,,,,,,,0%,0%,,,,,,,,,,,,,70.00%,,38.5,,50.00%,,,,,,,30.00%,,,50.00%,,,,,,,,100.00%,7.8,4.7,8.8,1.75,1.35,4.73,,,286,229,301,2.76,1.97,6.48,124,115,137,,45.1,17,23,3.8,3.3,5.9,3.61,29,103,1.14,,15.34,0.11,320,13.61,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0.4,,20,,0,0
114,1,China,Guangzhou,1,43.26%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 1,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,6.17,6.17,,6.17,6.17,0%,100%,0%,0%,100%,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,100.00%,,39.1,,100.00%,,,,,,,100.00%,,,0.00%,,,,,,,,100.00%,12,12,12,1.35,1.35,1.35,,,229,229,229,9.24,9.24,9.24,115,115,115,,44.6,20,33,3.5,3.5,3.5,3.5,29,117,2.43,,8.62,0.1,410,13.5,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0,,28,,0,0
114,2,China,Guangzhou,1,43.26%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 2,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,12.58,12.58,,12.58,12.58,0%,0%,0%,0%,100%,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,100.00%,,39.2,,0.00%,,,,,,,0.00%,,,100.00%,,,,,,,,100.00%,4.6,4.6,4.6,0.89,0.89,0.89,,,173,173,173,3.21,3.21,3.21,124,124,124,,47.9,6,17,5.9,5.9,5.9,2.4,49,64,0.31,,14.25,0.13,280,14.4,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,1,,10,,0,0
114,3,China,Guangzhou,1,43.26%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 3,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,7.08,7.08,,7.08,7.08,0%,0%,0%,0%,100%,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,100.00%,,38.4,,100.00%,,,,,,,100.00%,,,100.00%,,,,,,,,100.00%,7.9,7.9,7.9,0.65,0.65,0.65,,,301,301,301,6.48,6.48,6.48,116,116,116,,39.8,11,23,2.6,2.6,2.6,2.5,29,71,16.13,,60.09,0.12,330,13.1,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0,,23,,0,0
114,4,China,Guangzhou,1,42.70%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 4,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,13.75,13.75,,13.75,13.75,0%,100%,0%,0%,100%,0%,0%,100%,0.00%,100.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,0.00%,,,,0.00%,,,,,,,0.00%,,,0.00%,,,,,,,,100.00%,4.7,4.7,4.7,2.17,2.17,2.17,,,141,141,141,1.97,1.97,1.97,145,145,145,,44.5,11,16,8.7,8.7,8.7,3.61,55,64,0.3,,14.4,0.08,260,15.3,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,1,,9,,0,0
114,5,China,Guangzhou,1,43.26%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 5,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,1.17,1.17,,1.17,1.17,0%,100%,0%,0%,100%,0%,0%,100%,0.00%,100.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,100.00%,,37.8,,0.00%,,,,,,,0.00%,,,0.00%,,,,,,,,100.00%,7.8,7.8,7.8,6.19,6.19,6.19,,,363,363,363,1.08,1.08,1.08,115,115,115,,45.1,31,62,2.8,2.8,2.8,3.2,22,278,1.14,,8.47,0.08,320,12.1,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0,,23,,0,0
114,6,China,Guangzhou,1,42.70%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 6,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,3.42,3.42,,3.42,3.42,0%,100%,0%,0%,100%,0%,0%,100%,0.00%,100.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,0.00%,,,,0.00%,,,,,,,0.00%,,,100.00%,,,,,,,,100.00%,8.8,8.8,8.8,4.73,4.73,4.73,,,286,286,286,2.76,2.76,2.76,135,135,135,,46,21,36,3.3,3.3,3.3,4.6,29,75,0.3,,8.93,0.08,240,13.3,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0,,21,,0,0
114,7,China,Guangzhou,1,42.70%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 7,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,15.67,15.67,,15.67,15.67,0%,0%,0%,0%,100%,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,100.00%,,38.5,,0.00%,,,,,,,0.00%,,,0.00%,,,,,,,,100.00%,4,4,4,1.66,1.66,1.66,,,291,291,291,1.99,1.99,1.99,137,137,137,,48.3,14,20,3.8,3.8,3.8,4.8,50,113,11.86,,4.46,0.08,230,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,1,,8,,0,0
114,8,China,Guangzhou,1,42.70%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 8,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,13.67,13.67,,13.67,13.67,0%,100%,0%,0%,100%,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,100.00%,,38.5,,100.00%,,,,,,,0.00%,,,100.00%,,,,,,,,100.00%,7.8,7.8,7.8,1.75,1.75,1.75,,,240,240,240,51,51,51,163,163,163,,48.2,17,22,6.6,6.6,6.6,5.9,59,103,22.05,,16.58,0.2,500,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0,,19,,0,0
114,9,China,Guangzhou,1,42.13%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 9,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,0.17,0.17,,0.17,0.17,0%,0%,0%,0%,100%,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,0.00%,,,,100.00%,,,,,,,0.00%,,,100.00%,,,,,,,,100.00%,10.8,10.8,10.8,9.05,9.05,9.05,,,342,342,342,1.23,1.23,1.23,102,102,102,,39.5,172,127,4.9,4.9,4.9,4.6,15,112,1.04,,2.23,0.11,840,13.6,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,1,,,,0,0
114,10,China,Guangzhou,1,26.40%,Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding,Nature Medicine,Xu et. al.,https://www.nature.com/articles/s41591-020-0817-4.pdf,English,Yes,Observational,1/14/20,2/20/20,37,Subgroup,Patient 10,Positive only,End-point and active,Both,Both,No,ΝΑ,All,NA,1.75,1.75,,1.75,1.75,0%,100%,0%,0%,100%,0%,0%,100%,100.00%,0.00%,,,,,,,,,0.00%,0.00%,,,,,,,,,,,,,100.00%,,38,,100.00%,,,,,,,100.00%,,,0.00%,,,,,,,,100.00%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,1,,0,,,,0,0
115,1,China,Hainan,18,44.94%,Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients,Journal of Infection,Liu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30116-X/pdf,English,Yes,Observational,1/1/20,2/15/20,45,Subgroup,Elderly,Positive only,End-point only,Both,Both,Yes,Both,All,Both,68,,,65.25,69.75,,66.67%,0%,0%,100%,0%,0%,,,,,,,,,,,,44.44%,,,,,27.78%,16.67%,11.11%,,,5.56%,,0%,,77.78%,,,,33.33%,11.11%,,33.33%,,11.11%,,,16.67%,,5.56%,,,,,,,,,5.38,4.33,6.13,,,,,,207,159,287,,,,107.35,92.13,120.35,,33,,,,,,,106.44,,22.74,,,0.04,,,66.67%,83.33%,83.33%,0%,0%,,0%,0%,0%,,22.22%,,94.44%,94.44%,5.56%,22.22%,5.56%,11.11%,33.33%,,,,,22.22%,,16.67%,5.56%,,,,38.89%,22.22%,,,1,,0.94,,,,0.06,0.06
115,2,China,Hainan,38,44.94%,Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients,Journal of Infection,Liu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30116-X/pdf,English,Yes,Observational,1/1/20,2/15/20,45,Subgroup,Young,Positive only,End-point only,Both,Both,Yes,Both,All,Both,47,,,35.75,51.25,,50.00%,0%,0%,100%,0%,0%,,,,,,,,,,,,36.84%,,,,,13.16%,2.63%,0%,,,0%,,2.63%,,78.95%,,,,39.47%,5.26%,,39.47%,,7.89%,,,18.42%,,5.26%,,,,,,,,,4.48,3.74,5.88,,,,,,215,180,287,,,,125.21,114.23,140.15,,39,,,,,,,88.71,,6.49,,,0.04,,,73.68%,86.84%,86.84%,0%,0%,,0%,0%,0%,,13.16%,,97.37%,97.37%,5.26%,7.89%,2.63%,7.89%,39.47%,,,,,5.26%,,10.53%,5.26%,,,,7.89%,13.16%,,,1,,0.95,,,,0.05,0.05
116,0,China,Hunan,32,27.53%,Comparisons of nucleic acid conversion time of SARS-CoV-2 ofdifferent samples in ICU and non-ICU patients,Journal of Infection,Fang et. al.,https://doi.org/10.1016/j.jinf.2020.03.013,English,Yes,Observational,1/1/20,2/29/20,59,Top-level,General,Positive only,End-point and active,Both,Both,No,Both,All,NA,41,,,,,,50.00%,0%,0%,100%,0%,0%,87.50%,43.80%,37.50%,5,,,,,,,,,,24.5,,,15.60%,12.50%,3.10%,,0%,6.30%,,,6.30%,53.10%,,,,75%,31.20%,18.80%,,18.80%,15.60%,,9.40%,,,21.90%,,,,12.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.25,,,,,,
117,0,China,Yichang,197,50.56%,"Clinical features and outcomes of 197 adult discharged patients with COIVD-19 in Yichang, Hubei",MedRxiv,Zhou et. al.,https://www.medrxiv.org/content/10.1101/2020.03.26.20041426v1.full.pdf,English,No,Observational,1/17/20,2/26/20,40,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,55.94,,37.11,74.77,,50.30%,0%,0%,100%,0%,0%,,20.80%,75.50%,6.14,,,,,,,,,,,,,,9.10%,24.40%,,1.50%,,4.60%,1.50%,,77.66%,,,,45.20%,5.10%,,,4.60%,14.70%,,,,,5.60%,,,,,,,,,5.79,2.66,8.92,1.13,0.39,1.87,,,165.35,97.38,233.32,4.18,1.12,7.24,,,,,,38.4,38.84,16.31,2.45,30.17,7.69,106.8,133.67,54.97,,112.69,0.46,2.31,11.18,76.60%,90.90%,0%,0%,90.90%,,0%,0%,0%,38.10%,26.90%,,76.60%,,15.30%,8.10%,,,,,,,,13.20%,,7.10%,6.10%,4.10%,,,8.10%,,,,1,0.29,,,15.08,,0.14,
118,0,China,Wuhan,80,43.82%,The potential role of IL-6 in monitoring severe case of coronavirus disease 2019,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf,English,No,Observational,1/21/20,2/16/20,26,Top-level,General,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,53,,,,,,42.50%,0%,0%,100%,0%,0%,,,,,,,,,,,,10%,,,,35%,17.50%,13.75%,7.50%,,8.75%,1%,0%,0%,,57.50%,,,,66.25%,,,18.75%,15%,45%,,18.75%,8.75%,,10%,16.25%,,,,,,,,,,,1.11,0.6,1.62,,,,,,,,,127.1,111.78,142.42,,,,,,,,,,,,,,,,,91.25%,,6.25%,0%,25%,,,61.25%,0%,36.25%,45%,48.75%,13.75%,48.75%,7.50%,2.50%,0%,0%,87.50%,0%,,,,8.75%,,,1.25%,,0%,,0%,,,,1,0.04,0.59,,22,,0,0
118,1,China,Wuhan,11,43.82%,The potential role of IL-6 in monitoring severe case of coronavirus disease 2019,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf,English,No,Observational,1/21/20,2/16/20,26,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,Yes,Both,Mild only,Both,31,,,,,,9.09%,0%,0%,100%,0%,0%,,,,,,,,,,,,0%,,,,27.27%,0%,0%,0%,,27.27%,0%,0%,0%,,18.18%,,,,81.82%,,,9.09%,0%,9.09%,,36.36%,18.18%,,36.36%,0%,,,,,,,,,,,1.61,1.22,2,,,,,,,,,127.8,111.67,143.93,,,,,,,,,,,,,,,,,100%,,0%,0%,54.55%,,,90.91%,0%,0%,9.09%,9.09%,0%,9%,0%,0%,0%,0%,91%,0%,,,,0%,,,0%,,0%,,0%,,,,1,0,0.91,,26,,0,0
118,2,China,Wuhan,69,43.82%,The potential role of IL-6 in monitoring severe case of coronavirus disease 2019,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf,English,No,Observational,1/21/20,2/16/20,26,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,56,,,,,,47.83%,0%,0%,100%,0%,0%,,,,,,,,,,,,11.59%,,,,36.23%,20.29%,15.94%,8.70%,,5.80%,1%,0%,0%,,63.77%,,,,63.77%,,,20.29%,17.39%,50.72%,,15.94%,7.25%,,5.80%,18.84%,,,,,,,,,,,1.03,0.55,1.51,,,,,,,,,122.7,114.88,130.52,,,,,,,,,,,,,,,,,89.86%,,7.25%,0%,20.29%,,,52.17%,0%,42.03%,50.72%,55.07%,15.94%,55.07%,8.70%,2.90%,0%,0%,87%,0%,,,,10.14%,,,1.45%,,0%,,0%,,,,1,0.04,0.54,,22,,0,0
119,0,China,Northeast Region,55,38.20%,"Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study",MedRxiv,Fan et al,https://www.medrxiv.org/content/10.1101/2020.03.28.20045955v1.full.pdf,English,No,Observational,1/20/20,3/15/20,55,Top-level,General,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,All,NA,,46.8,,,,,54.50%,0%,0%,100%,0%,0%,,50.91%,32.72%,,,,,,,,,,,,,,14.55%,14.55%,5.45%,,,,,,,46.18%,,,,49.09%,14.55%,3.64%,,12.73%,14.55%,,10.91%,7.27%,,12.73%,,,,,,,,1,6.13,,,1.61,,,,,,,,,,,,,,,,40.65,,19.47,,,,54.25,,20.31,,,0.08,0.62,,52.73%,96.36%,16.36%,0.00%,5.70%,,37.74%,83.23%,0%,12.73%,,,,,,,,,34.50%,16.40%,,,,3.64%,27.27%,,,30.91%,,,,,,,1,,1,,,,0,0
119,1,China,Northeast Region,47,38.20%,"Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study",MedRxiv,Fan et al,https://www.medrxiv.org/content/10.1101/2020.03.28.20045955v1.full.pdf,English,No,Observational,1/20/20,3/15/20,55,Subgroup,Mild,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Mild only,NA,,46.4,,,,,51.10%,0%,0%,100%,0%,0%,,46.81%,34.04%,,,,,,,,,,,,,,17.02%,14.89%,4.26%,,,,,,,51.06%,,,,51.06%,10.64%,4.26%,,10.64%,17.02%,,8.51%,4.26%,,10.64%,,,,,,,,1,5.78,,,1.76,,,,,,,,,,,,,,,,37.85,,18.98,,,,54.13,,15.73,,,0.07,0.48,,46.67%,95.74%,10.64%,0.00%,6.67%,,37.78%,88.89%,0%,6.38%,,,,,,,,,36.17%,12.76%,,,,0%,14.89%,,,23.40%,,,,,,,1,,1,,,,0,0
119,2,China,Northeast Region,8,38.20%,"Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study",MedRxiv,Fan et al,https://www.medrxiv.org/content/10.1101/2020.03.28.20045955v1.full.pdf,English,No,Observational,1/20/20,3/15/20,55,Subgroup,Severe,Positive only,End-point only,Survivors only,Discharged only,Yes,ΝΑ,Severe/Critical Only,NA,,46.12,,,,,75%,0%,0%,100%,0%,0%,,75%,25%,,,,,,,,,,,,,,0%,12.50%,12.50%,,,,,,,100%,,,,37.50%,37.50%,0%,,25%,0%,,25%,25%,,25%,,,,,,,,1,8.18,,,0.78,,,,,,,,,,,,,,,,57.13,,22.38,,,,55,,47.21,,,0.11,1.44,,100.00%,100%,50%,0,0.00%,,37.50%,50.00%,0%,50%,,,,,,,,,25%,37.50%,,,,25%,100%,,,75%,,,,,,,0.1,,1,,,,0,0
120,0,USA,Washington,24,36.52%,Covid-19 in Critically Ill Patients in the Seattle Region — Case Series,NEJM,Bhatraju et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2004500?articleTools=true,English,Yes,Observational,2/24/20,3/9/20,14,Top-level,Severe,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,,64,18,,,,63%,,,,,,54%,,54%,,,,,7,,3,11,22%,,,,,,58%,,4%,0%,,,21%,21%,50%,,,83%,88%,88%,8%,42%,,,,,,,17%,,,,,,,,1,8.43,5.63,12.45,0.72,0.52,1.38,,,180,109,257,,,,,,,,,,,10.26,8.55,11.97,,,,,,,,,,,,,,,,,,,,,42%,0%,,,75%,,,,,,,,,,,,,,,,,,,1,1,0.21,9,12,17,0.5,0.71
121,0,China,Wuhan,206,27.53%,"Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes",,Han et. al.,https://journals.lww.com/ajg/Documents/COVID19_Han_et_al_AJG_Preproof.pdf,English,Yes,Observational,2/13/20,2/29/20,16,Top-level,General,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,ΝΑ,62.5,,,27,92,,44.17%,0%,0%,100%,0%,0%,,,,,,,,14.4,,,,,,,,,27.20%,10.20%,8.30%,3.90%,,,8.30%,,7.80%,67%,,38.5,,27.50%,14.60%,,,21.40%,45.10%,,32.50%,11.70%,15.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,23.7,,0,0
121,1,China,Wuhan,48,27.53%,"Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes",,Han et. al.,https://journals.lww.com/ajg/Documents/COVID19_Han_et_al_AJG_Preproof.pdf,English,Yes,Observational,2/13/20,2/29/20,16,Subgroup,Digestive Only,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,ΝΑ,63.5,,,32,92,,27.08%,0%,0%,100%,0%,0%,,,,,,,,16,,,,,,,,,25%,12.50%,12.50%,4.20%,,,12.50%,,6.30%,39.60%,,38.5,,0%,0%,,,12.50%,52.10%,,47.90%,14.60%,31.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,24.9,,0,0
121,2,China,Wuhan,89,27.53%,"Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes",,Han et. al.,https://journals.lww.com/ajg/Documents/COVID19_Han_et_al_AJG_Preproof.pdf,English,Yes,Observational,2/13/20,2/29/20,16,Subgroup,Respiratory Only,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,ΝΑ,65,,,27,91,,53.93%,0%,0%,100%,0%,0%,,,,,,,,11.6,,,,,,,,,27%,7.90%,7.90%,3.40%,,,7.90%,,7.90%,73%,,38.5,,29.60%,10.10%,,,13.50%,31.50%,,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,21.9,,0,0
121,3,China,Wuhan,69,27.53%,"Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes",,Han et. al.,https://journals.lww.com/ajg/Documents/COVID19_Han_et_al_AJG_Preproof.pdf,English,Yes,Observational,2/13/20,2/29/20,16,Subgroup,Digestive + Respiratory,Positive only,End-point only,Survivors only,Discharged only,No,ΝΑ,All,ΝΑ,56,,,27,84,,43.48%,0%,0%,100%,0%,0%,,,,,,,,12.2,,,,,,,,,29%,11.60%,5.80%,4.30%,,,5.80%,,8.70%,78.30%,,38.4,,39.10%,30.40%,,,37.70%,60%,,63.80%,24.60%,24.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,25.3,,0,0
122,1,USA,Washington,53,22.47%,"Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e1.htm,English,No,Observational,2/28/20,3/20/20,21,Subgroup,Negative Cases,Negative only,Active only,Both,Both,No,ΝΑ,All,NA,,75.1,,,,,39.60%,,,,,,,,,,,,,,,,,13.20%,,,21%,100%,,37.70%,67.90%,30.20%,,,36%,34%,,5.70%,,,,11.30%,0%,0%,,0%,,1.90%,5.70%,0%,,3.80%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
122,2,USA,Washington,23,22.47%,"Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e1.htm,English,No,Observational,2/28/20,3/20/20,21,Subgroup,Positive Cases,Positive only,Active only,Both,Both,No,ΝΑ,All,NA,,80.7,,,,,30.40%,,,,,,,,,,,,,,,,,4.40%,,,26.10%,95.70%,,39.10%,87%,43.50%,,,34.80%,39.10%,,4.30%,,,,30.40%,4.40%,0%,,0%,,0%,4.40%,13%,,8.70%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
123,0,China,Wuhan,67,46.63%,"A Multicentre Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China",MedRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20037127v1.full.pdf,English,No,Observational,1/5/20,3/10/20,65,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,Both,66,,,,,,61.10%,0%,0%,100%,0%,0%,,,,,,,,,,,,13.40%,,,,,53.70%,19.40%,11.90%,4.50%,100%,6%,7.50%,3%,,79.10%,,,,74.60%,65.70%,,44.80%,9%,44.80%,,16.40%,14.90%,,,,,,,,,,1,5.72,2.96,8.48,0.61,0.39,1.1,,,174,105.5,221.5,3.97,2.8,6.3,117.37,100.02,134.72,,35.15,28,28,9.7,7.4,14.8,5.16,67.7,,36.28,,,0.12,,,,85.10%,,,,,,,,44.80%,20.90%,,,73.10%,29.90%,11.90%,,,,,,,,20.90%,,16.40%,,,,,3%,,,,1,,0.58,,,,0.27,0.32
123,1,China,Wuhan,35,46.63%,"A Multicentre Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China",MedRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20037127v1.full.pdf,English,No,Observational,1/5/20,3/10/20,65,Subgroup,Mild,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Mild only,Both,64,,,,,,51.40%,0%,0%,100%,0%,0%,,,,,,,,,,,,11.40%,,,,,37.10%,11.40%,2.90%,0%,100%,8.60%,5.70%,0%,,84.40%,,,,77.10%,57.10%,,57.10%,14.30%,42.90%,,11.40%,11.40%,,,,,,,,,,1,5.09,3.52,6.66,0.9,0.44,1.22,,,196,151,244.75,3.9,3,4.98,120.18,104.78,135.58,,37.19,23,24,9.17,7.75,11.88,4.3,63,,39.29,,,0.06,,,,88.60%,,,,,,,,28.60%,11.40%,,,65.70%,25.70%,0%,,,,,,,,0%,,0%,,,,,0%,,,,1,,0.91,,,,0,0
123,2,China,Wuhan,32,46.63%,"A Multicentre Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China",MedRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20037127v1.full.pdf,English,No,Observational,1/5/20,3/10/20,65,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,ΝΑ,Severe/Critical Only,Both,69,,,,,,71.90%,0%,0%,100%,0%,0%,,,,,,,,,,,,15.60%,,,,,71.90%,28.10%,21.90%,9.40%,100%,3.10%,9.40%,6.30%,,86.70%,,,,71.90%,75%,,31.30%,3.10%,46.90%,,21.90%,18.80%,,,,,,,,,,1,6.41,2.83,9.99,0.56,0.31,0.92,,,144.5,80.75,194.25,4.38,2.69,7,113.94,94.43,133.45,,32.72,31.5,39.5,11.3,6.85,16.9,6.55,77.5,,94.47,,,0.26,,,,81.30%,,,,,,,,62.50%,31.30%,,,81.30%,34.40%,21.90%,,,,,,,,43.80%,,34.40%,,,,,6.30%,,,,1,,0.22,,,,0.56,0.72
123,3,China,Wuhan,49,47.19%,"A Multicentre Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China",MedRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20037127v1.full.pdf,English,No,Observational,1/5/20,3/10/20,65,Subgroup,Survivors,Positive only,End-point and active,Survivors only,Both,Yes,ΝΑ,All,Both,65,,,,,,55.10%,0%,0%,100%,0%,0%,,,,,,,,,,,,12.20%,,,,,49%,16.30%,4.10%,0%,100%,6.10%,4.10%,2%,,77.60%,,,,75.50%,61.20%,,46.90%,10.20%,38.80%,,18.40%,10.20%,,,,,,,,,,1,5.18,3.25,7.11,0.77,0.42,1.15,,,192,150,238,3.76,2.69,4.98,118.4,101,135.8,,35.57,28,25.5,9.44,7.45,14.36,4.67,64.5,,43.97,,,0.08,,,,87.80%,,,,,,,,36.70%,20.40%,,,69.40%,26.50%,0%,,,,,,,,0%,,0%,,,,,2.20%,,,,1,,0.8,,31,,0,0
123,4,China,Wuhan,18,47.19%,"A Multicentre Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China",MedRxiv,Zhang et al.,https://www.medrxiv.org/content/10.1101/2020.03.21.20037127v1.full.pdf,English,No,Observational,1/5/20,3/10/20,65,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,ΝΑ,Severe/Critical Only,Both,69.5,,,,,,77.80%,0%,0%,100%,0%,0%,,,,,,,,,,,,16.70%,,,,,66.70%,27.80%,33.30%,16.70%,100%,5.60%,16.70%,5.60%,,83.30%,,,,72.20%,77.80%,,0.389,5.60%,55.60%,,11.10%,27.80%,,,,,,,,,,1,7.38,3.04,11.72,0.4,0.23,0.55,,,101,59,140,6.91,4.42,7.37,113.24,95.18,131.3,,33.48,29,39,11.2,7.55,23.35,8.89,81,,149.43,,,0.72,,,,77.80%,,,,,,,,66.70%,22.20%,,,83.30%,38.90%,44.40%,,,,,,,,77.80%,,61.10%,,,,,5.60%,,,,1,,0,,20,,1,1
124,0,China,Wuhan,12,23.60%,"SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China",JAMA Oncology,Yu et. al.,doi:10.1001/jamaoncol.2020.0980,English,Yes,Observational,12/30/19,2/17/20,50,Top-level,General,Positive only,End-point and active,Both,Both,No,Both,All,,66,,,,,,83.30%,0%,0%,100%,0%,0%,,,,,,,,3.33,0,0,4,,,,,100%,,,,,100%,,,,,100%,,,,25%,25%,,,,,,,,,,,,,,75%,25%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.08,0.5,,20.1,,0.25,
125,0,China,Zhejiang,36,37.64%,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study",Lancet Infectious Disease,Qiu et. al.,https://www.sciencedirect.com/science/article/pii/S1473309920301985,English,Yes,Observational,1/17/20,3/1/20,44,Top-level,General,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,,8.3,3.5,4.8,11.8,,64%,0%,0%,100%,0%,0%,100%,33%,89%,,,,,,,,,,,,,,,,,,,,,,,36%,37.8,,,19%,3%,8%,,,,,6%,6%,,6%,,,,,100%,,,0,6.1,4,8.2,2.4,1.6,3.2,,,,,,,,,,,,,,21,30,,,,3.8,56,96,5,,,0.24,0.29,,,,39%,,,,,,,,,,,17%,0%,0%,,,100%,,,,,,,,,,,,,,,,1,0,,,14,10,0,
125,1,China,Zhejiang,17,36.52%,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study",Lancet Infectious Disease,Qiu et. al.,https://www.sciencedirect.com/science/article/pii/S1473309920301985,English,Yes,Observational,1/17/20,3/1/20,44,Subgroup,Mild,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,,7.5,3.2,4.3,10.7,,59%,0%,0%,100%,0%,0%,100%,29%,94%,,,,,,,,,,,,,,,,,,,,,,,24%,37.6,,,18%,0%,6%,,,,,,,,6%,,,,,100%,,,0,6.5,4.2,8.8,2.8,1.8,3.8,,,,,,,,,,,,,,21,32,,,,3.7,58,80,4,,,0.15,0.21,,,,12%,,,,,,,,,,,6%,0%,0%,,,100%,,,,,,,,,,,,,,,,1,0,,,12,9,0,
125,2,China,Zhejiang,19,37.64%,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study",Lancet Infectious Disease,Qiu et. al.,https://www.sciencedirect.com/science/article/pii/S1473309920301985,English,Yes,Observational,1/17/20,3/1/20,44,Subgroup,Moderate,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,,9,3.6,5.4,12.6,,69%,0%,0%,100%,0%,0%,100%,37%,84%,,,,,,,,,,,,,,,,,,,,,,,47%,38,,,21%,5%,10%,,,,,10%,10%,,5%,,,,,100%,,,0,5.8,3.9,7.7,2,1.3,2.7,,,,,,,,,,,,,,20,28,,,,3.9,54,110,5,,,0.32,0.36,,,,63%,,,,,,,,,,,26%,0%,0%,,,100%,,,,,,,,,,,,,,,,1,0,,,15,11,0,
125,3,China,Zhejiang,10,30.34%,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study",Lancet Infectious Disease,Qiu et. al.,https://www.sciencedirect.com/science/article/pii/S1473309920301985,English,Yes,Observational,1/17/20,3/1/20,44,Subgroup,<= 5 years old,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,,,,,,,60%,0%,0%,100%,0%,0%,100%,20%,100%,,,,,,,,,,,,,,,,,,,,,,,30%,37.7,,,10%,,,,,,,,,,,,,,,100%,,,0,6.5,4.3,8.7,2.9,1.8,4,,,,,,,,,,,,,,,,,,,,,124,4,,,0.13,0.2,,,,10%,,,,,,,,,,,10%,0%,0%,,,100%,,,,,,,,,,,,,,,,1,0,,,13,9,0,
125,4,China,Zhejiang,26,30.34%,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study",Lancet Infectious Disease,Qiu et. al.,https://www.sciencedirect.com/science/article/pii/S1473309920301985,English,Yes,Observational,1/17/20,3/1/20,44,Subgroup,5-16 years old,Positive only,End-point only,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,,,,,,,65%,0%,0%,100%,0%,0%,100%,38%,85%,,,,,,,,,,,,,,,,,,,,,,,38%,37.9,,,23%,,,,,,,,,,,,,,,100%,,,0,5.9,3.9,7.9,5.9,3.9,7.9,,,,,,,,,,,,,,,,,,,,,85,5,,,0.28,0.32,,,,50%,,,,,,,,,,,19%,0%,0%,,,100%,,,,,,,,,,,,,,,,1,0,,,15,11,0,
126,0,China,Wuhan,62,21.91%,Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2.full.pdf,English,No,RCT,2/4/20,2/28/20,24,Top-level,General,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,Both,,44.7,15.3,,,,46.80%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,62.90%,,,,59.68%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,,50%,,100%,,,100%,,,,,,,,,,,,,,,,,,,,,1,,0.39,,,,0.18,0.31
126,1,China,Wuhan,31,21.91%,Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2.full.pdf,English,No,RCT,2/4/20,2/28/20,24,Subgroup,Control,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,Both,,45.2,14.7,,,,48.30%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,54.84%,,,,48.39%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,,0%,,100%,,,100%,,,,,,,,,,,,,,,,,,,,,1,,0.16,,,,0.29,0.64
126,2,China,Wuhan,31,21.91%,Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial,MedRxiv,Chen et. al.,https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2.full.pdf,English,No,RCT,2/4/20,2/28/20,24,Subgroup,Hydroxychloroquine,Positive only,End-point and active,Both,Both,Yes,ΝΑ,All,Both,,44.1,16.1,,,,45.20%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,70.97%,,,,70.97%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,,100%,,100%,,,100%,,,,,,,,,,,,,,,,,,,,,1,,0.61,,,,0.07,0.1
127,0,China,Wuhan,118,17.42%,SARS-CoV-2 infection in health care workers: a retrospective analysis and model study,MedRxiv,Bai et. al.,https://www.medrxiv.org/content/10.1101/2020.03.29.20047159v1.full.pdf,English,No,Observational,12/25/19,2/15/20,52,Top-level,General,Positive and Negative/Unconfirmed,Active,,,,,,,,31.1,5.8,25.3,36.9,100%,36.40%,0%,0%,100%,0%,0%,,,,,,,,,,,,0.08%,0.08%,22.1,,12.70%,,,,7.60%,,,,,5.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
127,1,China,Wuhan,106,17.42%,SARS-CoV-2 infection in health care workers: a retrospective analysis and model study,MedRxiv,Bai et. al.,https://www.medrxiv.org/content/10.1101/2020.03.29.20047159v1.full.pdf,English,No,Observational,12/25/19,2/15/20,52,Subgroup,Negative Cases,Negative only,Active,,,,,,,,30.5,5.3,25.2,35.8,100%,35.90%,0%,0%,100%,0%,0%,,,,,,,,,,,,8.50%,9.40%,22,,13.30%,,,,7.60%,,,,,5.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
127,2,China,Wuhan,12,16.85%,SARS-CoV-2 infection in health care workers: a retrospective analysis and model study,MedRxiv,Bai et. al.,https://www.medrxiv.org/content/10.1101/2020.03.29.20047159v1.full.pdf,English,No,Observational,12/25/19,2/15/20,52,Subgroup,Positive Cases,Positive only,Active,,,,,,,,36.6,7.4,29.2,44,100%,41.70%,0%,0%,100%,0%,0%,,,,,,,,,,,,0%,0%,22.4,,8.30%,,,,8.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
128,0,Germany,Bavaria,12,20.79%,Outbreak of COVID-19 in Germany Resulting from a Single Travel-Associated Primary Case,The Lancet Preprints,Bohmer et. al.,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551335,English,No,Observational,1/16/20,2/19/20,34,Top-level,General,,,,,,,Mild only,,35,,,,,0%,,100%,0%,0%,0%,0%,100%,,100%,,4,,,,,,,,,,,,,,,,,,,,,43.80%,,,,50%,18.80%,37.50%,,25%,56.30%,,12.50%,25%,6.30%,43.80%,18.80%,12.50%,,6.20%,94%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
129,0,China,Wuhan,38,24.72%,"Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China",JAMA Opthamology,Wu et. al.,https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2764083,English,Yes,Observational,2/9/20,2/15/20,6,Top-level,General,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,All,Both,68,,,53,76,,65.80%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,60.60%,39.40%,,,7.36,,,0.89,,,,,184.39,,,5.92,,,,,,,,31.08,35.58,,,,41.24,1.61,101.82,5.17,,,,1.76,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
129,1,China,Wuhan,12,33.15%,"Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China",JAMA Opthamology,Wu et. al.,https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2764083,English,Yes,Observational,2/9/20,2/15/20,6,Subgroup,Ocular symptoms,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,All,Both,67,,,52,76,,58.30%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,66.67%,38.05,,,50%,16.67%,0%,25%,0%,0%,0%,0%,0%,0%,0%,0%,8.33%,,0%,33.30%,66.70%,,,10.9,,,0.71,,,,,184.58,,,9.51,,,,,,,,39.83,45.33,,,,20.21,1.94,91.08,8.55,,,,2.96,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
129,2,China,Wuhan,26,24.72%,"Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China",JAMA Opthamology,Wu et. al.,https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2764083,English,Yes,Observational,2/9/20,2/15/20,6,Subgroup,No ocular symptoms,Positive only,Active only,Both,Non-discharged only,No,ΝΑ,All,Both,70,,,62,79,,69.20%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,73.10%,26.90%,,,5.73,,,0.98,,,,,184.31,,,4.26,,,,,,,,27.04,31.08,,,,50.94,1.46,106.77,3.61,,,,1.35,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,
130,0,Germany,Munich,9,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Top-level,General,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,33%,0%,0%,0%,11%,0%,0%,0%,0%,22%,22%,,,,78%,0%,0%,0%,0%,0%,0%,22%,0%,0%,67%,0%,0%,,11%,89%,0%,0%,0,,,,1.5,0.9,1.9,,,,,,4.62,2.5,4.87,,,,,,,,,,,,,,4.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,1,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 1,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,100%,0%,0%,0%,0%,0%,0%,0%,0%,100%,100%,,,,100%,0%,0%,0%,0%,0%,0%,100%,0%,0%,0%,0%,0%,,0%,100%,0%,0%,0,,,,1.9,1.9,1.9,,,,,,4.87,4.87,4.87,,,,,,,,,,,,,,4.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,2,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 2,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,0%,,0%,100%,0%,0%,0,,,,1.2,1.2,1.2,,,,,,3.04,3.04,3.04,,,,,,,,,,,,,,4.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,3,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 3,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,100%,0%,0%,0%,100%,0%,0%,0%,0%,0%,0%,,,,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,0%,,0%,100%,0%,0%,0,,,,2.6,2.6,2.6,,,,,,5.04,5.04,5.04,,,,,,,,,,,,,,1.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,4,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 4,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,0%,,0%,100%,0%,0%,0,,,,2.22,2.22,2.22,,,,,,2.42,2.42,2.42,,,,,,,,,,,,,,5.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,5,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 5,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,100%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,,,,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,0%,,0%,100%,0%,0%,0,,,,0.9,0.9,0.9,,,,,,4.69,4.69,4.69,,,,,,,,,,,,,,4.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,6,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 6,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,0%,,0%,100%,0%,0%,0,,,,1.6,1.6,1.6,,,,,,2.5,2.5,2.5,,,,,,,,,,,,,,1.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,7,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 7,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,0%,,0%,100%,0%,0%,0,,,,0.7,0.7,0.7,,,,,,2.35,2.35,2.35,,,,,,,,,,,,,,7.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,8,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 8,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,,100%,0%,0%,0%,0%,0%,0%,100%,0%,0%,0%,0%,0%,,0%,100%,0%,0%,0,,,,1.5,1.5,1.5,,,,,,5.04,5.04,5.04,,,,,,,,,,,,,,9.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
130,9,Germany,Munich,1,36.52%,Virological assessment of hospitalized patients with COVID-2019,Nature,Wolfel et. al.,https://www.nature.com/articles/s41586-020-2196-x_reference.pdf,English,Yes,Observational,1/27/20,2/24/20,28,Subgroup,Patient 9,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,,,,,,,,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0,,,,0.9,0.9,0.9,,,,,,4.62,4.62,4.62,,,,,,,,,,,,,,0.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
131,0,China,Wuhan,339,52.25%,Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up,Journal of Infection,Wang et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30146-8/pdf,English,Yes,Observational,1/1/20,2/6/20,36,Top-level,General,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,69,,,65,76,,49%,0%,0%,100%,0%,0%,,,,,,,,10,10,7,14,,,,,,40.80%,16%,15.70%,6.20%,4.40%,0.60%,6.20%,3.80%,1.50%,92%,,,,53%,40.80%,3.50%,27.50%,4.70%,39.90%,,12.70%,3.80%,27.80%,,,26%,,0%,29.50%,46.90%,23.60%,0,5.74,4.37,8.29,0.9,0.59,1.29,,,205,151,259,4.43,2.76,6.62,121,109,130,,,27,32,,,,5.5,61,63,,,10.9,0.08,1.2,12.1,,,,,,,,,,,,,,,,,,,,,,21%,,21%,,,2.40%,,,21%,8.10%,42.80%,,,1,,0.81,,28,,0.19,0.19
131,1,China,Wuhan,274,52.25%,Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up,Journal of Infection,Wang et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30146-8/pdf,English,Yes,Observational,1/1/20,2/6/20,36,Subgroup,Survivors,Positive only,End-point only,Both,Discharged only,No,ΝΑ,All,Both,68,,,64,74,,46.40%,0%,0%,100%,0%,0%,,,,,,,,10,10,7,13,,,,,,38.80%,15.80%,11.70%,3.70%,4.40%,0.40%,4.00%,3.30%,1.50%,93.40%,,,,54.60%,36.60%,4.40%,27.80%,5.50%,39.90%,,12.80%,4.40%,28.90%,,,26.70%,,0.00%,36.10%,56.60%,7.30%,0,5.54,4.29,7.64,0.97,0.68,1.37,,,211,151,268,4.01,2.63,5.97,121,110,129,,,28,29,,,,5.1,60,60,,,10.5,0.06,1.08,12,,,,,,,,,,,,,,,,,,,,,,5.50%,,5.50%,,,1.80%,,,11.40%,4%,34.40%,,,1,,1,,28,,0,0
131,2,China,Wuhan,65,52.25%,Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up,Journal of Infection,Wang et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30146-8/pdf,English,Yes,Observational,1/1/20,2/6/20,36,Subgroup,Non-survivors,Positive only,End-point only,Non-Survivors only,Discharged only,No,ΝΑ,Severe/Critical Only,Both,76,,,70,83,,60%,0%,0%,100%,0%,0%,,,,,,,,10,10,7,14,,,,,,50%,17.20%,32.80%,17.20%,4.70%,1.60%,15.60%,6.30%,1.60%,87.50%,,,,46.90%,59.40%,0%,26.60%,1.60%,40.60%,,12.50%,1.60%,23.40%,,,23.40%,,0.00%,1.50%,6.20%,92.30%,0,8.61,5.27,13.25,0.57,0.39,0.84,,,172,103,219,7.65,4.35,11.74,122,106,137,,,24,43,,,,8.9,80,84,,,93.8,0.22,4.38,12.9,,,,,,,,,,,,,,,,,,,,,,87.50%,,87.50%,,,4.70%,,,65%,28.30%,81.70%,,,1,,0,,5,,1,1
132,0,China,Wuhan,75,44.94%,"ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of outbreak in Wuhan, China",MedRxiv,Lu et. al.,https://www.medrxiv.org/content/10.1101/2020.02.20.20025510v1.full.pdf,English,No,Observational,1/21/20,2/5/20,15,Subgroup,Confirmed positive cases,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,62,,,48,71,,49.30%,0%,0%,100%,0%,0%,,,,,,,,6,6,4,8,,,,,61.33%,43.50%,6.50%,8.70%,0%,,10.90%,,,4.30%,73.50%,,,,64.70%,7.40%,8.80%,,2.90%,42.60%,,7.40%,8.80%,,4.40%,,0%,,0%,79.20%,20.80%,0%,1,4.9,3.6,6.8,0.9,0.6,1.2,,,,,,3.7,2.3,5.4,,,,,33,23,,9.2,7.1,11.3,,67,,32.6,,,,0.4,14.2,96.90%,84.20%,,,,,,,,10.90%,54.60%,,,,,,,,,,,,,,,,,,,,,,,,1,,na,,,,0.01,
133,0,Germany,Munich,40,26.97%,Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients,MedRxiv,Herold et. al.,https://www.medrxiv.org/content/10.1101/2020.04.01.20047381v1.full.pdf,English,No,Observational,2/29/20,3/27/20,27,Top-level,All,Positive only,Active only,Both,Non-discharged only,Yes,Both,All,Both,57,,,,,,72%,0%,0%,100%,0%,0%,,,,,,,,2,2,1,4,,,,,82%,53%,8%,,9%,,,,,,,,,,,,,,,,,,,,,,,,,,,32.50%,0,5.3,,,,,,,,,,,,,,,,,,,,,0.5,,,,,0.9,2.8,,27.1,0,0.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.33,na,,,,na,
133,1,Germany,Munich,27,24.72%,Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients,MedRxiv,Herold et. al.,https://www.medrxiv.org/content/10.1101/2020.04.01.20047381v1.full.pdf,English,No,Observational,2/29/20,3/27/20,27,Subgroup,No Mechanical Ventilation,Positive only,Active only,Both,Non-discharged only,Yes,Both,Severe/Critical Only,Non-ventilation only,54,,,,,,59%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,77%,40%,4%,,8%,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0,4.75,,,,,,,,,,,,,,,,,,,,,0.5,,,,,0.9,1.7,,19.6,0,0.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,na,,,,na,
133,2,Germany,Munich,13,26.97%,Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients,MedRxiv,Herold et. al.,https://www.medrxiv.org/content/10.1101/2020.04.01.20047381v1.full.pdf,English,No,Observational,2/29/20,3/27/20,27,Subgroup,Mechanical Ventilation,Positive only,Active only,Both,Non-discharged only,Yes,Both,All,Ventilation only,64,,,,,,100%,0%,0%,100%,0%,0%,,,,,,,,3.5,3.5,1,5,,,,,92%,82%,17%,,9%,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0,6.64,,,,,,,,,,,,,,,,,,,,,0.5,,,,,1,7.8,,121,0.1,1.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,na,,,,na,
134,0,Japan,Diamond Princess,26,27.53%,Observation and analysis of 26 cases of asymptomatic SARS-COV2 infection,Journal of Infection,Zhou et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30156-0/pdf,English,Yes,Observational,1/20/20,2/29/20,40,Top-level,Asymptomatic only,Positive only,Active only,Survivors only,Both,No,Non-ICU only,Mild only,Non-ventilation only,37,37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,0%,0%,0%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,0,na,na,,0,0
136,0,Korea,,1,50.56%,Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR,J Korean Med Sci.,Lim et. al.,https://doi.org/10.3346/jkms.2020.35.e79,English,Yes,Observational,1/20/20,2/5/20,16,Top-level,,Positive only,Active only,Survivors only,Both,No,Non-ICU only,Mild only,Non-ventilation only,54,54,0,54,54,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,2.5,2.5,2.5,2.5,0%,0%,25.7,0%,,,,,,,,,,,0%,37,37,0%,100%,0%,100%,0%,100%,0%,0%,100%,0%,0%,0%,100%,0%,0%,0%,100%,0%,0%,0,7.2,7.2,7.2,,,,,,,,,,,,16.3,16.3,16.3,,4.5,29,27,0.5,0.5,0.5,,1,,0.43,,,0.06,0.28,12.5,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,na,17,17,0,0
137,0,China,Jiaxing,7,27.53%,"The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China",Journal of Infection,Ge et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30144-4/pdf,English,Yes,Observational,1/20/20,1/28/20,8,Top-level,All,Positive only,Active only,Both,Both,No,Non-ICU only,All,Both,41,39.05,,35,52.5,0%,57%,0%,0%,100%,0%,0%,100%,29%,71%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,86%,14%,0%,0,5.4,4.15,7.65,0.8,0.7,2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
137,1,China,Jiaxing,1,32.02%,"The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China",Journal of Infection,Ge et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30144-4/pdf,English,Yes,Observational,1/20/20,1/28/20,8,Subgroup,Patient 1,Positive only,Active only,Both,Both,No,Non-ICU only,All,Both,29,29,0,29,29,0%,100%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,100%,,,,100%,,,100%,,0%,,0%,,,0%,0%,,,0%,0%,100%,0%,0,7.8,7.8,7.8,0.8,0.8,0.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
137,2,China,Jiaxing,1,32.02%,"The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China",Journal of Infection,Ge et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30144-4/pdf,English,Yes,Observational,1/21/20,1/29/20,8,Subgroup,Patient 2,Positive only,Active only,Both,Both,No,Non-ICU only,All,Both,51,51,0,51,51,0%,0%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,,,,,,,,,,,,,,,,,,,0%,,,,0%,,,0%,,0%,,0%,,,100%,0%,,,0%,100%,0%,0%,0,1.3,1.3,1.3,0.6,0.6,0.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
137,3,China,Jiaxing,1,32.02%,"The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China",Journal of Infection,Ge et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30144-4/pdf,English,Yes,Observational,1/22/20,1/30/20,8,Subgroup,Patient 3,Positive only,Active only,Both,Both,No,Non-ICU only,All,Both,54,54,0,54,54,0%,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,,,,,,,,,,,,,,,,,,,100%,,,,100%,,,0%,,0%,,0%,,,0%,0%,,,0%,100%,0%,0%,0,2.9,2.9,2.9,0.7,0.7,0.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
137,4,China,Jiaxing,1,32.02%,"The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China",Journal of Infection,Ge et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30144-4/pdf,English,Yes,Observational,1/23/20,1/31/20,8,Subgroup,Patient 4,Positive only,Active only,Both,Both,No,Non-ICU only,All,Both,41,41,0,41,41,0%,100%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,100%,,,,100%,,,0%,,100%,,0%,,,0%,100%,,,0%,100%,0%,0%,0,5.4,5.4,5.4,7.6,7.6,7.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
137,5,China,Jiaxing,1,32.02%,"The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China",Journal of Infection,Ge et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30144-4/pdf,English,Yes,Observational,1/24/20,2/1/20,8,Subgroup,Patient 5,Positive only,Active only,Both,Both,No,Non-ICU only,All,Both,0.333333333,0.333333333,0,0.333333333,0.333333333,0%,0%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,100%,,,,0%,,,0%,,0%,,100%,,,0%,0%,,,0%,100%,0%,0%,0,7.5,7.5,7.5,3,3,3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
137,6,China,Jiaxing,1,32.02%,"The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China",Journal of Infection,Ge et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30144-4/pdf,English,Yes,Observational,1/25/20,2/2/20,8,Subgroup,Patient 6,Positive only,Active only,Both,Both,No,Non-ICU only,All,Both,57,57,0,57,57,0%,100%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,100%,,,,100%,,,100%,,0%,,0%,,,0%,0%,,,0%,100%,0%,0%,0,5.4,5.4,5.4,1,1,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
137,7,China,Jiaxing,1,28.09%,"The role of close contacts tracking management in COVID-19 prevention: A cluster investigation in Jiaxing, China",Journal of Infection,Ge et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30144-4/pdf,English,Yes,Observational,1/26/20,2/3/20,8,Subgroup,Patient 7,Positive only,Active only,Both,Both,No,Non-ICU only,All,Both,41,41,0,41,41,0%,0%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,0%,0%,0,8.9,8.9,8.9,0.7,0.7,0.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
138,0,Italy,Loumbardy,1591,28.65%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,63,,,56,70,,82%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,68%,49%,17%,21%,4%,8%,3%,,3%,20%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1%,11%,88%,,,,,,,,,,,,,,,,,,,1,1,0.16,,,,0.26,0.62
138,1,Italy,Loumbardy,4,28.09%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Subgroup,Age 0-20,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,16,,,14,19,,75%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,100%,0%,0%,0%,0%,0%,0%,,0%,100%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,100%,,,,,,,,,,,,,,,,,,,1,1,0,,,,0,
138,2,Italy,Loumbardy,56,28.65%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Subgroup,Age 21-40,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,34,,,31,38,,79%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,34%,11%,3%,3%,3%,0%,0%,,0%,17%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2%,17%,80%,,,,,,,,,,,,,,,,,,,1,1,0.36,,,,0.07,0.16
138,3,Italy,Loumbardy,143,28.65%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Subgroup,Age 41-50,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,47,,,44,49,,83%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,39%,26%,5%,5%,0%,2%,2%,,2%,12%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5%,15%,81%,,,,,,,,,,,,,,,,,,,1,1,0.25,,,,0.11,0.31
138,4,Italy,Loumbardy,427,28.65%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Subgroup,Age 51-60,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,56,,,54,59,,83%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,61%,44%,15%,16%,3%,4%,3%,,4%,18%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1%,9%,90%,,,,,,,,,,,,,,,,,,,1,1,0.21,,,,0.15,0.42
138,5,Italy,Loumbardy,598,28.65%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Subgroup,Age 61-70,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,65,,,63,68,,81%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,72%,51%,23%,23%,3%,9%,3%,,4%,20%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.50%,7%,92%,,,,,,,,,,,,,,,,,,,1,1,0.12,,,,0.29,0.71
138,6,Italy,Loumbardy,341,28.65%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Subgroup,Age 71-80,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,74,,,72,76,,82%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,81%,62%,18%,32%,8%,13%,2%,,3%,22%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1%,14%,86%,,,,,,,,,,,,,,,,,,,1,1,0.12,,,,0.4,0.77
138,7,Italy,Loumbardy,21,28.65%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Subgroup,Age 81-90,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,83,,,81,84,,90%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,100%,75%,19%,38%,6%,19%,0%,,0%,31%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,22%,78%,,,,,,,,,,,,,,,,,,,1,1,0.1,,,,0.52,0.84
138,8,Italy,Loumbardy,1,28.65%,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",JAMA,Grasselli et. al.,doi:10.1001/jama.2020.5394,English,Yes,Observational,2/20/20,3/27/20,36,Subgroup,Age 91-100,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,91,,,91,91,,100%,100%,0%,0%,0%,0%,,,,,,,,,,,,,,,,100%,0%,0%,100%,0%,0%,0%,,0%,0%,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,0%,,,,,,,,,,,,,,,,,,,1,1,0,,,,1,1
139,0,France,Paris,11,26.40%,No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection,Médecine et Maladies Infectieuses,Molina et. al.,https://doi.org/doi:10.1016/j.medmal.2020.03.006,English,Yes,RCT,,,8,Top-level,Patients who recieved hydroxychloroquine,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,,58.7,,,,,63.63%,,,,,,,,,,,,,,,,,,,,18.18%,72.72%,0%,0%,0%,0%,45.45%,0%,0%,0%,9.09%,90.09%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,0%,0%,0%,,0%,0%,100%,0%,0%,90.09%,,,,,,,,,,,,,,,,,,,,,,,1,0.09,0.18,,,,0.09,0.33
140,0,Germany,Nationwide,73522,16.85%,Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the Robert Koch Institute,Robert Koch Institute,Robert Koch Institute,https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-02-en.pdf?__blob=publicationFile,English,No,Observational,1/27/20,4/2/20,66,Top-level,All patients in Germany,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,49,,,,,,52%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,42%,,,,53%,,,,,,,,,,23%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.91%,,,,,,,,,,,,,,,,,,,0.13,0.03,,,,,0.01,0.04
142,0,China,Changsha,161,34.83%,Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha,European Review for Medical and Pharmacological Sciences,Zheng et al.,https://www.europeanreview.org/wp/wp-content/uploads/3404-3410.pdf,English,Unknown,Observational,1/17/20,2/7/20,21,Top-level,All,Positive only,End-point and active,Both,Both,No,Both,All,Both,45,45,,,,,49.70%,0%,0%,100%,0%,0%,100%,64.60%,35.40%,,,,,,,,,,,,,20.50%,13.70%,4.30%,2.50%,3.70%,,2.50%,2.50%,,,75.80%,,,,62.70%,14.30%,7.50%,,,39.80%,,10.60%,3.70%,,,,,,0%,81.30%,18.70%,0%,0,4.36,,,1.07,,,,,168,,,,,,,,,,,20.3,25.1,10.9,,,,,72.9,17.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,0,na
142,1,China,Changsha,131,34.27%,Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha,European Review for Medical and Pharmacological Sciences,Zheng et al.,https://www.europeanreview.org/wp/wp-content/uploads/3404-3410.pdf,English,Unknown,Observational,1/17/20,2/7/20,21,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,No,Non-ICU only,Mild only,Non-ventilation only,40,40,,,,,50.40%,0%,0%,100%,0%,0%,100%,64.10%,35.90%,,,,,,,,,,,,,,7.60%,3.80%,1.50%,3.10%,,3.10%,2.30%,,,71%,,,,61.10%,10.70%,6.10%,,,37.40%,,12.20%,4.60%,,,,,,0%,100%,0%,0%,0,4.17,,,1.12,,,,,171,,,,,,,,,,,19.3,23.4,10.7,,,,,68.7,15.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,0,na
142,2,China,Changsha,30,34.27%,Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha,European Review for Medical and Pharmacological Sciences,Zheng et al.,https://www.europeanreview.org/wp/wp-content/uploads/3404-3410.pdf,English,Unknown,Observational,1/17/20,2/7/20,21,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,Both,Severe/Critical Only,Both,57,57,,,,,46.70%,0%,0%,100%,0%,0%,100%,66.70%,33.30%,,,,,,,,,,,,,,40%,6.70%,6.70%,6.70%,,0%,3.30%,,,96.70%,,,,70%,30%,13.30%,,,30%,,3.30%,0%,,,,,,0%,0%,100%,0%,0,4.76,,,0.85,,,,,160,,,,,,,,,,,23.9,31.6,12.7,,,,,100.3,52.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0,,,,0,na
143,0,China,,79,34.83%,Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A Retrospective study,Liver International,Hansheng et al.,https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14449,English,Yes,Observational,2/2/20,2/23/20,21,Top-level,All,Positive only,End-point only,Survivors only,Discharged only,No,Non-ICU only,All,Non-ventilation only,60,60,,48,66,,55.70%,,,100%,,,,,,,,,,12,12,10,15,,,,,26.50%,17.70%,10.10%,8.90%,,,,,,,70.90%,,,,70.90%,50.60%,,25.30%,,,,8.90%,,,,,,,,,,,,5.2,4.3,6.9,1.2,0.9,1.6,,,,,,3.7,2.8,5.3,,,,,,34,30,13.6,8.8,17.6,,69.8,,13.9,31.5,,,0.69,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,0,,12.9,,0,
143,1,China,,51,33.71%,Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A Retrospective study,Liver International,Hansheng et al.,https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14449,English,Yes,Observational,2/2/20,2/23/20,21,Subgroup,Moderate ,Positive only,End-point only,Survivors only,Discharged only,No,Non-ICU only,Mild only,Non-ventilation only,59,59,,46,66,,51%,,,100%,,,,,,,,,,11,11,8,15,,,,,,19.60%,11.80%,9.80%,,,,,,,62.70%,,,,70.60%,47.10%,,25.50%,,,,5.80%,,,,,,,,,,,,4.9,4.1,6.8,1.2,0.9,1.6,,,,,,3.7,2.7,5.1,,,,,,30,28,13.9,8.9,18.7,,70.2,,11,25.5,,,0.67,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,0,,,,0,
143,2,China,,28,33.71%,Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A Retrospective study,Liver International,Hansheng et al.,https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14449,English,Yes,Observational,2/2/20,2/23/20,21,Subgroup,Severe,Positive only,End-point only,Survivors only,Discharged only,No,Non-ICU only,Severe/Critical Only,Non-ventilation only,62.5,62.5,,50.5,67.8,,64.30%,,,100%,,,,,,,,,,12,12,10,15,,,,,,14.30%,7.10%,7.10%,,,,,,,85.50%,,,,71.40%,57.10%,,25.00%,,,,14.30%,,,,,,,,,,,,5.5,4.5,7.7,1.1,0.7,1.6,,,,,,3.8,3.2,5.7,,,,,,36.5,35,12.7,8.1,15.4,,68.7,,35.2,35.5,,,0.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,0,,,,0,
143,3,China,,50,29.78%,Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A Retrospective study,Liver International,Hansheng et al.,https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14449,English,Yes,Observational,2/2/20,2/23/20,21,Subgroup,No liver injury,Positive only,End-point only,Survivors only,Discharged only,No,Non-ICU only,All,Non-ventilation only,56,56,,45.5,65,,44.70%,,,100%,,,,,,,,,,,,,,,,,,,19.10%,10.60%,10.60%,,,,,,,62%,,,,66%,51.10%,,23.40%,,,,8.50%,,,,,,,,,,,,4.8,4.1,6.1,1.3,1,1.7,,,,,,3.5,2.7,4.5,,,,,,23,25,,,,,,,6,23,,,0.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,0,,11.4,,0,
143,4,China,,29,29.78%,Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A Retrospective study,Liver International,Hansheng et al.,https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14449,English,Yes,Observational,2/2/20,2/23/20,21,Subgroup,Liver injury,Positive only,End-point only,Survivors only,Discharged only,No,Non-ICU only,All,Non-ventilation only,62,62,,46,67,,72.40%,,,100%,,,,,,,,,,,,,,,,,,,17.20%,10.30%,6.90%,,,,,,,86.20%,,,,75.90%,44.80%,,24.10%,,,,6.90%,,,,,,,,,,,,6.3,4.6,7.7,1.2,0.8,1.5,,,,,,4.7,3.5,5.7,,,,,,74,59,,,,,,,31.1,97,,,0.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,0,,15.4,,0,
144,0,China,,17,26.40%,Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus,Annals of Palliative Medicine,Zhou et al.,http://apm.amegroups.com/article/view/38244/29000,English,Yes,Observational,1/28/20,2/13/20,16,Top-level,All,Positive only,Active only,Survivors only,Non-discharged only,Yes,Non-ICU only,All,Non-ventilation only,41.71,41.71,,,,,64.70%,,,100%,,,100%,,100%,,,,,,,,,,,,,29.40%,,,,,,,,,,64.70%,,,,47.10%,11.80%,,,,17.60%,,,,,,,,,,,,,,5.03,,,1.05,,,603.79,300.18,,,,,,,,,,,45.23,,,,,,,,,2.68,,,,0.29,,,100%,100%,,,,,,,29.40%,,,,,,,,,,,,0%,,0%,,,0%,,,,,,,,1,0,,,,,0,
144,0,China,,12,30.34%,Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus,Annals of Palliative Medicine,Zhou et al.,http://apm.amegroups.com/article/view/38244/29000,English,Yes,Observational,1/28/20,2/13/20,16,Subgroup,Non-aggravation,Positive only,Active only,Survivors only,Non-discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,41.5,41.5,14.31,27.19,55.81,,50%,,,100%,,,100%,,100%,,,,,,,,,,,,,25%,,,,,,,,,,66.70%,,,,33.30%,16.70%,,,,8.30%,,,,,,,,,,,,,,5.65,3.57,7.73,1.22,0.78,1.67,698.2,364,,,,,,,,,,,44.91,,,,,,,,,1.8,,,,0.29,,,100%,100%,,,,,,,0%,,,,,,,,,,,,0%,,0%,,,0%,,,,,,,,1,0,,,,,0,
144,0,China,,5,30.34%,Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus,Annals of Palliative Medicine,Zhou et al.,http://apm.amegroups.com/article/view/38244/29000,English,Yes,Observational,1/28/20,2/13/20,16,Subgroup,Aggravation,Positive only,Active only,Survivors only,Non-discharged only,Yes,Non-ICU only,Severe/Critical Only,Non-ventilation only,42.2,42.2,14.91,27.29,57.11,,0%,,,100%,,,100%,,100%,,,,,,,,,,,,,40%,,,,,,,,,,60%,,,,80%,0%,,,,40%,,,,,,,,,,,,,,3.53,1.93,5.13,0.65,0.31,0.99,377.2,147,,,,,,,,,,,46,,,,,,,,,4.8,,,,0.28,,,100%,100%,,,,,,,100%,,,,,,,,,,,,0%,,0%,,,0%,,,,,,,,1,0,,,,,0,
145,0,China,Wuhan,10,40.45%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Top-level,General,Positive,End-point and active,Survivors only,Both,Yes,ICU only,Severe/Critical Only,Yes,52.5,53.4,,45,59.5,,60%,,,,,,,,,,,,,5.6,6,3,8,,,,,10%,30%,0%,10%,0%,0%,0%,10%,0%,0%,70%,,,,70%,80%,,50%,10%,,,20%,20%,,10%,,20%,,0%,100%,100%,100%,1,,,,0.65,,,,,,,,,,,,,,,,42,38.1,12.4,,,,,,55.98,,,,,,80%,100%,,,10%,10%,,,,60%,,70%,50%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,0.3,,,,0,0
145,1,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 1,Positive,End-point,Survivors only,Discharged only,Yes,ICU only,Severe/Critical Only,Yes,46,46,,46,46,,100%,,,,,,,,,,,,,8,8,,,,,,,0%,100%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,,100%,100%,,100%,0%,,,0%,0%,,0%,,100%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,0%,0%,,,,0%,,100%,100%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,0,,,,0,0
145,2,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 2,Positive,End-point and active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Yes,34,34,,34,34,,0%,,,,,,,,,,,,,0,0,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,0%,100%,,0%,0%,,,0%,100%,,0%,,100%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,0%,0%,,,,0%,,0%,0%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,1,,,,0,0
145,3,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 3,Positive,End-point and active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Yes,42,42,,42,42,,100%,,,,,,,,,,,,,8,8,,,,,,,0%,100%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,,100%,100%,,100%,0%,,,100%,0%,,100%,,0%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,0%,0%,,,,100%,,100%,100%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,0,,,,0,0
145,4,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 4,Positive,End-point and active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Yes,55,55,,55,55,,0%,,,,,,,,,,,,,10,10,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,,100%,100%,,100%,0%,,,0%,0%,,0%,,0%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,0%,0%,,,,100%,,0%,0%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,0,,,,0,0
145,5,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 5,Positive,End-point and active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Yes,57,57,,57,57,,100%,,,,,,,,,,,,,4,4,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,,0%,100%,,0%,0%,,,0%,0%,,0%,,0%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,0%,100%,,,,100%,,100%,0%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,0,,,,0,0
145,6,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 6,Positive,End-point and active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Yes,78,78,,78,78,,0%,,,,,,,,,,,,,8,8,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,,100%,100%,,100%,100%,,,0%,0%,,0%,,0%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,0%,0%,,,,100%,,100%,100%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,0,,,,0,0
145,7,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 7,Positive,End-point,Survivors only,Discharged only,Yes,ICU only,Severe/Critical Only,Yes,56,56,,56,56,,100%,,,,,,,,,,,,,4,4,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,,100%,0%,,100%,0%,,,0%,0%,,0%,,0%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,0%,0%,,,,100%,,100%,100%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,1,,,,0,0
145,8,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 8,Positive,End-point and active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Yes,67,67,,67,67,,100%,,,,,,,,,,,,,10,10,,,,,,,100%,0%,0%,100%,0%,0%,0%,100%,0%,0%,100%,,,,100%,0%,,0%,0%,,,100%,100%,,0%,,0%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,,,0%,0%,,,,0%,,0%,0%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,0,,,,0,0
145,9,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 9,Positive,End-point,Survivors only,Discharged only,Yes,ICU only,Severe/Critical Only,Yes,49,49,,49,49,,0%,,,,,,,,,,,,,1,1,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,100%,100%,,0%,0%,,,0%,0%,,0%,,0%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,,,100%,0%,,,,0%,,100%,0%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,1,,,,0,0
145,10,China,Wuhan,1,36.52%,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,PNAS,Duan et. al.,https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf,English,Yes,Observational,1/23/20,2/19/20,28,Subgroup,Patient 10,Positive,End-point and active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Yes,50,50,,50,50,,100%,,,,,,,,,,,,,3,3,,,,,,,0%,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,0%,100%,,0%,0%,,,0%,0%,,0%,,0%,,0%,100%,100%,100%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,0%,0%,,,,100%,,100%,100%,100%,,100%,,,,,,,,,,,,,,,,,,,1,1,0,,,,0,0
146,0,China,Shanghai,4,52.25%,Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment,BioScience Treands,Wang et. al.,https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01030/_pdf/-char/en,English,Yes,Observational,1/21/20,2/4/20,15,Top-level,General,Positive Only,End-point and active,Survivors Only,Both,Yes,,Both,Both,41,44,,25,63,,75%,,,,,,100%,75%,25%,,,,,5,4,2,9,,,,,0%,0%,0%,0%,0%,0%,25%,0%,0%,0%,100%,,,25%,75%,,,25%,,50%,25%,50%,,,25%,,,,0%,50%,50%,0%,100%,5.44,4.27,6.75,27.4,10.7,30.53,,,,,,57.1,51.75,84.05,,,,,,,,,,,,,,,,,,,,100%,100%,100%,0%,0%,0%,,100%,0%,0%,0%,100%,100%,100%,0%,25%,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,,0.5,,,,0,0
146,1,China,Shanghai,1,52.81%,Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment,BioScience Treands,Wang et. al.,https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01030/_pdf/-char/en,English,Yes,Observational,1/21/20,2/4/20,15,Subgroup,32yo Man (C1),Positive Only,End-point,Survivors Only,Yes,Yes,,Mild,No,32,32,,32,32,,100%,,,,,,100%,100%,0%,,,,,11,11,11,11,,,,,0%,0%,0%,0%,0%,0%,100%,0%,0%,0%,100%,,,0%,0%,,,0%,,100%,0%,0%,,,0%,,,,0%,100%,0%,0%,100%,4.23,4.23,4.23,30.3,30.3,30.3,,,,,,57.2,57.2,57.2,,,,,,,,,,,,,,,,,,,,100%,100%,100%,0%,0%,0%,,100%,0%,0%,0%,100%,100%,100%,0%,0%,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,,1,,7,,0,0
146,2,China,Shanghai,1,52.81%,Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment,BioScience Treands,Wang et. al.,https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01030/_pdf/-char/en,English,Yes,Observational,1/21/20,2/4/20,15,Subgroup,19yo Man (C2),Positive Only,End-point,Survivors Only,Yes,Yes,,Mild,No,19,19,,19,19,,100%,,,,,,100%,100%,0%,,,,,6,6,6,6,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,0%,100%,,,0%,,100%,100%,100%,,,100%,,,,0%,100%,0%,0%,100%,6.48,6.48,6.48,30.6,30.6,30.6,,,,,,57,57,57,,,,,,,,,,,,,,,,,,,,100%,100%,100%,0%,0%,0%,,100%,0%,0%,0%,100%,100%,100%,0%,0%,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,,1,,9,,0,0
146,3,China,Shanghai,1,52.25%,Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment,BioScience Treands,Wang et. al.,https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01030/_pdf/-char/en,English,Yes,Observational,1/21/20,2/4/20,15,Subgroup,63yo Man (C3),Positive Only,Active,Survivors Only,No,Yes,,Severe,No,63,63,,63,63,,100%,,,,,,100%,0%,100%,,,,,1,1,1,1,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,100%,100%,,,100%,,0%,0%,100%,,,0%,,,,0%,0%,100%,0%,100%,4.4,4.4,4.4,24.5,24.5,24.5,,,,,,50,50,50,,,,,,,,,,,,,,,,,,,,100%,100%,100%,0%,0%,0%,,100%,0%,0%,0%,100%,100%,100%,0%,0%,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,,0,,,,0,0
146,4,China,Shanghai,1,52.25%,Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment,BioScience Treands,Wang et. al.,https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01030/_pdf/-char/en,English,Yes,Observational,1/21/20,2/4/20,15,Subgroup,63yo Woman (C4),Positive Only,Active,Survivors Only,No,Yes,,Severe,Yes,63,63,,63,63,,0%,,,,,,100%,100%,0%,,,,,2,2,2,2,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,,,0%,100%,,,0%,,0%,0%,0%,,,0%,,,,0%,0%,100%,0%,100%,6.84,6.84,6.84,6.1,6.1,6.1,,,,,,93,93,93,,,,,,,,,,,,,,,,,,,,100%,100%,100%,0%,0%,0%,,100%,0%,0%,0%,100%,100%,100%,0%,100%,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,,,,0,,,,0%%,0
147,0,South Korea,Incheon,1,44.38%,"The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures",J. Korean Medical Science,Kim et. al.,https://www.jkms.org/Synapse/Data/PDFData/0063JKMS/jkms-35-e61.pdf,English,Yes,Observational,1/18/20,1/31/20,13,Top-level,Single patient,Positive only,End-point only,Both,Both,No,Non-ICU only,Mild only,Non-ventilation only,35,35,0,35,35,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,,,,,,,,100%,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,38.4,,0%,100%,100%,,100%,100%,,,100%,,,100%,100%,,,0%,100%,0%,0%,0,5.6,5.6,5.6,,,,,,193,193,193,,,,13.7,13.7,13.7,,4.6,70,60,,,,,0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,11,,0,0
148,0,South Korea,Goyang,1,74.16%,Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.,J. Korean Medical Science,Lim et. al.,https://www.jkms.org/Synapse/Data/PDFData/0063JKMS/jkms-35-e79.pdf,English,Yes,Observational,1/11/20,2/10/20,17,Top-level,Single patient,Positive only,End-point only,Survivors only,Discharged only,Yes,non-ICU only,Mild only,Non-ventilation only,54,54,0,,,0%,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,3,3,,,0%,0%,25.7,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,100%,37.5,38.6,0%,100%,0%,100%,0%,100%,100%,100%,100%,0%,0%,0%,100%,0%,0%,0%,100%,0%,0%,1,6.4,5.9,7.9,2.7,2.4,3.1,,,258,219,329,,,,153,145,157,,39,45,42,71,,81,33,58.6,,,,,,0.75,13.2,100%,100%,100%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,0%,0%,0%,0%,1,0,1,,17,,0,0
149,0,China,Shenzhen,12,52.25%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/11/20,1/23/20,13,Top-level,All,Positive only,End-point and active,Survivors only,Both,Yes,Both,All,Both,62,54,,44,65,,67%,0%,0%,100%,0%,0%,100%,92%,8%,,,,,8,7,5,10,,,,,,25%,17%,33%,8%,0%,0%,0%,17%,,83%,,,,92%,,0%,,33%,,,17%,17%,,,42%,,0%,0%,0%,66%,33%,1,5.11,4.46,6.71,0.88,0.88,1.31,40.3,16.9,156,118,210,3.35,2.81,5.39,,,,,41,31.6,40,,,,5.4,,220,41.14,,,0.82,,,,100%,,,,,,,,25%,33%,,,,50%,25%,,,,,,25%,25%,50%,,8%,8%,17%,,,,,,,1,0.33,0.17,,,,,
149,1,China,Shenzhen,1,52.25%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/12/20,1/24/20,13,Subgroup,65yo Woman (C1),Positive only,Active,Survivors only,Non-discharged only,Yes,Non-ICU only,Mild only,Ventilation only,65,65,,65,65,,0%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,8,8,8,8,,,,,,100%,0%,100%,0%,0%,0%,0%,0%,,100%,,,,100%,,0%,,100%,,,0%,0%,,,100%,,0%,0%,0%,100%,0%,1,4.31,4.31,4.31,0.88,0.88,0.88,47.3,16.7,161,161,161,3.13,3.13,3.13,,,,,36.8,26.6,26.7,,,,2.87,,46,52.6,,,0.05,,,,100%,,,,,,,,0%,0%,,,,100%,0%,,,,,,100%,0%,100%,,0%,0%,0%,,,,,,,1,0,0,,,,,
149,2,China,Shenzhen,1,52.25%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/13/20,1/25/20,13,Subgroup,66yo Man (C2),Positive only,Active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,66,66,,66,66,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,7,7,7,7,,,,,,100%,0%,100%,0%,0%,0%,0%,0%,,100%,,,,100%,,0%,,100%,,,0%,100%,,,100%,,0%,0%,0%,0%,100%,1,5.24,5.24,5.24,1.21,1.21,1.21,45.8,16.5,118,118,118,3.53,3.53,3.53,,,,,39.5,26.5,33.6,,,,5.37,,118,38.6,,,0.04,,,,100%,,,,,,,,100%,100%,,,,100%,100%,,,,,,100%,100%,100%,,0%,0%,100%,,,,,,,1,1,0,,,,,
149,3,China,Shenzhen,1,52.25%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/14/20,1/26/20,13,Subgroup,62yo Man (C3),Positive only,Active,Survivors only,Non-discharged only,Yes,Non-ICU only,Mild only,Ventilation only,62,62,,62,62,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,4,4,4,4,,,,,,0%,0%,100%,0%,0%,0%,0%,100%,,100%,,,,100%,,0%,,0%,,,100%,0%,,,100%,,0%,0%,0%,100%,0%,1,3.85,3.85,3.85,0.83,0.83,0.83,41.2,11.6,121,121,121,2.26,2.26,2.26,,,,,41.6,26,26,,,,5.51,,97,52.95,,,0.1,,,,100%,,,,,,,,0%,0%,,,,100%,0%,,,,,,100%,0%,100%,,0%,0%,0%,,,,,,,1,0,0,,,,,
149,4,China,Shenzhen,1,52.25%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/15/20,1/27/20,13,Subgroup,63yo Man (C4),Positive only,Active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,63,63,,63,63,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,5,5,5,5,,,,,,0%,0%,0%,100%,0%,0%,0%,0%,,100%,,,,100%,,0%,,0%,,,0%,0%,,,0%,,0%,0%,0%,0%,100%,1,6.79,6.79,6.79,0.26,0.26,0.26,18.7,10.9,119,119,119,6.31,6.31,6.31,,,,,35.1,62,107,,,,9.81,,876,89.94,,,9.18,,,,100%,,,,,,,,100%,100%,,,,100%,100%,,,,,,100%,100%,100%,,100%,100%,100%,,,,,,,1,1,0,,,,,
149,5,China,Shenzhen,1,51.69%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/16/20,1/28/20,13,Subgroup,63yo Woman (C5),Positive only,Active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,63,63,,63,63,,0%,0%,0%,100%,0%,0%,100%,0%,100%,,,,,8,8,8,8,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,,100%,,,,100%,,0%,,100%,,,0%,0%,,,100%,,0%,0%,0%,0%,100%,1,6.71,6.71,6.71,0.77,0.77,0.77,30.9,23,215,215,215,5.43,5.43,5.43,,,,,38.3,45.3,26.2,,,,4.8,,,53.6,,,0.03,,,,100%,,,,,,,,0%,100%,,,,100%,0%,,,,,,100%,0%,100%,,0%,0%,0%,,,,,,,1,1,0,,,,,
149,6,China,Shenzhen,1,52.25%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/17/20,1/29/20,13,Subgroup,36yo Man (C6),Positive only,End-point,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,36,36,,36,36,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,15,15,15,15,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,,100%,,,,100%,,0%,,0%,,,100%,100%,,,0%,,0%,0%,0%,100%,0%,1,13.55,13.55,13.55,2.37,2.37,2.37,,,250,250,250,10.49,10.49,10.49,,,,,48.9,30,29.3,,,,6.65,,111,5.8,,,0.02,,,,100%,,,,,,,,0%,0%,,,,0%,0%,,,,,,0%,0%,0%,,0%,0%,0%,,,,,,,1,0,1,,7,,,0
149,7,China,Shenzhen,1,52.25%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/18/20,1/30/20,13,Subgroup,10yo Man (C7),Positive only,End-point,Survivors only,Discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,10,10,,10,10,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,8,8,8,8,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,,0%,,,,0%,,0%,,0%,,,0%,0%,,,0%,,0%,0%,0%,100%,0%,1,6.72,6.72,6.72,3.79,3.79,3.79,,,196,196,196,2.26,2.26,2.26,,,,,46.4,32.8,34.7,,,,7.65,,70,5,,,0.02,,,,100%,,,,,,,,0%,0%,,,,0%,0%,,,,,,0%,0%,0%,,0%,0%,0%,,,,,,,1,0,1,,7,,,0
149,8,China,Shenzhen,1,50.56%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/19/20,1/31/20,13,Subgroup,35yo Man (C8),Positive only,Active,Survivors only,Non-discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,35,35,,35,35,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,7,7,7,7,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,,100%,,,,100%,,0%,,0%,,,0%,0%,,,0%,,0%,0%,0%,100%,0%,1,4.62,4.62,4.62,1.59,1.59,1.59,,,236,236,236,2.62,2.62,2.62,,,,,43.4,22.4,28.9,,,,4.21,,,35.6,,,0.03,,,,100%,,,,,,,,0%,0%,,,,0%,0%,,,,,,0%,0%,0%,,0%,0%,0%,,,,,,,1,0,0,,,,,
149,9,China,Shenzhen,1,51.69%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/20/20,2/1/20,13,Subgroup,51yo Man (C9),Positive only,Active,Survivors only,Non-discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,51,51,,51,51,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,13,13,13,13,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,,0%,,,,100%,,0%,,100%,,,0%,0%,,,100%,,0%,0%,0%,100%,0%,1,4.94,4.94,4.94,1.45,1.45,1.45,50.2,24.9,184,184,184,3.18,3.18,3.18,,,,,46.2,39.5,37.7,,,,3.71,,,13,,,0.02,,,,100%,,,,,,,,0%,0%,,,,0%,0%,,,,,,0%,0%,0%,,0%,0%,0%,,,,,,,1,0,0,,,,,
149,10,China,Shenzhen,1,51.69%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/21/20,2/2/20,13,Subgroup,65yo Woman (C10),Positive only,Active,Survivors only,Non-discharged only,Yes,ICU only,Severe/Critical Only,Ventilation only,65,65,,65,65,,0%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,16,16,16,16,,,,,,0%,100%,0%,0%,0%,0%,0%,0%,,100%,,,,100%,,0%,,0%,,,0%,0%,,,0%,,0%,0%,0%,0%,100%,1,5.89,5.89,5.89,0.42,0.42,0.42,34.9,14.3,118,118,118,5.35,5.35,5.35,,,,,34.6,15.7,52,,,,4.48,,,33.2,,,0.08,,,,100%,,,,,,,,100%,100%,,,,100%,100%,,,,,,100%,100%,100%,,0%,0%,0%,,,,,,,1,1,0,,,,,
149,11,China,Shenzhen,1,50.00%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/22/20,2/3/20,13,Subgroup,72yo Man (C11),Positive only,Active,Survivors only,Non-discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,72,72,,72,72,,100%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,16,16,16,16,,,,,,100%,0%,100%,0%,0%,0%,0%,100%,,100%,,,,100%,,0%,,0%,,,0%,0%,,,0%,,0%,0%,0%,100%,0%,1,4.99,4.99,4.99,,,,50.7,17,99,99,99,3.73,3.73,3.73,,,,,42.6,29,42.1,,,,6.89,,,85,,,0.22,,,,100%,,,,,,,,0%,0%,,,,0%,0%,,,,,,0%,0%,0%,,0%,0%,0%,,,,,,,1,0,0,,,,,
149,12,China,Shenzhen,1,51.69%,Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,Science China Life Sciences,Liu et. al.,https://link.springer.com/content/pdf/10.1007/s11427-020-1643-8.pdf,English,Yes,Observational,1/23/20,2/4/20,13,Subgroup,56yo Woman (C12),Positive only,Active,Survivors only,Non-discharged only,Yes,Non-ICU only,Mild only,Non-ventilation only,56,56,,56,56,,0%,0%,0%,100%,0%,0%,100%,100%,0%,,,,,6,6,6,6,,,,,,0%,100%,0%,0%,0%,0%,0%,0%,,100%,,,,100%,,0%,,0%,,,0%,0%,,,0%,,0%,0%,0%,100%,0%,1,3.98,3.98,3.98,0.83,0.83,0.83,43,17.4,152,152,152,3,3,3,,,,,38.4,23.6,36.1,,,,3.12,,,28.4,,,0.03,,,,100%,,,,,,,,0%,0%,,,,0%,0%,,,,,,0%,0%,0%,,0%,0%,0%,,,,,,,1,0,0,,,,,
150,0,USA,Washington,1,50.56%,First Case of 2019 Novel Coronavirus in the United States,,Holshue et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001191?articleTools=true,English,Yes,Observational,1/15/20,1/30/20,15,Top-level,Single Patient,Positive only,End-point only,Survivors only,Discharged Only ,Yes,non-ICU only,Mild only,Non-ventilation only,35,35,0,35,35,,100%,,,,,,100%,100%,0%,,,,,,4,4,,0%,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,,100%,38.1,39.4,,100%,100%,,0%,,100%,100%,100%,100%,100%,100%,,,,0%,100%,0%,0%,1,5.4,,,1.4,1.24,1.75,,,150,127,195,3.2,1.7,3.75,148,142,148,42,45,119,85,,,,,,,,,,,,11.9,0%,100%,,,,100%,,,,,,100%,,100%,,,,,,,0%,0%,0%,0%,,0%,,,,,,,,,1,,1,,14,,0,0
151,0,China,Wuhan,287,35.96%,"Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",MedRxiv,Xiao et. al.,https://www.medrxiv.org/content/10.1101/2020.04.06.20055194v1.full.pdf,English,No,Observational,1/5/20,3/8/20,63,Top-level,General,Positive only,End-point and active,Both,Both,Yes,,,,62,,,,,,56%,0%,0%,100%,0%,0%,,,,,,,,,10,,,,,23.6,0%,,30%,16%,12%,6%,3%,4%,8%,2%,,78%,,,7%,73%,48%,,,48%,48%,,,,,,,48%,,0%,57%,43%,0%,0,5,,,0.8,,,,,,,,,,,128.3,,,,33.4,25,27,8.9,,,,,100,23.4,,,0.07,0.6,15.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.28,,0.66,,18,,0.07,0.03
151,1,China,Wuhan,55,35.96%,"Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",MedRxiv,Xiao et. al.,https://www.medrxiv.org/content/10.1101/2020.04.06.20055194v1.full.pdf,English,No,Observational,1/5/20,3/8/20,63,Subgroup,AKI,Positive only,End-point and active,Both,Both,Yes,,,,66,,,,,,69%,0%,0%,100%,0%,0%,,,,,,,,,10,,,,,24.2,0%,,42%,22%,18%,11%,5%,2%,16%,5%,,73%,,,18%,75%,53%,,,45%,45%,,,,,,,44%,,0%,38%,62%,0%,0,5.8,,,0.7,,,,,,,,,,,125,,,,31.6,27,35,11,,,,,118,34.6,,,0.15,0.9,17.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.44,,0.35,,22.5,,0.03,0.03
151,2,China,Wuhan,232,35.96%,"Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",MedRxiv,Xiao et. al.,https://www.medrxiv.org/content/10.1101/2020.04.06.20055194v1.full.pdf,English,No,Observational,1/5/20,3/8/20,63,Subgroup,Non-AKI,Positive only,End-point and active,Both,Both,Yes,,,,60,,,,,,53%,0%,0%,100%,0%,0%,,,,,,,,,9,,,,,23.4,0%,,28%,14%,10%,4%,2%,4%,8%,1%,,79%,,,5%,72%,47%,,,48%,48%,,,,,,,49%,,0%,61%,39%,0%,0,4.9,,,0.9,,,,,,,,,,,129.1,,,,33.8,24,26,8.6,,,,,99,19.5,,,0.07,0.5,14.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.25,,0.72,,18,,0.22,0.06
152,0,USA,New York City,4103,26.40%,"Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City",MedRxiv,Petrilli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.08.20057794v1.full.pdf,English,No,Observational,3/1/20,4/2/20,32,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,51.23,,,40.26,63.74,,50.21%,44.20%,15.94%,6.93%,,32.94%,,,,,,,,,,,,21.38%,,,26.87%,50.36%,23.97%,15.00%,8.92%,7.58%,4.53%,,,5.29%,18.00%,,37.4,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.85%,,,,,,,,,,,,,,,,,,,0.49,0,0.23,,5.36,,0.07,0.12
152,1,USA,New York City,2104,27.53%,"Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City",MedRxiv,Petrilli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.08.20057794v1.full.pdf,English,No,Observational,3/1/20,4/2/20,32,Subgroup,Non-hospitalized,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,41,,,31,54,,39%,42.20%,17.30%,7.90%,,32.60%,,,,,,,,,,,,17.00%,,,14.50%,29.90%,11.50%,5.30%,2.10%,5.00%,2%,,,1%,10.50%,,37.3,,,,,,,,,,,,,,,,,,,0%,0%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,,,,,,,,,,,,,,,,0,0,0,,0,,0,0
152,2,USA,New York City,1999,26.97%,"Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City",MedRxiv,Petrilli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.08.20057794v1.full.pdf,English,No,Observational,3/1/20,4/2/20,32,Subgroup,Hospitalized,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,62,,,50,74,,62%,46.30%,14.50%,5.90%,,33.30%,,,,,,,,,,,,26.00%,,,39.90%,71.90%,37.10%,25.20%,16.10%,10.30%,7.20%,,,9.80%,25.90%,,37.5,,,,,,,,,,,,,,,,,0%,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22%,,,,,,,,,,,,,,,,,,,1,0,0.47,,5.36,,0.15,0.24
152,3,USA,New York City,1999,32.02%,"Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City",MedRxiv,Petrilli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.08.20057794v1.full.pdf,English,No,Observational,3/1/20,4/2/20,32,Subgroup,Discharged,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,58,,,46,71,,60.10%,44.10%,17.20%,4.60%,,34.10%,,,,,,,,,,,,25.50%,,,40.60%,70.70%,34.30%,22.90%,13.50%,9.80%,5.80%,,,8.70%,24.10%,,37.5,,,,,,,,,,,,,,,,,0%,,,,0,,,,0.9,0.7,1.3,,,,,,,,,,,,,,32,39,,,,,0.93,,80.8,,,0.09,0.31,,,,,,,,,,,,,,,,,0%,,,,,,,,,,,,,,,,,,,1,0,1,,4,,0,0
152,4,USA,New York City,650,33.15%,"Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City",MedRxiv,Petrilli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.08.20057794v1.full.pdf,English,No,Observational,3/1/20,4/2/20,32,Subgroup,Critical,Positive only,End-point only,Both,Both,Yes,ICU only,Severe/Critical Only,Both,67,,,56,77,,68%,48.30%,11.40%,8%,,32.30%,,,,,,,,,,,,26.60%,,,40.00%,73.40%,39.50%,27.10%,20.60%,10.90%,8.60%,,,11.50%,26.60%,,37.6,,,,,,,,,,,,,,,,,0%,,0%,100%,0,,,,0.8,0.5,1.1,,,,,,,,,,,,,,35,52,,,,,1.06,,139.3,,,0.27,0.51,,,,,,,,,,,,,,,,,68.50%,,,,,,,,,,,,,,,,,,,1,1,0.08,,7.31,,0.45,0.86
154,0,China,Wuhan,274,42.70%,"Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",MedRxiv,Zeng et. al.,https://www.medrxiv.org/content/10.1101/2020.04.06.20054825v1.full.pdf,English,No,Observational,1/5/20,3/8/20,63,Top-level,All patients,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,60,60,15,,,,55.00%,0%,0%,100%,0%,0%,,,,,,,,10,10,6,14,,,23.6,,,,15.00%,11.00%,6.00%,3.00%,4.00%,8.00%,2.00%,,78%,,,,73%,47%,,,50%,,,,,,,,,,0%,57%,43%,0%,1,4.9,3.8,7.1,0.8,0.6,1.2,,,,,,3.6,2.3,5.4,128,,,,33.4,25,27,9,6.6,12,,69,100,22.5,,,0.07,0.6,14.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.78,,20,,0.08,
154,1,China,Wuhan,75,42.70%,"Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",MedRxiv,Zeng et. al.,https://www.medrxiv.org/content/10.1101/2020.04.06.20054825v1.full.pdf,English,No,Observational,1/5/20,3/8/20,63,Subgroup,Patients with hypertension,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,67,67,11,,,,55.00%,0%,0%,100%,0%,0%,,,,,,,,10,10,7,15,,,24.3,,,,31.00%,21.00%,9.00%,3.00%,4.00%,15.00%,5.00%,,76%,,,,71%,47%,,,52%,,,,,,,,,,0%,60%,40%,0%,1,5.3,3.9,7.1,0.9,0.6,1.2,,,,,,4,2.4,6.4,124,,,,32.6,24,28,8.6,6.6,13,,74,103,21.7,,,0.08,0.5,14.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.84,,22,,0.09,
154,2,China,Wuhan,199,42.70%,"Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",MedRxiv,Zeng et. al.,https://www.medrxiv.org/content/10.1101/2020.04.06.20054825v1.full.pdf,English,No,Observational,1/5/20,3/8/20,63,Subgroup,Patients without hypertension,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,58,58,15,,,,55.00%,0%,0%,100%,0%,0%,,,,,,,,9,9,5,12,,,23.3,,,,10.00%,8.00%,4.00%,3.00%,4.00%,6.00%,1.00%,,78%,,,,73%,47%,,,48%,,,,,,,,,,0%,56%,44%,0%,1,4.9,3.6,7.2,0.8,0.6,1.2,,,,,,3.4,2.3,5.2,130,,,,33.7,25,27,9.2,6.4,11.8,,68,98,23.2,,,0.07,1,14.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.76,,19,,0.07,
155,0,China,Wuhan,214,35.96%,"Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China",JAMA Neurology,Mao et. al.,doi:10.1001/jamaneurol.2020.1127,English,Yes,Observational,1/16/20,2/19/20,34,Top-level,All,Positive only,End-point and active,Both,Both,No,Both,All,Both,52.7,52.7,15.5,37.2,68.2,,40.70%,0%,0%,100%,0%,0%,,,,,,,,8,8,,,,,,,38.80%,23.80%,14%,7%,,6.10%,,,2.80%,,61.70%,50%,,,50%,,13.10%,,4.70%,,,19.20%,,31.80%,14.50%,,,,0%,58.88%,20.56%,20.56%,,4.9,,,1.1,,,,,209,,,3,,,,,,,,26,26,,,,4.1,68.2,64,12.2,,,,0.5,,,,,,,,,,,,,,,,,,,,,,,,,,2.80%,,,,,,,,,,1,,,,,,,
155,0,China,Wuhan,88,35.96%,"Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China",JAMA Neurology,Mao et. al.,doi:10.1001/jamaneurol.2020.1127,English,Yes,Observational,1/16/20,2/19/20,34,Subgroup,Severe,Positive only,End-point and active,Both,Both,No,Both,Severe/Critical Only,Both,58.2,58.2,15,43.2,73.2,,50%,0%,0%,100%,0%,0%,,,,,,,,10,10,,,,,,,47.70%,36.40%,17%,8%,,5.70%,,,2.30%,,45.50%,34.10%,,,34.10%,,17%,,6.80%,,,14.80%,,23.90%,11.40%,,,,0%,0%,50%,50%,,5.4,,,0.9,,,,,204.5,,,3.8,,,,,,,,32.5,34,,,,4.6,71.6,83,37.1,,,,0.9,,,,,,,,,,,,,,,,,,,,,,,,,,5.70%,,,,,,,,,,1,,,,,,,
155,0,China,Wuhan,126,35.96%,"Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China",JAMA Neurology,Mao et. al.,doi:10.1001/jamaneurol.2020.1127,English,Yes,Observational,1/16/20,2/19/20,34,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,No,Both,Mild only,Both,48.9,48.9,14.7,34.2,63.6,,34.10%,0%,0%,100%,0%,0%,,,,,,,,1,1,,,,,,,32.50%,15.10%,11.90%,6.30%,,6.30%,,,3.20%,,73%,61.10%,,,61.10%,,10.30%,,3.20%,,,22.20%,,37.30%,16.70%,,,,0%,100%,0%,0%,,4.5,,,1.3,,,,,219,,,2.6,,,,,,,,23,23,,,,3.8,65.6,59,9.4,,,,0.4,,,,,,,,,,,,,,,,,,,,,,,,,,0.80%,,,,,,,,,,1,,,,,,,
156,0,Europe/North America,Various,53,28.09%,Compassionate Use of Remdesivir for Patients with Severe Covid-19,NEJM,Grein et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007016?articleTools=true,English,Yes,Observational,1/25/20,3/7/20,42,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,64,,,48,71,,75%,,,,,,,,,,,,,,,,,,,,,68%,25%,17%,11%,11%,,,,,,,,,,,,,,,,,9%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37,36,,,,,78.68,,,,,,,,,100%,,,,100%,,,,,,,9%,35.85%,0%,57.00%,8%,,,,,,,4%,,,4%,,,,6%,,,,1,1,0.47,10,16,,0.13,0.22
156,1,Europe/North America,Various,34,28.09%,Compassionate Use of Remdesivir for Patients with Severe Covid-19,NEJM,Grein et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007016?articleTools=true,English,Yes,Observational,1/25/20,3/7/20,42,Subgroup,Invasive ventilation,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,67,,,56,72,,79%,,,,,,,,,,,,,,,,,,,,,74%,26%,24%,18%,15%,,,,,,,,,,,,,,,,,3%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,48,39,,,,,79.56,,,,,,,,,100%,,,,100%,,,,,,,0%,0%,0%,88%,12%,,,,,,,3%,,,6%,,,,5%,,,,1,1,0.24,12,17,,0.18,0.43
156,2,Europe/North America,Various,19,28.09%,Compassionate Use of Remdesivir for Patients with Severe Covid-19,NEJM,Grein et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007016?articleTools=true,English,Yes,Observational,1/25/20,3/7/20,42,Subgroup,Noninvasive oxygen support,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Severe/Critical Only,Non-ventilation only,53,,,41,68,,68%,,,,,,,,,,,,,,,,,,,,,58%,21%,5%,0%,5%,,,,,,,,,,,,,,,,,21%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,27,35,,,,,69.84,,,,,,,,,100%,,,,100%,,,,,,,26%,100%,0%,0%,0%,,,,,,,5%,,,0%,,,,6%,,,,1,1,0.89,0,13,,0.05,0.06
157,0,China,Wuhan ,245,34.83%,Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19,Journal of Infection,Liu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30208-5/pdf,English,Yes,Observational,1/1/20,2/29/20,59,Top-level,All,Positive only,End-point only,Both,Both,No,Both,All,Both,52.94333333,52.94333333,15.97,36.97333333,68.91333333,,46.54%,0%,0%,100%,0%,0%,,,,,,,,,,,,4.09%,,23.69,,,21.21%,9.38%,7.33%,3.27%,3.66%,3%,,,,80.80%,,,,57.15%,18.35%,4.90%,27.36%,30.62%,47.73%,,7.36%,4.08%,22.84%,6.95%,,,,,,,,,5.53,,,0.98,,,,,181.53,,,4.08,,,127.54,,,,,,,,,,,,,48.33,,,,1.09,12.87,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.87,,,,0.13,0.13
157,1,China,Wuhan ,82,34.83%,Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-20,Journal of Infection,Liu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30208-5/pdf,English,Yes,Observational,1/1/20,2/29/20,59,Subgroup,Tertile 1,Positive only,End-point only,Both,Both,No,Both,All,Both,44.74,44.74,15.83,28.91,60.57,,29.27%,0%,0%,100%,0%,0%,,,,,,,,,,,,1.22%,,22.66,,,13.41%,6.10%,6.10%,2.44%,2.44%,0%,,,,74.39%,,,,47.56%,9.76%,6.10%,18.29%,29.27%,43.90%,,7.32%,3.66%,17.07%,10.98%,,,,,,,,,3.86,,,1.39,,,,,178.39,,,2.03,,,127.89,,,,,,,,,,,,,14.18,,,,0.3,12.39,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.98,,,,0.02,0.02
157,2,China,Wuhan ,81,34.83%,Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-21,Journal of Infection,Liu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30208-5/pdf,English,Yes,Observational,1/1/20,2/29/20,59,Subgroup,Tertile 2,Positive only,End-point only,Both,Both,No,Both,All,Both,52.68,52.68,17.07,35.61,69.75,,49.38%,0%,0%,100%,0%,0%,,,,,,,,,,,,4.94%,,24.41,,,17.28%,7.41%,3.70%,4.94%,1.23%,3.70%,,,,76.54%,,,,60.49%,12.35%,6.17%,29.63%,33.33%,44.40%,,9.88%,2.47%,18.52%,8.64%,,,,,,,,,4.23,,,0.92,,,,,174.7,,,2.83,,,130.39,,,,,,,,,,,,,36.18,,,,0.69,12.81,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.94,,,,0.06,0.06
157,3,China,Wuhan ,82,34.83%,Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-22,Journal of Infection,Liu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30208-5/pdf,English,Yes,Observational,1/1/20,2/29/20,59,Subgroup,Tertile 3,Positive only,End-point only,Both,Both,No,Both,All,Both,61.41,61.41,15.01,46.4,76.42,,60.98%,0%,0%,100%,0%,0%,,,,,,,,,,,,6.10%,,23.99,,,32.93%,14.63%,12.20%,2.44%,7.32%,4.88%,,,,91.46%,,,,63.41%,32.93%,2.44%,34.15%,29.27%,54.88%,,4.88%,6.10%,32.93%,1.22%,,,,,,,,,8.49,,,0.62,,,,,191.49,,,7.38,,,124.33,,,,,,,,,,,,,94.63,,,,2.29,13.42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.68,,,,0.32,0.32
158,0,China,Jiangsu,50,26.40%,Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19,Journal of Infection,Zhu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30188-2/pdf,English,Yes,Observational,1/23/20,2/29/20,37,Top-level,All,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,36.02,36.02,,31.12,52.364,,51.98%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,0%,,,,,4.98,,,1.26,,,,,,,,2.85,,,,,,,,19.24,,,,,,,,5.59,,,,0.37,,,,68%,,,,,32%,,,,,,100%,,,,,100%,,,,,,,,,,,,,,,,1,0,1,,,,0,0
158,1,China,Jiangsu,34,27.53%,Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19,Journal of Infection,Zhu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30188-2/pdf,English,Yes,Observational,1/23/20,2/29/20,37,Subgroup,Kaletra,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,40.5,40.5,,34.8,52.3,,58.80%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,0%,,,,,5.2,,,1.1,,,,,,,,3.2,,,,,,,,20.9,,,,,,,,7.7,,,,0.4,,,,100%,,,,,0%,,,,,,100%,,,,,100%,,,,,,,,,,,,,,,,1,0,1,,11.5,11.5,0,0
158,2,China,Jiangsu,16,27.53%,Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19,Journal of Infection,Zhu et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30188-2/pdf,English,Yes,Observational,1/23/20,2/29/20,37,Subgroup,Arbidol,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,26.5,26.5,,23.3,52.5,,37.50%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,,,,,,,,,,,,0%,,,,,4.5,,,1.6,,,,,,,,2.1,,,,,,,,15.7,,,,,,,,1.1,,,,0.3,,,,0%,,,,,100%,,,,,,100%,,,,,100%,,,,,,,,,,,,,,,,1,0,1,,9.5,9.5,0,0
159,0,China,Xiangyang,119,30.34%,"Clinical and Laboratory-Derived Parameters of 119 Hospitalized Patients with Coronavirus Disease 2019 in Xiangyang, Hubei Province, China",Journal of Infection,Shen et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30166-3/pdf,English,Yes,Observational,1/1/20,2/29/20,59,Top-level,All,Positive only,End-point only,Both,Both ,No,Both,All,NA,,49,,38,61,,47%,0%,0%,100%,0%,0%,,15%,,,,,,,5,3,7,,,,,,19%,10%,6%,,,2%,,2%,,86%,,,,63%,,14%,18%,,75%,,12%,3%,,,,,,0%,83%,0.00%,16.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.17,0.98,,,,0.03,0.03
159,1,China,Xiangyang,99,29.78%,"Clinical and Laboratory-Derived Parameters of 119 Hospitalized Patients with Coronavirus Disease 2019 in Xiangyang, Hubei Province, China",,Shen et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30166-3/pdf,English,Yes,Observational,1/1/20,2/29/20,59,Subgroup,Non-severe,Positive only,End-point only,Both,Both,No,Both,Mild only,NA,,45,,34,57,,44%,0%,0%,100%,0%,0%,,15%,,,,,,,5,3,7,,,,,,10%,7%,3%,,,2%,,1%,,86%,,,,53%,,15%,16%,,75%,,11%,3%,,,,,,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0,1,,,,0,0
159,2,China,Xiangyang,20,29.78%,"Clinical and Laboratory-Derived Parameters of 119 Hospitalized Patients with Coronavirus Disease 2019 in Xiangyang, Hubei Province, China",,Shen et. al.,https://www.journalofinfection.com/article/S0163-4453(20)30166-3/pdf,English,Yes,Observational,1/1/20,2/29/20,59,Subgroup,Severe,Positive only,End-point only,Both,Both,No,Both,Severe/Critical Only,NA,,67.5,,60,77,,60%,0%,0%,100%,0%,0%,,15%,,,,,,,5,4,9,,,,,,65%,25%,20%,,,0%,,5%,,80%,,,,65%,,10%,30%,,70%,,15%,5%,,,,,,0%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,1,0.98,,,,0.03,0.03
160,0,China,Anhui,125,52.81%,"Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China",Journal of Infection,Wang et. al.,https://pdf.sciencedirectassets.com/272991/AIP/1-s2.0-S1201971220302034/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBwaCXVzLWVhc3QtMSJHMEUCIQCDD9BTeT1s9fHxSa%2BTpLonA1chQ%2Fa8roE08yAbRxaGbwIgBa7aJhjuVkM4sRoYzgXuvoTPu5wa0Fn8V9EamUdb%2Bi8qtAMINBADGgwwNTkwMDM1NDY4NjUiDIutyPbzA8yUb%2BCgviqRA%2Bksr8IW6o5eVf6IIXmQCdVQZ3PY6a5u8ztgwIDeaDSzl9QwyJERW7Q7lsSexQJa2bCffAhjfbgM3kdijTchcNRH97RdCnproJC6N93cZU%2FKpjbTDiYFY4qapStqPrPzfIFYSh6k3cTu8Qtl7FOTfmG3mvc2DMOJRrXcuS%2F6kTYTdtsfv9h8MSRgpqfVfbRZnEG%2FmeGzijkPPCt8U3CNjzMEA0%2Bv6M6VlmJqRAEnzLDXLpbKRW2N3qi3eRRUyOSJ3So%2Fo9isC0bIigz1sQePdqKHDHh2ON2jNf3i%2F9Q3dUmsPbQve2Fd4obwKgixtKD%2BpmF6L8GYTBMo1c7C94O228keDJDSVto0C8xKZc8uADXISleh9kqfgmrzHUAuGRuXrAHLsqBApNgitlwnuEeeifF6DSOit%2BaylVu8dxVt59IgdV%2FiLRwi9dpSUnH5Kw%2BoFLm0djRLfh2vxOlxJgi1AC%2FZbLpCZDV1LX%2FnKnkTD%2B5lk8Fl7VRLd8024%2FqU%2BpFjXkHYZ%2FZiKBwfeojBN31v4e61MJCsyPQFOusBTgDlXYsaS96Wr%2Baf0XqL6mvIt8HQJ2OlqOdJUbCP01KTTLCirRjey2cCsIaBHrBdP0N2InY9R0d6Z11tM8j9cdw8rXcs%2BGo58s4cxW%2B2tzLkbH84Yr1ujAlzomW0OLqR753sSpixMIACuFg4V%2FdkXzy7WfUM5sdYAbUEhQWWDNYvKvOZVoOGS5GhNx02O7ft0Kd6GVUiQV2ef159KiAKFL130JkFqQe1tLtZx%2FAryyu3kha6EXFZkVsLD0rfJxzHdsdy%2BwuAs5EI5ImZGNVD9te%2FVQquH9L1ONhDcniQqb0iqdsRZnmr8F8IFA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20200411T202256Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRV7VN77N%2F20200411%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=6708b3b64bb120f5f9f81e874929f95b282318d7dbc9e4ea2fa1ee2e1ede5979&hash=7a31add5bbaab378a04cbd499ab42d7f86ddcf29b114a1577bf23f4b7fd8b402&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1201971220302034&tid=spdf-74bd40cf-2415-45c9-9fba-62b9ed24c6ae&sid=2f2bd7105a9e534f93485498cba7fa201c27gxrqa&type=client,English,Yes,Observational,1/20/20,2/18/20,29,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,38.76,13.799,,,,56.80%,0%,0%,100%,0%,0%,67.20%,57.60%,,,,,,4,,,,12.80%,,,,27.20%,,,14.40%,1.60%,0.80%,6.40%,,,,92.80%,,,,81.60%,45.60%,8.80%,41.60%,3.20%,34.40%,,40.00%,19.20%,,13.60%,,1.60%,,0%,80%,0%,20%,1,4.78,3.78,6.11,1.04,0.74,1.34,,,167,133,212,3.27,2.23,4.36,14,129,151,,,24,27,9.6,6.5,14.55,,,66,15.4,,,0.03,0.28,11.6,63.20%,100%,,,,,,,,28.00%,19.20%,60.00%,12.80%,,12.80%,3.20%,,,,,,,,4.80%,,,,,,,,56.80%,,,1,0.15,0.38,,14.8,,0,0
160,1,China,Anhui,25,32.58%,"Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China",Journal of Infection,Wang et. al.,https://pdf.sciencedirectassets.com/272991/AIP/1-s2.0-S1201971220302034/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBwaCXVzLWVhc3QtMSJHMEUCIQCDD9BTeT1s9fHxSa%2BTpLonA1chQ%2Fa8roE08yAbRxaGbwIgBa7aJhjuVkM4sRoYzgXuvoTPu5wa0Fn8V9EamUdb%2Bi8qtAMINBADGgwwNTkwMDM1NDY4NjUiDIutyPbzA8yUb%2BCgviqRA%2Bksr8IW6o5eVf6IIXmQCdVQZ3PY6a5u8ztgwIDeaDSzl9QwyJERW7Q7lsSexQJa2bCffAhjfbgM3kdijTchcNRH97RdCnproJC6N93cZU%2FKpjbTDiYFY4qapStqPrPzfIFYSh6k3cTu8Qtl7FOTfmG3mvc2DMOJRrXcuS%2F6kTYTdtsfv9h8MSRgpqfVfbRZnEG%2FmeGzijkPPCt8U3CNjzMEA0%2Bv6M6VlmJqRAEnzLDXLpbKRW2N3qi3eRRUyOSJ3So%2Fo9isC0bIigz1sQePdqKHDHh2ON2jNf3i%2F9Q3dUmsPbQve2Fd4obwKgixtKD%2BpmF6L8GYTBMo1c7C94O228keDJDSVto0C8xKZc8uADXISleh9kqfgmrzHUAuGRuXrAHLsqBApNgitlwnuEeeifF6DSOit%2BaylVu8dxVt59IgdV%2FiLRwi9dpSUnH5Kw%2BoFLm0djRLfh2vxOlxJgi1AC%2FZbLpCZDV1LX%2FnKnkTD%2B5lk8Fl7VRLd8024%2FqU%2BpFjXkHYZ%2FZiKBwfeojBN31v4e61MJCsyPQFOusBTgDlXYsaS96Wr%2Baf0XqL6mvIt8HQJ2OlqOdJUbCP01KTTLCirRjey2cCsIaBHrBdP0N2InY9R0d6Z11tM8j9cdw8rXcs%2BGo58s4cxW%2B2tzLkbH84Yr1ujAlzomW0OLqR753sSpixMIACuFg4V%2FdkXzy7WfUM5sdYAbUEhQWWDNYvKvOZVoOGS5GhNx02O7ft0Kd6GVUiQV2ef159KiAKFL130JkFqQe1tLtZx%2FAryyu3kha6EXFZkVsLD0rfJxzHdsdy%2BwuAs5EI5ImZGNVD9te%2FVQquH9L1ONhDcniQqb0iqdsRZnmr8F8IFA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20200411T202256Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRV7VN77N%2F20200411%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=6708b3b64bb120f5f9f81e874929f95b282318d7dbc9e4ea2fa1ee2e1ede5979&hash=7a31add5bbaab378a04cbd499ab42d7f86ddcf29b114a1577bf23f4b7fd8b402&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1201971220302034&tid=spdf-74bd40cf-2415-45c9-9fba-62b9ed24c6ae&sid=2f2bd7105a9e534f93485498cba7fa201c27gxrqa&type=client,English,Yes,Observational,1/20/20,2/18/20,29,Subgroup,Severe,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,,49.4,13.64,,,,64%,0%,0%,100%,0%,0%,,,,,,,,5.72,,,,28%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,0%,0%,100%,,5.11,2.79,7.43,0.74,0.62,1.04,,,163.4,103.14,223.66,3.86,1.68,6.04,13.67,119.76,153.6,,,25,29,10.4,7,17.9,,,,56.26,,,0.05,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
160,2,China,Anhui,100,32.58%,"Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China",Journal of Infection,Wang et. al.,https://pdf.sciencedirectassets.com/272991/AIP/1-s2.0-S1201971220302034/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBwaCXVzLWVhc3QtMSJHMEUCIQCDD9BTeT1s9fHxSa%2BTpLonA1chQ%2Fa8roE08yAbRxaGbwIgBa7aJhjuVkM4sRoYzgXuvoTPu5wa0Fn8V9EamUdb%2Bi8qtAMINBADGgwwNTkwMDM1NDY4NjUiDIutyPbzA8yUb%2BCgviqRA%2Bksr8IW6o5eVf6IIXmQCdVQZ3PY6a5u8ztgwIDeaDSzl9QwyJERW7Q7lsSexQJa2bCffAhjfbgM3kdijTchcNRH97RdCnproJC6N93cZU%2FKpjbTDiYFY4qapStqPrPzfIFYSh6k3cTu8Qtl7FOTfmG3mvc2DMOJRrXcuS%2F6kTYTdtsfv9h8MSRgpqfVfbRZnEG%2FmeGzijkPPCt8U3CNjzMEA0%2Bv6M6VlmJqRAEnzLDXLpbKRW2N3qi3eRRUyOSJ3So%2Fo9isC0bIigz1sQePdqKHDHh2ON2jNf3i%2F9Q3dUmsPbQve2Fd4obwKgixtKD%2BpmF6L8GYTBMo1c7C94O228keDJDSVto0C8xKZc8uADXISleh9kqfgmrzHUAuGRuXrAHLsqBApNgitlwnuEeeifF6DSOit%2BaylVu8dxVt59IgdV%2FiLRwi9dpSUnH5Kw%2BoFLm0djRLfh2vxOlxJgi1AC%2FZbLpCZDV1LX%2FnKnkTD%2B5lk8Fl7VRLd8024%2FqU%2BpFjXkHYZ%2FZiKBwfeojBN31v4e61MJCsyPQFOusBTgDlXYsaS96Wr%2Baf0XqL6mvIt8HQJ2OlqOdJUbCP01KTTLCirRjey2cCsIaBHrBdP0N2InY9R0d6Z11tM8j9cdw8rXcs%2BGo58s4cxW%2B2tzLkbH84Yr1ujAlzomW0OLqR753sSpixMIACuFg4V%2FdkXzy7WfUM5sdYAbUEhQWWDNYvKvOZVoOGS5GhNx02O7ft0Kd6GVUiQV2ef159KiAKFL130JkFqQe1tLtZx%2FAryyu3kha6EXFZkVsLD0rfJxzHdsdy%2BwuAs5EI5ImZGNVD9te%2FVQquH9L1ONhDcniQqb0iqdsRZnmr8F8IFA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20200411T202256Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRV7VN77N%2F20200411%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=6708b3b64bb120f5f9f81e874929f95b282318d7dbc9e4ea2fa1ee2e1ede5979&hash=7a31add5bbaab378a04cbd499ab42d7f86ddcf29b114a1577bf23f4b7fd8b402&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1201971220302034&tid=spdf-74bd40cf-2415-45c9-9fba-62b9ed24c6ae&sid=2f2bd7105a9e534f93485498cba7fa201c27gxrqa&type=client,English,Yes,Observational,1/20/20,2/18/20,29,Subgroup,Non-severe,Positive only,End-point and active,Both,Both,Yes,Both,Mild Only,Both,,39.47,14.84,,,,55%,0%,0%,100%,0%,0%,,,,,,,,3.5,,,,9%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,100%,0%,0%,,4.92,3.82,6.09,1.11,0.83,1.37,,,169.5,142,212,3.49,1.87,5.11,14.09,125.59,156.13,,,24,26,9.25,6.25,13.78,,,,10.8,,,0.03,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
160,3,China,Anhui,1,21.91%,"Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China",Journal of Infection,Wang et. al.,https://pdf.sciencedirectassets.com/272991/AIP/1-s2.0-S1201971220302034/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBwaCXVzLWVhc3QtMSJHMEUCIQCDD9BTeT1s9fHxSa%2BTpLonA1chQ%2Fa8roE08yAbRxaGbwIgBa7aJhjuVkM4sRoYzgXuvoTPu5wa0Fn8V9EamUdb%2Bi8qtAMINBADGgwwNTkwMDM1NDY4NjUiDIutyPbzA8yUb%2BCgviqRA%2Bksr8IW6o5eVf6IIXmQCdVQZ3PY6a5u8ztgwIDeaDSzl9QwyJERW7Q7lsSexQJa2bCffAhjfbgM3kdijTchcNRH97RdCnproJC6N93cZU%2FKpjbTDiYFY4qapStqPrPzfIFYSh6k3cTu8Qtl7FOTfmG3mvc2DMOJRrXcuS%2F6kTYTdtsfv9h8MSRgpqfVfbRZnEG%2FmeGzijkPPCt8U3CNjzMEA0%2Bv6M6VlmJqRAEnzLDXLpbKRW2N3qi3eRRUyOSJ3So%2Fo9isC0bIigz1sQePdqKHDHh2ON2jNf3i%2F9Q3dUmsPbQve2Fd4obwKgixtKD%2BpmF6L8GYTBMo1c7C94O228keDJDSVto0C8xKZc8uADXISleh9kqfgmrzHUAuGRuXrAHLsqBApNgitlwnuEeeifF6DSOit%2BaylVu8dxVt59IgdV%2FiLRwi9dpSUnH5Kw%2BoFLm0djRLfh2vxOlxJgi1AC%2FZbLpCZDV1LX%2FnKnkTD%2B5lk8Fl7VRLd8024%2FqU%2BpFjXkHYZ%2FZiKBwfeojBN31v4e61MJCsyPQFOusBTgDlXYsaS96Wr%2Baf0XqL6mvIt8HQJ2OlqOdJUbCP01KTTLCirRjey2cCsIaBHrBdP0N2InY9R0d6Z11tM8j9cdw8rXcs%2BGo58s4cxW%2B2tzLkbH84Yr1ujAlzomW0OLqR753sSpixMIACuFg4V%2FdkXzy7WfUM5sdYAbUEhQWWDNYvKvOZVoOGS5GhNx02O7ft0Kd6GVUiQV2ef159KiAKFL130JkFqQe1tLtZx%2FAryyu3kha6EXFZkVsLD0rfJxzHdsdy%2BwuAs5EI5ImZGNVD9te%2FVQquH9L1ONhDcniQqb0iqdsRZnmr8F8IFA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20200411T202256Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRV7VN77N%2F20200411%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=6708b3b64bb120f5f9f81e874929f95b282318d7dbc9e4ea2fa1ee2e1ede5979&hash=7a31add5bbaab378a04cbd499ab42d7f86ddcf29b114a1577bf23f4b7fd8b402&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1201971220302034&tid=spdf-74bd40cf-2415-45c9-9fba-62b9ed24c6ae&sid=2f2bd7105a9e534f93485498cba7fa201c27gxrqa&type=client,English,Yes,Observational,1/20/20,2/18/20,29,Subgroup,Severe,Positive only,Active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,69,69,,,,,100%,0%,0%,100%,0%,0%,,,,,,,,6,,,,,,,,,,,100%,,,,,,,100%,37.8,39,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,100%,,,,,,,,,,,,,,,,,,,1,1,,,,,0,
160,4,China,Anhui,1,21.91%,"Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China",Journal of Infection,Wang et. al.,https://pdf.sciencedirectassets.com/272991/AIP/1-s2.0-S1201971220302034/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBwaCXVzLWVhc3QtMSJHMEUCIQCDD9BTeT1s9fHxSa%2BTpLonA1chQ%2Fa8roE08yAbRxaGbwIgBa7aJhjuVkM4sRoYzgXuvoTPu5wa0Fn8V9EamUdb%2Bi8qtAMINBADGgwwNTkwMDM1NDY4NjUiDIutyPbzA8yUb%2BCgviqRA%2Bksr8IW6o5eVf6IIXmQCdVQZ3PY6a5u8ztgwIDeaDSzl9QwyJERW7Q7lsSexQJa2bCffAhjfbgM3kdijTchcNRH97RdCnproJC6N93cZU%2FKpjbTDiYFY4qapStqPrPzfIFYSh6k3cTu8Qtl7FOTfmG3mvc2DMOJRrXcuS%2F6kTYTdtsfv9h8MSRgpqfVfbRZnEG%2FmeGzijkPPCt8U3CNjzMEA0%2Bv6M6VlmJqRAEnzLDXLpbKRW2N3qi3eRRUyOSJ3So%2Fo9isC0bIigz1sQePdqKHDHh2ON2jNf3i%2F9Q3dUmsPbQve2Fd4obwKgixtKD%2BpmF6L8GYTBMo1c7C94O228keDJDSVto0C8xKZc8uADXISleh9kqfgmrzHUAuGRuXrAHLsqBApNgitlwnuEeeifF6DSOit%2BaylVu8dxVt59IgdV%2FiLRwi9dpSUnH5Kw%2BoFLm0djRLfh2vxOlxJgi1AC%2FZbLpCZDV1LX%2FnKnkTD%2B5lk8Fl7VRLd8024%2FqU%2BpFjXkHYZ%2FZiKBwfeojBN31v4e61MJCsyPQFOusBTgDlXYsaS96Wr%2Baf0XqL6mvIt8HQJ2OlqOdJUbCP01KTTLCirRjey2cCsIaBHrBdP0N2InY9R0d6Z11tM8j9cdw8rXcs%2BGo58s4cxW%2B2tzLkbH84Yr1ujAlzomW0OLqR753sSpixMIACuFg4V%2FdkXzy7WfUM5sdYAbUEhQWWDNYvKvOZVoOGS5GhNx02O7ft0Kd6GVUiQV2ef159KiAKFL130JkFqQe1tLtZx%2FAryyu3kha6EXFZkVsLD0rfJxzHdsdy%2BwuAs5EI5ImZGNVD9te%2FVQquH9L1ONhDcniQqb0iqdsRZnmr8F8IFA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20200411T202256Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRV7VN77N%2F20200411%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=6708b3b64bb120f5f9f81e874929f95b282318d7dbc9e4ea2fa1ee2e1ede5979&hash=7a31add5bbaab378a04cbd499ab42d7f86ddcf29b114a1577bf23f4b7fd8b402&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1201971220302034&tid=spdf-74bd40cf-2415-45c9-9fba-62b9ed24c6ae&sid=2f2bd7105a9e534f93485498cba7fa201c27gxrqa&type=client,English,Yes,Observational,1/20/20,2/18/20,29,Subgroup,Severe,Positive only,Active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,40,40,,,,,100%,0%,0%,100%,0%,0%,,,,,,,,4,,,,,,,,,,,0%,,,,,,,100%,37.4,40.6,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,100%,,,,,,,,,,,,,,,,,,,1,1,,,,,0,
160,5,China,Anhui,1,30.90%,"Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China",Journal of Infection,Wang et. al.,https://pdf.sciencedirectassets.com/272991/AIP/1-s2.0-S1201971220302034/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBwaCXVzLWVhc3QtMSJHMEUCIQCDD9BTeT1s9fHxSa%2BTpLonA1chQ%2Fa8roE08yAbRxaGbwIgBa7aJhjuVkM4sRoYzgXuvoTPu5wa0Fn8V9EamUdb%2Bi8qtAMINBADGgwwNTkwMDM1NDY4NjUiDIutyPbzA8yUb%2BCgviqRA%2Bksr8IW6o5eVf6IIXmQCdVQZ3PY6a5u8ztgwIDeaDSzl9QwyJERW7Q7lsSexQJa2bCffAhjfbgM3kdijTchcNRH97RdCnproJC6N93cZU%2FKpjbTDiYFY4qapStqPrPzfIFYSh6k3cTu8Qtl7FOTfmG3mvc2DMOJRrXcuS%2F6kTYTdtsfv9h8MSRgpqfVfbRZnEG%2FmeGzijkPPCt8U3CNjzMEA0%2Bv6M6VlmJqRAEnzLDXLpbKRW2N3qi3eRRUyOSJ3So%2Fo9isC0bIigz1sQePdqKHDHh2ON2jNf3i%2F9Q3dUmsPbQve2Fd4obwKgixtKD%2BpmF6L8GYTBMo1c7C94O228keDJDSVto0C8xKZc8uADXISleh9kqfgmrzHUAuGRuXrAHLsqBApNgitlwnuEeeifF6DSOit%2BaylVu8dxVt59IgdV%2FiLRwi9dpSUnH5Kw%2BoFLm0djRLfh2vxOlxJgi1AC%2FZbLpCZDV1LX%2FnKnkTD%2B5lk8Fl7VRLd8024%2FqU%2BpFjXkHYZ%2FZiKBwfeojBN31v4e61MJCsyPQFOusBTgDlXYsaS96Wr%2Baf0XqL6mvIt8HQJ2OlqOdJUbCP01KTTLCirRjey2cCsIaBHrBdP0N2InY9R0d6Z11tM8j9cdw8rXcs%2BGo58s4cxW%2B2tzLkbH84Yr1ujAlzomW0OLqR753sSpixMIACuFg4V%2FdkXzy7WfUM5sdYAbUEhQWWDNYvKvOZVoOGS5GhNx02O7ft0Kd6GVUiQV2ef159KiAKFL130JkFqQe1tLtZx%2FAryyu3kha6EXFZkVsLD0rfJxzHdsdy%2BwuAs5EI5ImZGNVD9te%2FVQquH9L1ONhDcniQqb0iqdsRZnmr8F8IFA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20200411T202256Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRV7VN77N%2F20200411%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=6708b3b64bb120f5f9f81e874929f95b282318d7dbc9e4ea2fa1ee2e1ede5979&hash=7a31add5bbaab378a04cbd499ab42d7f86ddcf29b114a1577bf23f4b7fd8b402&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1201971220302034&tid=spdf-74bd40cf-2415-45c9-9fba-62b9ed24c6ae&sid=2f2bd7105a9e534f93485498cba7fa201c27gxrqa&type=client,English,Yes,Observational,1/20/20,2/18/20,29,Subgroup,Severe,Positive only,Active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,21,21,,,,,0%,0%,0%,100%,0%,0%,,,,,,,,10,,,,,,,,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,0%,37.1,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,100%,,,,,,,,100%,100%,,100%,,,100%,,,,,,100%,,,,,,,,,,,,,1,1,1,10,,,0,0
160,6,China,Anhui,1,21.91%,"Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China",Journal of Infection,Wang et. al.,https://pdf.sciencedirectassets.com/272991/AIP/1-s2.0-S1201971220302034/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBwaCXVzLWVhc3QtMSJHMEUCIQCDD9BTeT1s9fHxSa%2BTpLonA1chQ%2Fa8roE08yAbRxaGbwIgBa7aJhjuVkM4sRoYzgXuvoTPu5wa0Fn8V9EamUdb%2Bi8qtAMINBADGgwwNTkwMDM1NDY4NjUiDIutyPbzA8yUb%2BCgviqRA%2Bksr8IW6o5eVf6IIXmQCdVQZ3PY6a5u8ztgwIDeaDSzl9QwyJERW7Q7lsSexQJa2bCffAhjfbgM3kdijTchcNRH97RdCnproJC6N93cZU%2FKpjbTDiYFY4qapStqPrPzfIFYSh6k3cTu8Qtl7FOTfmG3mvc2DMOJRrXcuS%2F6kTYTdtsfv9h8MSRgpqfVfbRZnEG%2FmeGzijkPPCt8U3CNjzMEA0%2Bv6M6VlmJqRAEnzLDXLpbKRW2N3qi3eRRUyOSJ3So%2Fo9isC0bIigz1sQePdqKHDHh2ON2jNf3i%2F9Q3dUmsPbQve2Fd4obwKgixtKD%2BpmF6L8GYTBMo1c7C94O228keDJDSVto0C8xKZc8uADXISleh9kqfgmrzHUAuGRuXrAHLsqBApNgitlwnuEeeifF6DSOit%2BaylVu8dxVt59IgdV%2FiLRwi9dpSUnH5Kw%2BoFLm0djRLfh2vxOlxJgi1AC%2FZbLpCZDV1LX%2FnKnkTD%2B5lk8Fl7VRLd8024%2FqU%2BpFjXkHYZ%2FZiKBwfeojBN31v4e61MJCsyPQFOusBTgDlXYsaS96Wr%2Baf0XqL6mvIt8HQJ2OlqOdJUbCP01KTTLCirRjey2cCsIaBHrBdP0N2InY9R0d6Z11tM8j9cdw8rXcs%2BGo58s4cxW%2B2tzLkbH84Yr1ujAlzomW0OLqR753sSpixMIACuFg4V%2FdkXzy7WfUM5sdYAbUEhQWWDNYvKvOZVoOGS5GhNx02O7ft0Kd6GVUiQV2ef159KiAKFL130JkFqQe1tLtZx%2FAryyu3kha6EXFZkVsLD0rfJxzHdsdy%2BwuAs5EI5ImZGNVD9te%2FVQquH9L1ONhDcniQqb0iqdsRZnmr8F8IFA%3D%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20200411T202256Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYRV7VN77N%2F20200411%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=6708b3b64bb120f5f9f81e874929f95b282318d7dbc9e4ea2fa1ee2e1ede5979&hash=7a31add5bbaab378a04cbd499ab42d7f86ddcf29b114a1577bf23f4b7fd8b402&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1201971220302034&tid=spdf-74bd40cf-2415-45c9-9fba-62b9ed24c6ae&sid=2f2bd7105a9e534f93485498cba7fa201c27gxrqa&type=client,English,Yes,Observational,1/20/20,2/18/20,29,Subgroup,Severe,Positive only,Active,Both,Both,Yes,ICU only,Severe/Critical Only,Ventilation only,67,67,,,,,100%,0%,0%,100%,0%,0%,,,,,,,,7,,,,,,,,,,,100%,,,,,,,100%,37.5,39,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,100%,,,,,,,,,,,,,,,,,,,1,1,,,,,0,
161,0,China,Shanghai,799,16.29%,Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study,BMJ,Chen et. al.,https://www.bmj.com/content/368/bmj.m1091,English,Yes,Observational,1/13/20,2/28/20,46,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,Both,NA,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.1,,,,0.14,0.58
161,1,China,Shanghai,274,60.11%,Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study,BMJ,Chen et. al.,https://www.bmj.com/content/368/bmj.m1091,English,Yes,Observational,1/13/20,2/28/20,46,Subgroup,End-point only,Positive only,End-point only,Both,Both,Yes,Both,Both,NA,62,44,70,,,7%,62%,0%,0%,100%,0%,0%,,2%,17%,,,,,,10,7,12,7%,,,,49%,34%,17%,8%,7%,3%,4%,,1%,,91%,,,32%,68%,44%,11%,30%,22%,50%,,28%,9%,24%,4%,,38%,,,,,,,5.9,4.3,9.2,0.8,0.6,1.2,,,179,133,235,4.4,2.8,8,12.8,116,140,,,23,30,9.6,6.7,13.5,4.9,76,109,53.4,,22,0.09,1.1,14.3,91%,86%,,,,,,,,79%,38%,,31%,92%,37%,6%,,1%,,,65%,72%,27%,72%,,24%,17%,5%,8%,44%,11%,,,12%,1,,,,,,0.41,
161,2,China,Shanghai,113,60.11%,Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study,BMJ,Chen et. al.,https://www.bmj.com/content/368/bmj.m1091,English,Yes,Observational,1/13/20,2/28/20,46,Subgroup,Non-survivors,Positive only,End-point only,Non-survivors only,Both,Yes,Both,Both,NA,68,62,77,,,1%,73%,0%,0%,100%,0%,0%,,4%,12%,,,,,,10,7,13,8%,,,,63%,48%,21%,14%,10%,4%,4%,,4%,,92%,,,59%,70%,62%,10%,31%,19%,57%,,24%,7%,27%,4%,,49%,,,,,,,10.2,6.2,13.6,0.6,0.4,0.7,,,156,111.8,219.3,9,5.4,12.7,12.8,114,145,,,28,45,12.6,9.4,16.7,8.4,88,189,113,,72,0.33,4.6,15.5,93%,79%,,,,,,,,88%,39%,,68%,100%,67%,15%,,3%,,,100%,100%,51%,100%,,49%,41%,9%,17%,77%,25%,,,14%,1,,,,,,1,
161,3,China,Shanghai,161,61.24%,Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study,BMJ,Chen et. al.,https://www.bmj.com/content/368/bmj.m1091,English,Yes,Observational,1/13/20,2/28/20,46,Subgroup,Survivors,Positive only,End-point only,Survivors only,Both,Yes,Both,Both,NA,51,37,66,,,11%,55%,0%,0%,100%,0%,0%,,1%,20%,,,,,,9,6,12,6%,,,,39%,24%,14%,4%,4%,1%,4%,,1%,,90%,,,14%,66%,31%,12%,30%,24%,45%,,31%,10%,22%,5%,,30%,,,,,,,5,3.7,6.3,1,0.7,1.4,,,198,160,256,3.2,2.4,4.5,12.8,118,138,,,20,25,8.4,5.8,11.2,4,66,84,26.2,,13,0.05,0.6,13.9,89%,91%,,,,,,,,73%,37%,,5%,86%,16%,0%,,0%,,,41%,52%,0%,52%,,3%,0%,2%,1%,17%,1%,,,9%,1,,1,,,,0,0
162,0,China,Zhuhai,95,30.34%,Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection,Gut,Lin et. al.,https://gut.bmj.com/content/early/2020/04/02/gutjnl-2020-321013,English,Yes,Observational,1/17/20,2/15/20,29,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,45.3,,,,,47.40%,0%,0%,100%,0%,0%,100%,80%,20%,,,,,,,,,6.30%,9.50%,,,,16.50%,6.30%,4.20%,5.30%,5.30%,,4.20%,1.10%,,,,,,,,,,,,,20%,15.20%,13.30%,,,,,0%,78.90%,21.10%,0%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,72.60%,93.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.21,0.39,,,,0,0
162,1,China,Zhuhai,58,29.78%,Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection,Gut,Lin et. al.,https://gut.bmj.com/content/early/2020/04/02/gutjnl-2020-321014,English,Yes,Observational,1/17/20,2/15/20,29,Subgroup,Patients wtih GI Symptoms,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,48,,,,,46.60%,0%,0%,100%,0%,0%,100%,77.60%,22.40%,,,,,,,,,8.60%,10.30%,,,,17.20%,5.20%,5.20%,1.70%,6.90%,,5.20%,1.70%,,,,,,,,,,,,,24.20%,17.90%,17.90%,,,,,0%,75.90%,24.10%,0%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,32.60%,,,,,,,1,0.24,0.4,,,,0,0
162,2,China,Zhuhai,37,27.53%,Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection,Gut,Lin et. al.,https://gut.bmj.com/content/early/2020/04/02/gutjnl-2020-321015,English,Yes,Observational,1/17/20,2/15/20,29,Subgroup,Patients without GI Symptoms,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,41.1,,,,,48.60%,0%,0%,100%,0%,0%,100%,83.80%,16.20%,,,,,,,,,2.70%,8.10%,,,,16.20%,8.10%,2.70%,10.80%,2.70%,,2.70%,0%,,,,,,,,,,,,,,,,,,,,0%,83.80%,16.20%,0%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.16,0.38,,,,0,0
169,0,China,Jiangsu,55,57.87%,"Clinical features and management of severe COVID-19: A retrospective study in Wuxi, Jiangsu Province, China",MedRxiv,Jiang et. al.,https://www.medrxiv.org/content/10.1101/2020.04.10.20060335v1.full.pdf,English,No,Observational,1/23/20,2/16/20,24,Top-level,All,Positive only,End-point only,Both,Both,Yes,Both,All,Both,45,45,,27,60,,49%,0%,0%,100%,0%,0%,100%,40%,78.20%,7,7,3.5,10,,,,,,,,,52.70%,30.90%,16.40%,3.60%,,3.60%,,1.80%,1.80%,,85.50%,,,,61.80%,20%,18.20%,49.10%,,40%,,32.70%,7.30%,5.50%,,,,,,,,,,5.2,4.25,6.05,1.36,0.95,1.91,,,191,154,212,3.01,2.32,3.71,138,125,148,,,21,24,7,4,10,3.9,55,,6.2,,,,0.31,,52.70%,100%,100%,,,,,40%,7.30%,10.90%,9.10%,47.30%,5.50%,,,12.70%,1.80%,,100%,36.40%,,,18.20%,7.30%,,,1.80%,29.10%,,1.80%,5.50%,7.30%,,,1,0.15,1,,16,,0,0
169,1,China,Jiangsu,47,57.87%,"Clinical features and management of severe COVID-19: A retrospective study in Wuxi, Jiangsu Province, China",MedRxiv,Jiang et. al.,https://www.medrxiv.org/content/10.1101/2020.04.10.20060335v1.full.pdf,English,No,Observational,1/23/20,2/16/20,24,Subgroup,Non-severe,Positive only,End-point only,Both,Both,Yes,Both,All,Both,40,40,,26,57,,46.80%,0%,0%,100%,0%,0%,100%,38.30%,78.70%,7,7,3.75,9.75,,,,,,,,,48.90%,29.80%,10.60%,2.10%,,4.30%,,0%,0%,,83%,,,,55.30%,6.40%,17%,42.60%,,36.20%,,29.80%,8.50%,4.30%,,,,,,,,,,5.15,4.42,6.05,1.4,1.02,2.05,,,191,155,212,3.01,2.34,3.51,140,126,150,,,22,24,7,4,10,3.9,53,,4.5,,,,0.28,,44.70%,100%,100%,,,,,40.40%,2.10%,0%,2.10%,38.30%,0%,,,0%,0%,,100%,25.50%,,,4.30%,4.30%,,,0%,25.50%,,0%,2.10%,4.30%,,,1,0,1,,16,,0,0
169,2,China,Jiangsu,8,57.87%,"Clinical features and management of severe COVID-19: A retrospective study in Wuxi, Jiangsu Province, China",MedRxiv,Jiang et. al.,https://www.medrxiv.org/content/10.1101/2020.04.10.20060335v1.full.pdf,English,No,Observational,1/23/20,2/16/20,24,Subgroup,Severe,Positive only,End-point only,Both,Both,Yes,Both,All,Both,59,59,,50,73,,62.50%,0%,0%,100%,0%,0%,100%,50%,75.00%,4,4,3,5,,,,,,,,,75%,37.50%,50%,12.50%,,0%,,12.50%,12.50%,,100.00%,,,,100.00%,100%,25.00%,87.50%,,62.50%,,50%,0%,12.50%,,,,,,,,,,5.35,3.04,10.8,0.83,0.39,1.24,,,160,142,223,3.39,1.82,9.52,136,104,140,,,19,29,7,3,11,6.5,66,,70.27,,,,0.6,,100%,100%,100%,,,,,37.50%,37.50%,75%,50%,100%,37.50%,,,87.50%,12.50%,,100%,100%,,,100%,25%,,,12.50%,50%,,12.50%,25%,25%,,,1,1,1,,23,,0,0
170,0,Iceland,Nationwide,1321,19.66%,Spread of SARS-CoV-2 in the Icelandic Population,NEJM,Gudbjartsson et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2006100?articleTools=true,English,Yes,Observational,1/31/20,4/4/20,64,Top-level,,Positive only,End-point and active,Both,Both,No,Both,All,Both,41.77,41.77,,,,,50.17%,100%,0%,0%,0%,0%,,,53.48%,,,,,,,,,,,,,,,,,,,,,,,45.49%,,,,30.65%,,23.37%,,29.71%,,,,,,13.84%,,,,9.58%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.01,
170,1,Iceland,Nationwide,177,23.60%,Spread of SARS-CoV-2 in the Icelandic Population,NEJM,Gudbjartsson et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2006100?articleTools=true,English,Yes,Observational,1/31/20,3/15/20,44,Subgroup,Targeted testing,Positive only,End-point and active,Both,Both,No,Both,All,Both,44.4,44.4,,,,,52%,100%,0%,0%,0%,0%,,,40.10%,,,,,,,,,,,,,,,,,,,,,,,42.10%,,,,25.50%,,23.30%,,28.80%,13.30%,,,,,16.60%,,,2.20%,13.60%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.02,0.01,0,,,,0.01,0.02
170,2,Iceland,Nationwide,87,20.22%,Spread of SARS-CoV-2 in the Icelandic Population,NEJM,Gudbjartsson et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2006100?articleTools=true,English,Yes,Observational,3/13/20,4/1/20,19,Subgroup,Population screening,Positive only,End-point and active,Both,Both,No,Both,All,Both,40.8,40.8,,,,,52.90%,100%,0%,0%,0%,0%,,,6.90%,,,,,,,,,,,,,,,,,,,,,,,19.50%,,,,36.80%,,20.70%,,21.80%,,,,,,29.90%,,,,41.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,
170,3,Iceland,Nationwide,1044,21.35%,Spread of SARS-CoV-2 in the Icelandic Population,NEJM,Gudbjartsson et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2006100?articleTools=true,English,Yes,Observational,3/16/20,3/31/20,15,Subgroup,Targeted testing,Positive only,End-point and active,Both,Both,No,Both,All,Both,41.3,41.3,,,,,49.40%,100%,0%,0%,0%,0%,,,60.20%,,,,,,,,,,,,,,,,,,,,,,,48.80%,,,,31.10%,,23.70%,,30.80%,20.60%,,,,,12.20%,,,11.50%,5.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.01,
170,4,Iceland,Nationwide,13,20.79%,Spread of SARS-CoV-2 in the Icelandic Population,NEJM,Gudbjartsson et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2006100?articleTools=true,English,Yes,Observational,4/1/20,4/4/20,3,Subgroup,Population screening,Positive only,End-point and active,Both,Both,No,Both,All,Both,50.5,50.5,,,,,69.20%,100%,0%,0%,0%,0%,,,7.70%,,,,,,,,,,,,,,,,,,,,,,,0%,,,,23.10%,,15.40%,,7.70%,,,,,,0%,,,7.70%,53.80%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,
171,0,USA,Boston,147,20.22%,COVID-19 outbreak at a large homeless shelter in Boston: Implications for universal testing,JAMA,Bagget et. al.,https://jamanetwork.com/journals/jama/fullarticle/2765378,English,Yes,Observational,3/15/20,4/15/20,31,Top-level,Positive cases,Positive only,Active only,Both,Non-discharged only,No,Both,All,Both,53.1,53.1,12.8,40.3,65.9,,84.40%,47.20%,31.90%,2.80%,16.10%,2.00%,,,,,,,,,,,,,,,,,,,,,,,,,,1%,36.8,,,7.50%,1.40%,,,,,,1.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
171,1,USA,Boston,261,20.22%,COVID-19 outbreak at a large homeless shelter in Boston: Implications for universal testing,JAMA,Bagget et. al.,https://jamanetwork.com/journals/jama/fullarticle/2765378,English,Yes,Observational,3/15/20,4/15/20,31,Subgroup,Negative cases,Negative only,Active only,Both,Non-discharged only,No,Both,All,Both,50.8,50.8,12.7,38.1,63.5,,64.40%,46%,33.70%,1.60%,19%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,1.20%,36.9,,,8.40%,0.40%,,,,,,1.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
172,0,China,Changsha,159,31.46%,The clinical characteristics and mortal causes analysis of COVID-19 death patients,MedRxiv,Guo et. al.,https://www.medrxiv.org/content/10.1101/2020.04.12.20062380v1,English,No,Observational,12/28/19,3/4/20,68,Top-level,Positive cases,Positive only,End-point only,,Non-discharged only,Yes,Both,All,Both,71,,,64,80,,62.26%,0%,0%,0%,0%,0%,,42.86%,,,,,,,,,,,,,,99.14%,56.90%,32.76%,56.90%,,5.17%,8.62%,14.66%,,,71.19%,,,,55.08%,7.63%,2.54%,,3.39%,14.41%,,5.93%,1.69%,,,2.54%,10.17%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,47.37%,,,,,6.11%,53.72%,47.93%,5.79%,,,10.74%,3.31%,2.48%,11.57%,,,,,,,,,,,1,
173,0,China,Shandong,24,13.48%,Epidemiological investigation and intergenerational clinical characteristics of 24 COVID-19 patients associated with supermarket cluster,MedRxiv,Tian et. al.,https://www.medrxiv.org/content/10.1101/2020.04.11.20058891v1.full.pdf,English,No,Observational,,,24,Subgroup,Positive cases,Positive only,End-point and active,Both,,Yes,Both,All,Both,,48,,,,,37.50%,0%,0%,0%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
175,0,China,Wuhan,504,28.09%,The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world data from three hospitals in Wuhan,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.04.11.20056523v1.full.pdf,English,No,Observational,12/13/19,3/21/20,99,Top-level,Top level,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,59.5,59.5,14.9,44.6,74.4,,51.40%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,52%,,,24.20%,4%,,,,2.60%,14.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,51.40%,0.81%,13.10%,,,51%,1.40%,45.60%,30.20%,,,84.70%,,10.90%,,,,,,,,,,,,,,,,,,,1,,0.84,,14,,0.16,0.16
175,1,China,Wuhan,373,21.35%,The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world data from three hospitals in Wuhan,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.04.11.20056523v1.full.pdf,English,No,Observational,12/13/19,3/21/20,99,Subgroup,WPH,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,65.70%,1.10%,12.30%,,,37.80%,1.90%,40.50%,31.40%,,,85.30%,,11.50%,,,,,,,,,,,,,,,,,,,1,,0.82,,,,0.18,0.18
175,2,China,Wuhan,100,21.35%,The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world data from three hospitals in Wuhan,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.04.11.20056523v1.full.pdf,English,No,Observational,12/13/19,3/21/20,99,Subgroup,Tongji,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4%,0%,19%,,,94%,0%,73%,25%,,,86%,,12%,,,,,,,,,,,,,,,,,,,1,,0.88,,,,0.12,0.12
175,3,China,Wuhan,31,21.35%,The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world data from three hospitals in Wuhan,MedRxiv,Liu et. al.,https://www.medrxiv.org/content/10.1101/2020.04.11.20056523v1.full.pdf,English,No,Observational,12/13/19,3/21/20,99,Subgroup,Union,Positive only,End-point only,Both,Discharged only,Yes,Both,All,Both,,,,,,,,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,32.30%,0%,3.20%,,,71%,0%,19.40%,32.30%,,,74.20%,,0%,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
176,0,USA,New York City,393,35.39%,Clinical Characteristics of Covid-19 in New York City,NEJM,Goyal et al.,https://www.nejm.org/doi/full/10.1056/NEJMc2010419,English,Yes,Observational,3/3/20,3/27/20,24,Top-level,Top level,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,62.6,,,48.6,73.7,6.10%,60.60%,37.40%,12.50%,17%,,45.80%,,,,,,,,5,5,3,8,5.10%,,,35.80%,,50.10%,25.20%,13.70%,5.10%,5.90%,,,,,25.50%,,,9.90%,79.40%,56.50%,,,27.20%,,,23.70%,,,,,,,0%,0%,66.92%,33.07%,1,,,,,,,,,,,,,,,136,,,,,,,,,,,,,,,,,,,,,,,,4.30%,,,63.60%,11.70%,,,,,,33.07%,,4.80%,,,,,,,,1.80%,,,,,,4.80%,,,1,,0.66,,,,0.1,0.13
176,1,USA,New York City,130,35.39%,Clinical Characteristics of Covid-19 in New York City,NEJM,Goyal et al.,https://www.nejm.org/doi/full/10.1056/NEJMc2010419,English,Yes,Observational,3/3/20,3/27/20,24,Subgroup,Invasive Mechanical Ventilation,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/critical only,Ventilation only,64.5,,,51.7,73.6,6.20%,70.80%,35.40%,11.50%,19.20%,,33.90%,,,,,,,,6,6,3,8,4.60%,,,43.40%,,53.80%,27.70%,19.20%,5.40%,7.70%,,,,,34.60%,,,21.50%,83.10%,66.20%,,,23.80%,,,20.80%,,,,,,,0%,0%,0%,100%,1,,,,,,,,,,,,,,,137,,,,,,,,,,,,,,,,,,,,,,,,4.60%,,,97.70%,24.60%,,,,,,100%,,13.30%,,,,,,,,2.30%,,,,,,11.90%,,,1,,0.18,,,,0.15,0.45
176,2,USA,New York City,263,35.39%,Clinical Characteristics of Covid-19 in New York City,NEJM,Goyal et al.,https://www.nejm.org/doi/full/10.1056/NEJMc2010419,English,Yes,Observational,3/3/20,3/27/20,24,Subgroup,No invasive mechanical ventilation,Positive only,End-point and active,Both,Both,Yes,Both,All,Non-ventilation only,61.5,,,47,75,6.10%,55.50%,38.40%,12.90%,16%,,33%,,,,,,,,5,5,2,7,5.30%,,,31.90%,,48.30%,24%,11%,4.90%,4.90%,,,,,21%,,,4.20%,77.60%,51.70%,,,28.90%,,,25.10%,,,,,,,0%,0%,100%,0%,1,,,,,,,,,,,,,,,135,,,,,,,,,,,,,,,,,,,,,,,,4.20%,,,46.80%,5.30%,,,,,,0%,,0.40%,,,,,,,,1.50%,,,,,,1.80%,,,1,,0.9,,,,0.08,0.08
177,0,China,Nationwide,731,25.28%,Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China,Pediatrics,Dong et. al.,https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf,English,Yes,Observational,12/1/19,2/8/20,69,Top-level,Top level,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,10,,,5,15,,56.60%,0%,0%,100%,0%,0%,100%,45.90%,54.10%,,,,,2,2,0,4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12.90%,84.20%,2.50%,0.40%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.97,,,,0,0
181,0,USA,South Carolina,368,23.60%,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,MedRxiv,Magagnoli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf,English,No,Observational,3/1/20,4/11/20,41,Top-level,Top level-US veterans,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,68.96,,59.26,74.69,,,,28.52%,64.13%,,,7.35%,,,,,,,,,,,,14.14%,,29.93,,,,67.67%,17.97%,19.58%,16.04%,9.27%,12.79%,,,42.31%,36.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,57.07%,,,,,,,11.68%,,,,,,,,,,,,,,,,,,,1,,0.81,,,,0.19,0.19
181,1,USA,South Carolina,97,23.60%,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,MedRxiv,Magagnoli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf,English,No,Observational,3/1/20,4/11/20,41,Subgroup,Hydroxychloroquine group,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,70,,60,75,,,,23.70%,68.00%,,,8.30%,,,,,,,,,,,,18.60%,,30.5,,,,79.40%,25.80%,22.70%,18%,8.20%,20.70%,,,43.00%,36.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,13.30%,,,,,,,,,,,,,,,,,,,1,,0.72,,,,0.28,0.28
181,2,USA,South Carolina,113,23.60%,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,MedRxiv,Magagnoli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf,English,No,Observational,3/1/20,4/11/20,41,Subgroup,Hydroxychloroquine and azithromyncin group,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,68,,59,74,,,,34.50%,59.30%,,,6.20%,,,,,,,,,,,,11.50%,,29.9,,,,54.90%,13.30%,17.70%,13%,10.70%,7.10%,,,46.90%,36.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100%,,,,,,,6.90%,,,,,,,,,,,,,,,,,,,1,,0.78,,,,0.22,0.22
181,3,USA,South Carolina,158,23.60%,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,MedRxiv,Magagnoli et. al.,https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf,English,No,Observational,3/1/20,4/11/20,41,Subgroup,No hydroxy group,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,69,,59,75,,,,27.20%,65.20%,,,7.60%,,,,,,,,,,,,13.30%,,29.6,,,,69.60%,16.50%,19.00%,17%,8.90%,12%,,,38.60%,36.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,,,,14.10%,,,,,,,,,,,,,,,,,,,1,,0.89,,,,0.11,0.11
182,0,USA,New York,5700,33.15%,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",JAMA,Richardson et. al.,https://jamanetwork.com/journals/jama/fullarticle/2765184,English,Yes,Observational,1/31/20,4/20/20,80,Top-level,Top level,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,63,,,52,75,,60.30%,39.80%,22.60%,8.70%,23%,5.90%,,,,,,,,,,,,15.60%,,,41.70%,,56.60%,33.80%,18.00%,5.40%,6%,0.60%,,5%,,,37.5,,17.30%,,,,,,,,,,,,,,,,,,,,7,5.2,9.5,0.88,0.6,1.2,,,,,,5.3,3.7,7.7,,,,,,33,46,,,,,,171,130,,,0.2,0.44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.37,,,,0.1,0.21
182,1,USA,New York,2634,17.42%,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",JAMA,Richardson et. al.,https://jamanetwork.com/journals/jama/fullarticle/2765184,English,Yes,Observational,1/31/20,4/20/20,80,Subgroup,Total discharged dead and alive patients,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,,,,,,,,,,,,,,,,,,,,,,,,,,,,,51.86%,28.74%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12.20%,,3.20%,,,,,,,,,,,,,22.20%,,,,1,0.14,0.79,,4.1,,0.21,0.21
183,0,UK,Nationwide,202,26.40%,Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection,JAMA,Spinto et. al.,https://jamanetwork.com/journals/jama/fullarticle/2765183,English,Yes,Observational,1/31/20,3/22/20,51,Top-level,Top level,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,56,,,45,67,,48%,,,,,,,,,,,,,,,,,31.20%,60.40%,,,55.90%,,,,,,,,,,55.90%,,,,60.40%,41.10%,42.60%,,44.60%,68.30%,,43.60%,26.10%,54.50%,36.10%,,,64.40%,0%,100%,0%,0%,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
184,0,USA,Washington,48,23.60%,"Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington",JAMA,Chow et. al.,https://jamanetwork.com/journals/jama/fullarticle/2764953,English,Yes,Observational,2/28/20,3/13/20,14,Top-level,Top level,Positive only,End-point and active,Both,Both,No,Both,All,Both,43,,,,,100%,77.10%,,,,,,,,,,,,,,,,,,,,,47.90%,,,,,,,,,,41.70%,,,,50%,10.40%,16.70%,,35.40%,,,6.30%,2.10%,2.10%,14.60%,14.60%,,,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.06,0,,,,,0,0
184,1,USA,Washington,40,21.91%,"Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington",JAMA,Chow et. al.,https://jamanetwork.com/journals/jama/fullarticle/2764953,English,Yes,Observational,2/28/20,3/13/20,14,Subgroup,With fever/cough/shortness of breath,Positive only,End-point and active,Both,Both,No,Both,All,Both,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50%,,,,60%,13%,17.50%,,37.50%,,,7.50%,2.50%,2.50%,17.50%,12.50%,,,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.08,0,,,,,0,0
184,2,USA,Washington,8,22.47%,"Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington",JAMA,Chow et. al.,https://jamanetwork.com/journals/jama/fullarticle/2764953,English,Yes,Observational,2/28/20,3/13/20,14,Subgroup,Without fever/cough/shortness of breath,Positive only,End-point and active,Both,Both,No,Both,All,Both,,,,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0%,,,,0%,0%,12.50%,,25%,,,0%,0%,0%,0%,25%,,,0%,100%,0%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,0,,,,0,0
185,0,China,Wuhan,171,32.58%,SARS-CoV-2 Infection in Children,NEJM,Lu et. al.,https://www.nejm.org/doi/full/10.1056/NEJMc2005073,English,Yes,Observational,1/28/20,2/26/20,29,Top-level,Top level,Positive only,End-point and active,Both,Both,No,Both,All,Both,6.7,,,2,9.8,,60.80%,0%,0%,100%,0%,0%,100%,,90.10%,,,,,,,,,,,,,,,,,,,,,,,41.50%,,,,48.50%,,,,,8.80%,,8.80%,6.40%,,7.60%,,,,15.79%,28.21%,63.16%,1.75%,1,6.8,,,2.9,,,,,,,,2.5,,,126,,,,,15,30,,,,4.1,33.9,,4,,,50,0.2,10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.86,,,,0.01,0.01
185,0,China,Wuhan,27,28.09%,SARS-CoV-2 Infection in Children,NEJM,Lu et. al.,https://www.nejm.org/doi/full/10.1056/NEJMc2005073,English,Yes,Observational,1/28/20,2/26/20,29,Subgroup,Asymptomatic,Positive only,End-point and active,Both,Both,No,Both,Asymptomatic only,Non-ventilation only,9.6,,,7.6,12.6,,,0%,0%,100%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,1,7,,,2.8,,,,,,,,3.4,,,132,,,,,13,25,,,,4.7,42.6,,2,,,40,0.2,10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
185,0,China,Wuhan,33,28.09%,SARS-CoV-2 Infection in Children,NEJM,Lu et. al.,https://www.nejm.org/doi/full/10.1056/NEJMc2005073,English,Yes,Observational,1/28/20,2/26/20,29,Subgroup,UPPER RESPIRATORY TRACT INFECTION,Positive only,End-point and active,Both,Both,No,Both,Mild only,Non-ventilation only,3.9,,,1.4,8.4,,,0%,0%,100%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,100.00%,0.00%,0.00%,1,6.9,,,3.1,,,,,,,,2.5,,,128,,,,,13,30,,,,4.1,29,,4,,,50,0.2,10.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
185,0,China,Wuhan,111,28.09%,SARS-CoV-2 Infection in Children,NEJM,Lu et. al.,https://www.nejm.org/doi/full/10.1056/NEJMc2005073,English,Yes,Observational,1/28/20,2/26/20,29,Subgroup,Pneumonia,Positive only,End-point and active,Both,Both,No,Both,Severe/critical only,Both,5.9,,,1.2,9.3,,,0%,0%,100%,0%,0%,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,0.00%,97.30%,2.70%,1,6.6,,,2.9,,,,,,,,2.3,,,125,,,,,16,32,,,,4.1,31.7,,4,,,60,0.4,11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.8,,,,0.01,0.01
186,0,China,Guangzhou,86,28.09%,Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial,Cell Press,Li et. al.,https://marlin-prod.literatumonline.com/pb-assets/products/coronavirus/MEDJ1.pdf,English,Yes,Observational,2/1/20,4/17/20,77,Top-level,All,Positive only,End-point and active,Survivors,Both,Yes,Both,Both,Both,49.4,49.4,14.7,34.7,64.1,,46.50%,,,100%,,,,,,,,,,,,,,,,,,,,,,,,,,,,67.40%,,,,64.00%,0%,0%,,,,,14%,2.30%,5.80%,,,,,,84.90%,12.80%,2.30%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,80.23%,39.53%,0.00%,0.00%,0.00%,0.00%,40.70%,0.00%,14.00%,,,,62.80%,2.30%,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
186,1,China,Guangzhou,34,28.09%,Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial,Cell Press,Li et. al.,https://marlin-prod.literatumonline.com/pb-assets/products/coronavirus/MEDJ1.pdf,English,Yes,Observational,2/1/20,4/17/20,77,Subgroup,Randomly assigned to receive LPV/r,Positive only,End-point and active,Survivors,Both,Yes,Both,Both,,50.7,50.7,15.4,35.3,66.1,,50.00%,,,100%,,,,,,,,,,,3.5,2,6,,,,,20.60%,,,,,,,,,,79.40%,,,,61.80%,0%,0%,,,,,27%,0%,14.70%,,,,,,76.40%,17.60%,6%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,100.00%,0.00%,0.00%,0.00%,0.00%,0.00%,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
186,2,China,Guangzhou,35,28.09%,Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial,Cell Press,Li et. al.,https://marlin-prod.literatumonline.com/pb-assets/products/coronavirus/MEDJ1.pdf,English,Yes,Observational,2/1/20,4/17/20,77,Subgroup,Arbidol,Positive only,End-point and active,Survivors,Both,Yes,Both,Both,,50.5,50.5,14.6,35.9,65.1,,45.70%,,,100%,,,,,,,,,,,6,2,8,,,,,14.30%,,,,,,,,,,62.90%,,,,71.40%,0%,0%,,,,,8.60%,5.90%,0%,,,,,,91.40%,8.60%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.00%,0.00%,0.00%,0.00%,0.00%,0.00%,100.00%,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
186,3,China,Guangzhou,17,26.40%,Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial,Cell Press,Li et. al.,https://marlin-prod.literatumonline.com/pb-assets/products/coronavirus/MEDJ1.pdf,English,Yes,Observational,2/1/20,4/17/20,77,Subgroup,No antiviral medication,Positive only,End-point and active,Survivors,Both,Yes,Both,Both,,44.3,44.3,,,,,41.20%,,,100%,,,,,,,,,,,5,2,8,,,,,35.30%,,,,,,,,,,52.90%,,,,52.90%,0%,0%,,,,,0%,0%,0%,,,,,,88.20%,11.80%,0%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,0.00%,0.00%,0.00%,0.00%,0.00%,0.00%,0.00%,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,0,
186,4,China,Guangzhou,13,28.65%,Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial,Cell Press,Li et. al.,https://marlin-prod.literatumonline.com/pb-assets/products/coronavirus/MEDJ1.pdf,English,Yes,Observational,2/1/20,4/17/20,77,Subgroup,Severe/Critical,Positive only,End-point and active,Survivors,Both,Yes,Both,Severe/critical only,Both,60.1,60.1,13.8,46.3,73.9,,61.50%,,,100%,,,,,,,,,,,,,,,,,,,38.50%,15.40%,,,,7.70%,,,,100%,,,,69.20%,0%,0%,,,,,,,,,,,,,0%,84.60%,15.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,84.60%,61.50%,0.00%,0.00%,0.00%,0.00%,23.10%,0.00%,,,,,,15.40%,,,,,,,,,,,,,,,,,,,,1,1,0.92,,,,0,0
188,0,USA,Washington,57,26.97%,Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility,NEJM,Arons et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2008457?articleTools=true,English,Yes,Observational,3/13/20,4/3/20,21,Subgroup,All positive tests,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,78.6,78.6,9.5,,,,,,,,,,,,,,4,3,5,,,,,,,,22.90%,97.90%,,37.50%,81.30%,37.50%,,,39.60%,37.50%,,10.40%,,,,58.30%,10.40%,4.20%,,2.10%,,,4.20%,10.40%,,14.60%,0.00%,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.19,0.05,,,,,0.26,0.26
188,1,USA,Washington,28,21.91%,Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility,NEJM,Arons et. al.,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2008457?articleTools=true,English,Yes,Observational,3/13/20,4/3/20,21,Subgroup,Negative and participated in data collection,Negative only,Active only,,,,,,,73.8,73.8,11.5,,,,,,,,,,,,,,,,,,,,,,,,21.40%,100.00%,,39.30%,60.70%,28.60%,,,28.60%,32.10%,,50.00%,,,,35.70%,10.70%,7.10%,,3.60%,,,7.10%,7.10%,,17.90%,0.00%,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,0,,,,,0,
190,0,USA,Houston,754,16.29%,Racial and Ethnic Disparities in SARS-CoV-2 Pandemic: Analysis of a COVID-19 Observational Registry for a Diverse U.S. Metropolitan Population,MedRxiv,Vahidy et. al.,https://www.medrxiv.org/content/10.1101/2020.04.24.20073148v1.full.pdf,English,No,Observational,1/28/20,3/5/20,37,Top-level,Tested positive,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,53.2,53.2,17.8,,,,43.10%,51.70%,32.60%,10.30%,21.80%,5.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
190,1,USA,Houston,3759,12.92%,Racial and Ethnic Disparities in SARS-CoV-2 Pandemic: Analysis of a COVID-19 Observational Registry for a Diverse U.S. Metropolitan Population,MedRxiv,Vahidy et. al.,https://www.medrxiv.org/content/10.1101/2020.04.24.20073148v1.full.pdf,English,No,Observational,1/28/20,3/5/20,37,Subgroup,Tested negative,Negative only,Active only,,,,,,,50.1,50.1,19.1,,,,36.80%,58.80%,24.30%,9.20%,18.10%,7.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
191,0,China,Nationwide,21,53.37%,Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: A multicenter cohort study,MedRxiv,Qi et. al.,https://www.medrxiv.org/content/10.1101/2020.04.24.20072611v1.full.pdf,English,No,Observational,12/31/19,3/24/20,84,Top-level,All patients with cirrhosis,Positive only,End-point only,Both,Both,Yes,Both,All,Both,68,68,,52,75,,52%,0%,0%,100%,0%,0%,0.952,,,,,,,,8,3,14,,,,,1,33.30%,19.00%,19.00%,,14.30%,0.095,,9.50%,,76.20%,,,,71.40%,57.10%,,33.30%,,,,9.50%,,,14.30%,,,,0.00%,,,,1,4.3,2.8,5.5,0.8,0.5,1.2,,,120,70,182,3,1.7,4.3,,,,,34.2,30,38,15,11,23,6,66,87,18.3,23,,0.1,,12.8,71.40%,81.00%,33.30%,,,,,,,38.10%,23.80%,,,95.20%,19.00%,14.30%,9.50%,9.50%,,,,,,28.60%,,,14.30%,4.80%,,,4.80%,28.60%,,,1,0.24,0.76,,16,,0.24,0.24
191,1,China,Nationwide,5,54.49%,Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: A multicenter cohort study,MedRxiv,Qi et. al.,https://www.medrxiv.org/content/10.1101/2020.04.24.20072611v1.full.pdf,English,No,Observational,12/31/19,3/24/20,84,Subgroup,Non-survivor,Positive only,End-point only,Non-Survivors only,Both,Yes,Both,Severe/Critical Only,Both,68,68,,50,75,,80%,0%,0%,100%,0%,0%,1,,,,,,,,3,3,20,,,,,1,40.00%,49.00%,40.00%,,20.00%,0.2,,0.00%,,100.00%,,,,80.00%,60.00%,,40.00%,,,,20.00%,,,0.00%,,,,0.00%,0.00%,0.00%,100.00%,1,4.6,1.9,9.1,0.4,0.2,1.1,,,77,44,93,4,1.5,7.5,,,,,29,30,42,22.2,16.6,34.6,5.5,66.2,63,50,61,,0.1,,14,100.00%,80.00%,,,,,,,,100.00%,60.00%,,,100.00%,60.00%,60.00%,40.00%,40.00%,,,,,,100.00%,,,40.00%,20.00%,,,20.00%,60.00%,,,1,0.8,0,,16,,1,1
191,2,China,Nationwide,16,52.81%,Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: A multicenter cohort study,MedRxiv,Qi et. al.,https://www.medrxiv.org/content/10.1101/2020.04.24.20072611v1.full.pdf,English,No,Observational,12/31/19,3/24/20,84,Subgroup,Survivor,Positive only,End-point only,Survivors only,Both,Yes,Both,All,Both,69,69,,52,75,,44%,0%,0%,100%,0%,0%,0.938,,,,,,,,8,4,15,,,,,1,31.30%,12.50%,12.50%,,12.50%,0.062,,12.50%,,68.80%,,,,68.80%,56.30%,,31.30%,,,,6.30%,,,18.80%,,,,0.00%,,,,1,4.3,3.1,5.2,0.9,0.7,1.3,,,126,83,201,3,1.6,4.2,,,,,37.5,28,31,12.6,8.9,20,5.3,60.1,91,7.2,22,,0,,12.6,62.50%,81.30%,,,,,,,,18.80%,12.50%,,,93.80%,6.30%,0.00%,0.00%,0.00%,,,,,,6.30%,,,6.30%,0.00%,,,6.30%,18.80%,,,1,0.06,1,,16,,0,0
192,0,USA,New York,3055,27.53%,Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive New York City Patients,MedRxiv,Vaid et. al.,https://www.medrxiv.org/content/10.1101/2020.04.26.20073411v1.full.pdf,English,No,Observational,3/9/20,4/11/20,33,Top-level,Across hospitals,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,65.7,64.5,16.5,54.4,76.5,,58.10%,,,,,,,,,,,,,,,,,0.436,,,,,38.00%,25.00%,16.00%,,7.00%,,,10.00%,,,37.1,,,,,,,,,,,,,,,,,,,,,,8.39,5.4,10.3,,,,,,221,155,268,,,,12.7,11.3,13.9,,2.97,,,,,,,,1.73,94.8,,,1.71,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,0.17,,,,,0.06,
193,0,China,Shenzhen,420,41.01%,"Characterization of clinical progression of COVID-19 patients in Shenzhen, China",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.04.22.20076190v1.full.pdf,English,No,Observational,1/11/20,4/7/20,87,Top-level,Full sample,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,45.9,45.9,,,,,47.60%,0.00%,0.00%,100.00%,0.00%,0.00%,,,15.00%,,,,,4.2,4.2,3.8,4.6,,,,,21.90%,11.70%,5.70%,2.60%,3.10%,,3.10%,0.50%,0.20%,3.40%,74.80%,,,,73.10%,15.70%,10.70%,46.70%,13.10%,28.60%,,17.60%,11.00%,,14.00%,3.30%,16.00%,,0.00%,77.90%,17.60%,4.50%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.30%,,,,,2.60%,,,9.30%,,,,66.90%,1.40%,1.00%,2.60%,5.00%,,,1,0.05,,34,24,,0.01,0.02
193,1,China,Shenzhen,23,38.20%,"Characterization of clinical progression of COVID-19 patients in Shenzhen, China",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.04.22.20076190v1.full.pdf,English,No,Observational,1/11/20,4/7/20,87,Subgroup,Full sample,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,25.3,25.3,,,,,30.40%,0.00%,0.00%,100.00%,0.00%,0.00%,,,30.40%,,,,,,,,,,,,,,4.30%,0.00%,0.00%,0.00%,,0.00%,0.00%,0.00%,0.00%,47.80%,,,,56.50%,0.00%,4.30%,13.00%,8.70%,8.70%,,8.70%,4.30%,,13.00%,0.00%,4.30%,,0.00%,100.00%,0.00%,0.00%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,0.00%,,,0.00%,,,,47.80%,0.00%,0.00%,0.00%,0.00%,,,1,0,,0,21,,0,0
193,2,China,Shenzhen,304,38.20%,"Characterization of clinical progression of COVID-19 patients in Shenzhen, China",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.04.22.20076190v1.full.pdf,English,No,Observational,1/11/20,4/7/20,87,Subgroup,Full sample,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Mild only,Non-ventilation only,43.4,43.4,,,,,44.10%,0.00%,0.00%,100.00%,0.00%,0.00%,,,16.40%,,,,,,,,,,,,,,7.60%,3.60%,1.30%,2.60%,,3.30%,0.00%,1.40%,3.60%,71.10%,,,,70.40%,6.20%,10.50%,43.80%,8.90%,23.40%,,17.40%,10.90%,,12.80%,3.00%,11.50%,,0.00%,100.00%,0.00%,0.00%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,0.30%,,,0.00%,,,,61.50%,0.00%,0.00%,0.70%,1.60%,,,1,0,,0,21,,0,0
193,3,China,Shenzhen,74,38.20%,"Characterization of clinical progression of COVID-19 patients in Shenzhen, China",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.04.22.20076190v1.full.pdf,English,No,Observational,1/11/20,4/7/20,87,Subgroup,Full sample,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,Severe/Critical Only,Non-ventilation only,58.3,58.3,,,,,60.80%,0.00%,0.00%,100.00%,0.00%,0.00%,,,8.10%,,,,,,,,,,,,,,24.30%,12.20%,9.50%,2.70%,,4.10%,1.40%,0.00%,4.10%,94.60%,,,,87.80%,40.50%,14.90%,68.90%,28.40%,48.60%,,23.00%,13.50%,,17.60%,5.40%,35.10%,,0.00%,0.00%,100.00%,0.00%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.00%,,,,,2.70%,,,27.00%,,,,86.50%,2.70%,0.00%,1.40%,6.80%,,,1,0,,0,30,,0,0
193,4,China,Shenzhen,19,38.20%,"Characterization of clinical progression of COVID-19 patients in Shenzhen, China",MedRxiv,Bi et. al.,https://www.medrxiv.org/content/10.1101/2020.04.22.20076190v1.full.pdf,English,No,Observational,1/11/20,4/7/20,87,Subgroup,Full sample,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,62.4,62.4,,,,,73.70%,0.00%,0.00%,100.00%,0.00%,0.00%,,,0.00%,,,,,,,,,,,,,,36.80%,21.10%,0.00%,15.80%,,0.00%,5.30%,0.20%,5.30%,89.50%,,,,78.90%,89.50%,5.30%,47.40%,26.30%,57.90%,,10.50%,10.50%,,21.10%,5.30%,26.30%,,0.00%,0.00%,0.00%,100.00%,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,94.70%,,,,,42.10%,,,100.00%,,,,100.00%,21.10%,21.10%,42.10%,57.90%,,,1,1,,34,52,,0.21,0.42
195,0,USA,Georgia,217,28.65%,ICU and ventilator mortality among critically ill adults with COVID-19,MedRxiv,Auld et. al.,https://www.medrxiv.org/content/10.1101/2020.04.23.20076737v1,English,No,Observational,3/6/20,4/17/20,42,Top-level,All ICU admissions,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,64,,,54,73,,54.80%,18.00%,70.50%,3.20%,0.00%,8.30%,,,,,,,,,,,,,,30,9.70%,,61.70%,45.60%,14.30%,9.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,190,,,,1731,,,,,,,22.60%,,,52.50%,,,,,,,76.00%,1.80%,29.00%,,,,76.00%,,,,,65.90%,,,,,,,,1,1,0.4,8,13,,0.26,0.39
195,1,USA,Georgia,129,28.65%,ICU and ventilator mortality among critically ill adults with COVID-19,MedRxiv,Auld et. al.,https://www.medrxiv.org/content/10.1101/2020.04.23.20076737v1,English,No,Observational,3/6/20,4/17/20,42,Subgroup,Transferred out of ICU,Positive only,End-point and active,Both,Both,Yes,ICU only,Severe/Critical Only,Both,61,,,51,69,,55.00%,22.50%,69.80%,0.80%,0.00%,7.00%,,,,,,,,,,,,,,31,12.40%,,64.30%,46.50%,11.60%,10.90%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,167,,,,1545,,,,,,,22.50%,,,53.50%,,,,,,,66.70%,1.50%,14.70%,,,,66.70%,,,,,50.40%,,,,,,,,1,1,0.67,7,15,,0.03,0.04
195,2,USA,Georgia,52,28.65%,ICU and ventilator mortality among critically ill adults with COVID-19,MedRxiv,Auld et. al.,https://www.medrxiv.org/content/10.1101/2020.04.23.20076737v1,English,No,Observational,3/6/20,4/17/20,42,Subgroup,Died in ICU,Positive only,End-point only,Non-Survivors only,Discharged only,Yes,ICU only,Severe/Critical Only,Both,70,,,63,77,,46.10%,11.50%,73.10%,3.90%,0.00%,11.50%,,,,,,,,,,,,,,29,1.90%,,65.40%,50.00%,25.00%,7.70%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,224,,,,3780,,,,,,,21.10%,,,51.90%,,,,,,,90.40%,0.00%,53.90%,,,,90.40%,,,,,92.30%,,,,,,,,1,1,0,8,11,,1,1
196,0,Mexico,Nationwide,7497,22.47%,COVID-19 Fatality and Comorbidity Risk Factors among Diagnosed Patients in Mexico,MedRxiv,Solis et. al.,https://www.medrxiv.org/content/10.1101/2020.04.21.20074591v1.full.pdf,English,No,Observational,2/29/20,4/18/20,49,Top-level,All Positive Patients in Mexico,Positive only,End-point and active,Both,Both,Yes,Both,All,Both,46,46,,,,,57.90%,0.00%,0.00%,0.00%,100.00%,0.00%,,,,,,,,,,,,0.094,,,19.40%,50.30%,20.60%,16.70%,3.00%,2.70%,,,,1.90%,10.40%,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.09,0.12
197,0,China,Wuhan,223,37.64%,A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19,MedRxiv,Huang et. al.,https://www.medrxiv.org/content/10.1101/2020.04.18.20070656v1.full.pdf,English,No,Observational,1/1/20,3/8/20,67,Top-level,All,Positive only,End-point-only,Both,Both,No,,All,NA,62,,,49,70,,56.50%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,17.90%,8.50%,5.80%,,2.20%,,,,,78.90%,,,,69.10%,,,,,56.50%,,6.70%,,,,,,,,,,,,5.57,4.37,8.08,0.91,0.56,1.33,,,184,143,217,4.05,2.83,6.92,12.5,11.05,13.4,,,23.9,29.25,10.4,7.2,14.8,4.88,68,90.3,3.96,,6.73,0.08,0.57,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.7,,,,0.3,0.3
197,1,China,Wuhan,125,37.64%,A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19,MedRxiv,Huang et. al.,ttps://www.medrxiv.org/content/10.1101/2020.04.18.20070656v1.full.pdf,English,No,Observational,1/1/20,3/8/20,67,Subgroup,Non-severe,Positive only,End-point-only,Both,Both,No,,Mild only,NA,52,,,26,65,,48.80%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,9.60%,5.60%,3.20%,,0.80%,,,,,73.60%,,,,68.00%,,,,,58.40%,,8.00%,,,,,,,,,,,,5.03,4.04,6.19,1.14,0.81,1.54,,,194,160,244.5,3.25,2.44,4.6,12.8,10.95,13.3,,,20.45,22,8.15,6.43,11.5,3.89,64,67.5,2,,3.5,0.06,0.32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1,,,,0,0
197,2,China,Wuhan,98,37.64%,A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19,MedRxiv,Huang et. al.,ttps://www.medrxiv.org/content/10.1101/2020.04.18.20070656v1.full.pdf,English,No,Observational,1/1/20,3/8/20,67,Subgroup,Severe,Positive only,End-point-only,Both,Both,No,,Severe/Critical Only,NA,66,,,56.25,71,,66.30%,0%,0%,100%,0%,0%,,,,,,,,,,,,,,,,,38.80%,12.20%,9.20%,,4.10%,,,,,85.70%,,,,70.40%,,,,,54.10%,,5.10%,,,,,,,,,,,,6.92,5.1,11.96,0.58,0.41,0.91,,,176,120.5,200.5,5.94,4.05,11.2,12.4,11.35,13.8,,,27.3,41.3,12.8,9.8,18.3,6.7,77.15,127.2,25.7,,8.96,0.24,1.51,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.32,,,,0.68,0.68
198,0,USA,New York,257,46.07%,"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study",MedRxiv,Cummings et. al.,https://www.medrxiv.org/content/medrxiv/early/2020/04/20/2020.04.15.20067157.full.pdf,English,No,Observational,3/2/20,4/1/20,31,Top-level,General,Positive,End-point and active,Both,Both,Yes,,,Both,62,,,,,5%,66%,12%,19%,4%,62%,3%,,,,6,,,,,,,,13%,,30.8,46%,,63%,36%,19%,9%,7%,2%,9%,14%,,71%,38.3,,,66%,74%,4%,,26%,,7%,12%,,,6%,,,,0%,100%,100%,100%,0,9.8,,,0.8,,,,,199,,,,,,,,,,,39,61,0.6,,,,1.5,236,165,,65,5.5,4.4,14.7,89%,81%,,,,9%,,,72%,26%,,5%,5%,45%,1%,78%,,29%,,,,,54%,,,,,,,,30%,,,,0.47,0.47,0.16,,,,0.33,
199,0,China,Hubei,237,41.57%,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",The Lancet,Wang et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext,English,Yes,RCT,2/6/20,3/12/20,35,Top-level,Full sample,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,65,65,,56,72,,59%,,,,,,,,,,,,,,7,5,8,,,,,0.71,43.36%,23.68%,7.02%,,,,,0.00%,,36.65%,36.8,,20.00%,,,,,,,,3.00%,4.30%,0.70%,,,,,0%,0%,82%,18%,0,6.3,4.4,8.3,0.8,0.6,1.1,,,187,143,245,,,,,,,,,26,32,,,,,69,76,,,,,,,,,,,,0.67,,,,0.66,,,,0.81,0.15,0.06,,,,,0,0.09,,,,0.06,0.01,,,0.01,0.01,0.05,,,1,,0.6,,25,,0.14,0.19
199,1,China,Hubei,158,41.01%,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",The Lancet,Wang et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext,English,Yes,RCT,2/6/20,3/12/20,35,Subgroup,Remdesivir treatment,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,66,66,,57,73,,56%,,,,,,,,,,,,,,7,5,8,,,,,0.71,46.00%,25.00%,9.00%,,,,,0.00%,,35.00%,36.8,,23.00%,,,,,,,,3.00%,5.00%,1.00%,,,,,0%,0%,74%,26%,0,6.2,4.4,8.3,0.8,0.6,1.1,,,183,144,235,,,,,,,,,26,31,,,,,68,75.9,,,,,,,,,,,,1,,,,,,,,0.83,0.17,0.04,,,,,0,0.1,,,,0.05,0.01,,,0.01,0.01,0.03,,,1,,0.61,,25,,0.15,0.2
199,2,China,Hubei,78,39.89%,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",The Lancet,Wang et. al.,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext,English,Yes,RCT,2/6/20,3/12/20,35,Subgroup,Placebo control,Positive only,End-point and active,Both,Both,Yes,Both,Severe/Critical Only,Both,64,64,,53,70,,65%,,,,,,,,,,,,,,7,6,9,,,,,0.71,38.00%,21.00%,3.00%,,,,,0.00%,,40.00%,36.8,,14.00%,,,,,,,,3.00%,3.00%,0.00%,,,,,0%,0%,,,0,6.4,4.5,8.3,0.7,0.6,1.1,,,195,141,266,,,,,,,,,26,33,,,,,71.3,75,,,,,,,,,,,,0,,,,,,,,0.76,0.1,0.09,,,,,0.01,0.08,,,,0.09,0.01,,,0.01,0,0.09,,,1,,0.58,,24,,0.13,0.18
200,0,USA,New York,151,27.53%,Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series,MedRxiv,Argenziano et. al.,https://www.medrxiv.org/content/10.1101/2020.04.20.20072116v1.full.pdf,English,No,Observational,3/1/20,4/15/20,45,Subgroup,Emergency Department,Positive only,End-point and active,Both,Both,Yes,Both,,NA,55,55.6,19.1,40.5,69,,57%,,,,,,,,,,,,,,,,,21.20%,,30.3,,,49.70%,25.80%,10.60%,6.60%,2.60%,1.30%,,7.90%,16.60%,73.50%,,,,76.80%,54.30%,13.90%,6%,,,,19.90%,9.30%,,11.30%,15.20%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.90%,,,,,,,,,,,,,,,,,,,0,,0.85,,,,0.15,0.15
200,1,USA,New York,618,34.27%,Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series,MedRxiv,Argenziano et. al.,https://www.medrxiv.org/content/10.1101/2020.04.20.20072116v1.full.pdf,English,No,Observational,3/1/20,4/15/20,45,Subgroup,Floor,Positive only,End-point and active,Both,Both,Yes,Non-ICU only,,NA,64,63,17.1,51,77,,57.30%,,,,,,,,,,,,,,,,,22.60%,,29.3,,,59.20%,37.70%,13.90%,6.80%,7.80%,1.90%,,15.90%,9.50%,72.50%,,,,72.80%,60.80%,10.40%,9.20%,,,,25.20%,22.30%,,7.80%,19.40%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,53.20%,,0.20%,,0.30%,1.30%,,,54.40%,,0.60%,,,,,0.50%,,,,,,14.40%,,14.40%,,1.10%,2.60%,,,,17%,,,,1,,0.78,10.1,,,0.13,0.14
200,2,USA,New York,231,34.27%,Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series,MedRxiv,Argenziano et. al.,https://www.medrxiv.org/content/10.1101/2020.04.20.20072116v1.full.pdf,English,No,Observational,3/1/20,4/15/20,45,Subgroup,ICU,Positive only,End-point and active,Both,Both,Yes,ICU only,,NA,63,62.2,14.7,53,72,,67.50%,,,,,,,,,,,,,,,,,24.20%,,31.2,,,68%,43.30%,12.60%,6.10%,6.10%,1.70%,,11.70%,12.60%,73.20%,,,,71.90%,74%,6.50%,6.50%,,,,20.80%,10%,,8.20%,16.50%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,93.50%,,0.40%,,0.40%,4.30%,,,88.30%,,1.70%,,,,,93.10%,,,,,,90%,,90%,,7.40%,70.10%,,,,75.30%,,,,1,,0.09,14.6,,,0.31,0.78
200,3,USA,New York,1000,34.27%,Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series,MedRxiv,Argenziano et. al.,https://www.medrxiv.org/content/10.1101/2020.04.20.20072116v1.full.pdf,English,No,Observational,3/1/20,4/15/20,45,Top-level,All,Positive only,End-point and active,Both,Both,Yes,Both,,NA,63,61.7,17.5,50,75,,59.60%,,,,,,,,,,,,,,,,,22.80%,,29.9,,,59.80%,37.20%,13.10%,6.60%,6.60%,1.80%,,13.70%,11.30%,72.80%,,,,73.20%,62.90%,10%,8.10%,,,,23.40%,17.50%,,8.40%,18.10%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,64.20%,,0.20%,,0.40%,2.10%,,,63.60%,,0.90%,,,,,23.00%,,,,,,35%,,35%,,2.80%,21%,,,,32.90%,,,,0.85,,0.63,11.4,,,0.17,0.21
202,0,USA,Georgia,305,28.65%,"Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e1-H.pdf?deliveryName=USCDC_921-DM26922,English,No,Observational,3/1/20,3/20/20,19,Top-level,All,Positive only,End-point and active,,Both,Yes,Both,All,NA,60,,,23,95,,49.50%,10.80%,83.20%,2.70%,3.40%,,,,,,,,,,,,,5.20%,,,12.70%,73.80%,67.50%,39.70%,25.60%,20.30%,3.90%,2.30%,,10.50%,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,72.10%,22.60%,76.10%,3.60%,30.20%,,7.50%,,,,,,,,,,,,,,,,,1,0.39,0.76,8,8.5,,0.17,0.18
202,1,USA,Georgia,89,23.60%,"Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e1-H.pdf?deliveryName=USCDC_921-DM26922,English,No,Observational,3/1/20,3/20/20,19,Subgroup,Age 18-49,Positive only,End-point and active,,Both,Yes,Both,All,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,21.80%,47.20%,33.70%,23.60%,11.20%,15.70%,3.40%,0%,,2.20%,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,64%,14.60%,65.20%,2.20%,19.10%,,2.20%,,,,,,,,,,,,,,,,,1,0.27,0.96,7,7,,0.03,0.03
202,2,USA,Georgia,99,23.60%,"Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e1-H.pdf?deliveryName=USCDC_921-DM26922,English,No,Observational,3/1/20,3/20/20,19,Subgroup,Age 50-64,Positive only,End-point and active,,Both,Yes,Both,All,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,14.60%,66.70%,75.80%,46.50%,13.10%,26.30%,3.00%,4.00%,,12.10%,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,67.70%,17.20%,70.70%,4.00%,27.30%,,8.10%,,,,,,,,,,,,,,,,,1,0.32,0.84,8,8,,0.1,0.1
202,3,USA,Georgia,117,23.03%,"Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e1-H.pdf?deliveryName=USCDC_921-DM26922,English,No,Observational,3/1/20,3/20/20,19,Subgroup,Age 65+,Positive only,End-point and active,,Both,Yes,Both,All,NA,,,,,,,,,,,,,,,,,,,,,,,,,,,3.70%,,86.30%,46.20%,47%,18.80%,5.10%,2.60%,,15.40%,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,82.10%,33.30%,88.90%,4.30%,41%,,11.10%,,,,,,,,,,,,,,,,,1,0.54,0.56,9,10,,0.36,0.39
202,4,USA,Georgia,247,25.84%,"Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e1-H.pdf?deliveryName=USCDC_921-DM26922,English,No,Observational,3/1/20,3/20/20,19,Subgroup,Black Race,Positive only,End-point and active,,Both,Yes,Both,All,NA,60,,,45.5,69,,,,100%,,,,,,,,,,,,,,,,,,13.90%,74.90%,69.60%,41.70%,25.10%,21.50%,4.00%,1.60%,,9.70%,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71.70%,22.30%,75.30%,4.00%,30.40%,,7.70%,,,,,,,,,,,,,,,,,1,0.39,0.78,8,8,,0.16,0.17
202,5,USA,Georgia,50,25.28%,"Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020",CDC,CDC,https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e1-H.pdf?deliveryName=USCDC_921-DM26922,English,No,Observational,3/1/20,3/20/20,19,Subgroup,Other Race,Positive only,End-point and active,,Both,Yes,Both,All,NA,64.5,,,44.8,74,,,,,,,,,,,,,,,,,,,,,,4.20%,68%,54%,32%,30%,12%,4.00%,4.00%,,16.00%,,,,,,,,,,,,,,,,,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,74%,28%,80%,0%,32%,,6%,,,,,,,,,,,,,,,,,1,0.42,0.68,9,8,,0.23,0.25